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Abstract 
Recombinant protein therapeutics have transformed healthcare by paving the way 
for the treatment of refractory illnesses like cancer and arthritis. Chinese hamster ovary 
(CHO) cells are the major workhorse for the production of these therapeutics. Striving for 
continual improvements in the productivity and quality of protein produced in CHO cells, 
many process enhancements have been successfully implemented. However, many 
processes are still empirical, and we have little understanding of the mechanisms for these 
methods.  
The availability of genomic resources for CHO cells has ushered in a ‘genomics’ 
era in bioprocessing. Genomic resources can now be employed to understand and improve 
cell lines and processes to enhance the productivity and quality of protein therapeutics 
produced by CHO cells. Seeking the development of genomic resources for CHO cells, the 
Chinese hamster genome and transcriptome were sequenced, assembled and annotated.  
Such transcriptomic resources can be used to study the inherent transcriptomic 
variability in CHO cells. The genetic cues identified from the study of the variability in the 
glycosylation pathway genes opens up several opportunities to manipulate protein quality. 
The relative expression of isozymes in CHO cells affect metabolic characteristics, which 
in turn may potentially impact product quality or even process robustness. The comparative 
study of isozymes can give important clues for cell engineering and process development. 
The isozyme distribution in CHO cells indicates a very high overall glycolytic rate, 
insinuating to the possibility of manipulating glycolytic flux for improving processes.  
Engineering superior metabolism through cell engineering can be used to reduce 
glycolytic flux in the late stage of the fed batch culture to reduce lactate accumulation. A 
novel dynamic promoter was used to drive the expression of a fructose transporter 
selectively in the late stages of the culture. By maintaining adequately low fructose levels 
in the late stage, the glycolytic flux was reduced significantly to induce lactate 
consumption. Since lactate accumulation is well accepted to be detrimental to productivity, 
this phenotype is desired for bioprocessing.  
In addition to such high productivity processes, high producing cells are also 
desired. The lengthy process of cell line development transforms non-producing cells to 
high producers. The molecular changes in this transformation were elucidated by studying 
the transcriptome of CHO cells during cell line development. We hypothesize that 
methotrexate treatment not only increases the transgene copy number, but also enriches 
cells with superior growth, energy metabolism, and secretion capabilities. This leads to an 
enriched population of high producers. The sustenance of high productivity over several 
generations depends on the stability of the integration site of the transgene. Two methods 
for identifying the cell’s transgene integration site were developed and optimized. These 
methods can be applied for high throughput investigation of stability of integration sites. 
The application of genomics in bioprocessing has sparked a systems approach to 
investigate genetic regulation. This knowledge paved the way for controlling cellular 
metabolism and achieve stable and high producing cell lines and processes. Such genome 
scale analyses have a great potential to advance the capacity of CHO cells for 
biopharmaceutical applications. 
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Chapter 1: Introduction 
In the year 1982, Humulin, recombinant human insulin, produced in E. coli became 
the first recombinant protein to be licensed by the regulatory bodies for therapeutic 
applications. While E. coli can produce small protein molecules very effectively, they lack 
the necessary machinery to process larger and more complex molecules, especially 
glycoproteins like immunoglobulin G (IgG) or blood coagulation factor VIII. The 
production of such molecules requires post translational modifications such as 
glycosylation which is carried out in the endoplasmic reticulum (ER) and Golgi organelles 
in mammalian cells. Because of this, recombinant protein production soon resorted to 
mammalian cell as hosts for production. 
The first mammalian cell based recombinant therapeutic, Activase by Genentech, 
was approved to be marketed by the US Food and drug Drug Administration (FDA) in the 
year 1987. Since then, the US FDA has approved over 100 recombinant protein 
therapeutics, culminating into global sales of US$120 billion in 2012 (Bandaranayake & 
Almo, 2014; Zhu, 2012). 
Chinese hamster ovary (CHO) cells are indisputably the most popular cell line host 
for recombinant protein therapeutic production producing almost 60% of the therapeutics 
produced totally in mammalian cells. The ease of adaptation to suspension, serum-free or 
even chemically defined media makes them attractive for commercial production. The 
ability to use animal component-free media alleviates the risk of potential viral 
contamination coming from animal sources. These attributes have made CHO cells a major 
workhorse in bioprocessing.  
The enormous success of these drugs in treating serious illnesses like cancer and 
arthritis has propelled drug discovery research to churn out an ever increasing number of 
drug candidates. All these candidates are very diverse in their structure, modality and 
requirement for post-translational modifications. This poses a great challenge for process 
engineers, who are required to develop robust processes for a large and diverse range of 
drugs. In the event of the patent expiration of older generation of therapeutics, follow-on 
  2 
biologics, called ‘biosimilars’ are entering the market creating a wave of generic drugs. In 
order to cope with the increasing number of drug candidates, it has become imperative to 
expedite the development of these processes. However, since most stages in process 
development are largely empirical, the extensive optimization steps makes process 
intensification very difficult. To overcome this shortcoming, information gained from the 
knowledge of process variables influences on the host cells and products produced will 
prove to be valuable. A better understanding the process can help us make rational 
improvements.  
 
Figure 0-1: Role of genomics in bioprocessing 
In the course of characterizing the impact of process variables, the cells cannot be 
treated as a black box as cellular physiology plays an important role in determining the 
product quality. Systems biology approaches are powerful tools that can be used to 
understand the molecular basis of changes in cellular behavior. Several thousands of 
variables can be measured in a single experiment. For example, using transcriptomics one 
can measure the gene expression levels of several thousands of genes in a single 
experiment. The use of systems biology was restricted in the past decade because of 
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insufficient genomic resources for CHO cells. The availability of the Chinese hamster 
genome (Brinkrolf et al, 2013; Lewis et al, 2013) and CHO cell genome (Xu et al, 2011) 
in the past two years, has revolutionized bioprocessing with the ability to harness genomics 
and transcriptomics methods for bioprocess advancements. The past three years have seen 
an overwhelming response to the use of genomics in CHO cell culture (reviewed in 
(Kildegaard et al, 2013)). Transcriptomics has helped to improve bioprocessing by 
providing us with scientific understanding of the hyper-productivity trait. Novel cell 
engineering strategies have improved product quality and yield (Figure 0-1).  
Studies of the interaction of transcriptome with the epigenome are just beginning 
to emerge (Figure 0-1). The increasing evidence of epigenetic dysregulation in cancer cells 
makes us wonder about its prevalence and effect on the phenotype of CHO cells. Often we 
have attempted to seek master regulators for improving CHO productivity. Could this 
master regulator be an epigenetic event? The answer to this question can be found only 
through careful investigation of the epigenetic state of CHO cells. 
This dissertation will focus on the application of genomic tools to understand and 
manipulate some physiological characteristics of CHO cells in the context of 
bioprocessing. 
1.1 Thesis Organization 
This thesis is an attempt to understand the molecular characteristics CHO cells in 
their role as recombinant protein producers. A brief background of mammalian cell culture 
along with a brief description of host cell lines that are commonly used in bioprocessing 
will be discussed in Chapter 2. A typical cell line development process is explained 
followed by a brief description of RNA sequencing and microarray technology for 
transcriptomics in Chapter 2. Chapter 3 summarizes the recent findings from transcriptome 
studies in CHO cells, and further discusses the challenges and the potential scope for 
further improvement. The transcriptomic diversity among different CHO host cells and 
producing cell lines derived from them is discussed in Chapter 4. A study characterizing 
the physiological changes in CHO cells during the cell line development process is 
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presented in Chapter 5. Chapter 6 shows an application of transcriptomic analyses in CHO 
cells to identify endogenous dynamic promoters. Such a promoter was used to engineer 
dynamic nutrient uptake in CHO cells leading to process improvements. Chapter 7 
discusses the efforts towards building high quality genomic resources for CHO cells, 
including the assembly and annotation of the Chinese hamster genome and transcriptome. 
The development of methods for probing the transgene integration site in CHO cells is also 
described. Chapter 8 presents a brief conclusion and possible avenues for the future. 
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Chapter 2: Background 
The first half of this chapter provides brief background in mammalian cell culture 
based production of recombinant protein therapeutics. Most of the background is given in 
the context of CHO cells because they are the most prominent hosts in biopharmaceutical 
production, and is also the focus of this dissertation. A description of the popular CHO host 
cell lines along with the details of their historical derivation is provided. This is followed 
by a description of cell line development process for selection of a stable CHO cell clone 
for production. The section on processes for protein production gives a brief summary of 
the fed-batch, perfusion and other processes for therapeutics production in mammalian 
cells. The second half of this chapter provides some background on the available genomic 
resources for CHO cells. This is followed by a brief description of the methods for 
transcriptome analysis, specifically RNA-sequencing and microarray technologies. 
2.1 Recombinant Protein Production in Mammalian Cells 
Mammalian cells produce almost half of all the currently approved biologics 
(Kantardjieff & Zhou, 2014). Their ability to fold many complex protein structures and to 
perform important post-translational modification like glycosylation make them essential 
for protein therapeutics production (Wurm, 2004). The glycan profile influences several 
characteristics of the protein drug, for example efficacy in eliciting immune response or 
the circulatory half-life. (reviewed in (Hossler, 2012; Hossler et al, 2009)). 
2.1.1 Host Cells for Recombinant Protein Production 
Protein therapeutics are commonly produced in  human cell lines like HEK 29, 3T3, 
HeLa, HepG2 or rodent cell lines like mouse myeloma (NS0 and SP2/0), baby hamster 
kidney (BHK) or Chinese hamster ovary (CHO) cell lines, among the mammalian cell 
producers. The most prominent of these are CHO cells because of their ease of adaptability 
to different culture conditions, compatibility with large scale production, insusceptibility 
to human viruses and production of human compatible glycoforms. CHO cells alone 
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produce almost 60% of the mammalian cell based recombinant protein therapeutics and 
30% of the currently approved global .biologics (Kantardjieff & Zhou, 2014).  
Chinese hamster ovary (CHO) cell lines were derived from Chinese hamster ovary 
tissue biopsy over five decades ago, to study the karyotype of cells in tissue culture (Puck 
et al, 1958; Tijo & Puck, 1958). CHO cells have recently been given a “quasispecies” status 
because it is not a single cell line but a group of closely related cell lines having slightly 
different genomic compositions (Wurm, 2013). Since their derivation, they were among 
the most important cell lines used in biomedical research for decades. The low diploid 
number of chromosomes (2n = 22) in the Chinese hamster and functional haploidy made it 
relatively easy to derive mutant lines and hence, made these cell lines a valuable 
cytogenetic tool. They are also used as model organisms to study diabetes mellitus and 
toxicity studies. In the past two decades, CHO has also become the most prominent host 
cell for producing therapeutic proteins, acquiring much genomic reorganization in the 
process. 
Cells that are isolated from tissue can normally grow only for a limited number of 
doublings after which they reach a ‘crisis’ state beyond which they no longer multiply. 
This is called the ‘Hayflick phenomenon’. However, a few cells can overcome this state 
and become immortalized. CHO cells, are such immortalized cell lines. After its first 
derivation in 1958, the CHO cell line CHO-K1 was extensively distributed among different 
laboratories around the world for different cytogenetic studies. A few laboratories isolated 
mutants of CHO-K1 deficient in dihydrofolate reductase (DHFR) activity. CHO-DXB11 
was derived in 1980  (Urlaub & Chasin, 1980), followed by CHO-DG44 in 1983 (Urlaub 
et al, 1983; Urlaub et al, 1986). The parentage details of only a few cell lines are known. 
Figure 0-2 shows the most accepted family tree of CHO cell lines. Several different 
parental CHO cells were further adapted to serum free or suspension medium at various 
laboratories. 
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Figure 0-2: Best known genealogy of commonly used CHO host cell lines showing 
that the historical propagation of these different CHO host cell lines are rather 
different (Reconstructed from (Wurm & Hacker, 2011)). 
The host cells that are available today may have genetically diversified due to 
repeated mutagenesis, adaptation and sub-culturing in the past five decades. Although the 
general phenotypes of these cells appear to be similar in the context of bioprocessing, their 
genotypes can be rather different. The differences in genotypes have been ignored in the 
past 25 years, potentially because of the unavailability of genomic resources. Also, 
probably there was no pressing need for understanding this diversity due to the limited 
range of molecules produced in CHO cells. With the increasing number of drug candidates, 
and the burst of genomic information available for CHO cells, it is now relevant to revisit 
this aspect to catalogue the genomic differences between CHO cell lines. 
2.1.2 Cell Line Development 
The transformation of CHO host cells into production cell lines begins with the 
introduction of the recombinant gene of interest along with a selection marker gene. In 
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most cases, the cells are also subjected to an amplification step after selection. These cells 
may or may not be sub-cloned using limited dilution at this stage.  
Commonly used CHO host cell lines, such as DG44 and DXB11 (Figure 0-2), are 
auxotrophic mutants of the di hydrofolate reductase gene (dhfr) negative. Since they do not 
possess the dhfr gene, they cannot convert di hydrofolate into tetra hydrofolate. Tetra 
hydrofolate is necessary for DNA synthesis, and CHO cells deficient in DHFR activity 
require supplementation of hypoxanthine and thymidine (HT-media) for growth. By co-
introducing the dhfr gene with the recombinant gene of interest and the selection marker, 
additional selection pressure can be applied by adding a dhfr antagonist. Methotrexate 
(MTX), a commonly used dhfr antagonist, is added to the cell culture medium. The 
concentration of MTX maybe gradually increased over a period of 15 days to intensify the 
amplification process. In order to cope with the high amount of selection pressure, the cells 
significantly amplify the dhfr genes, co-amplifying the surrounding genomic region 
including the recombinant gene. The selected cells typically have multiple copies of an 
approximately 100 kilo base of the chromosomal region containing the DHFR gene locus 
(Milbrandt et al, 1981). This process is called amplification because it results in a very high 
copy number, from hundreds to thousands of .copies of the transfected vector (Barsoum, 
1990; Johnston et al, 1983; Kaufman & Schimke, 1981; Kaufman & Sharp, 1982; Kaufman 
et al, 1985; Ma et al, 1993; Mariani & Schimke, 1983; Niwa et al, 1991; Nunberg et al, 
1978; Trask & Hamlin, 1989). 
After MTX amplification, the cells are heterogeneous, so they have to be sub-
cloned using limited dilution before mass production (Kim et al, 2001; Kim et al, 1998b). 
A few sub-clones are selected based on their growth and productivity, and later expanded. 
The cells are usually adapted to suspension culture in order to facilitate their cultivation in 
bioreactor vessels. Their performance is evaluated in shake flasks, and later in bioreactors. 
A few clones are selected and banked (Figure 0-3). 
To test for stability, the selected clones are propagated for multiple generations 
through which the growth and productivity of the cells is monitored. The clone showing 
stable expression is selected for the final production. 
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Figure 0-3: A typical cell line development process for recombinant protein 
production in mammalian cells. The host cell is first transfected with the 
recombinant gene along with a selection marker in order to select for successfully 
transfected cells. If amplification systems are used, the cells are subjected to high 
concentrations of the drug (MTX or MSX). Following amplification, cells are sub-
cloned in limited dilution and screened for clones producing high amount of the 
recombinant product. A few candidate clones may be adapted to suspension culture 
and banked. In parallel, the candidate clones are characterized for stable 
production in shake flasks for many generations after which the most suitable clone 
is selected for production (Adapted from (Lai et al, 2013)). 
The process of cell line development typically requires about 6 – 12 months, and is 
labor and capital intensive (reviewed in (Jayapal et al, 2007)). In past few years, there have 
been many advancements in this field towards increasing automation and process 
  10 
reproducibility (reviewed in (Lai et al, 2013)). On the other hand, there has been little 
progress in understanding the molecular changes within CHO cells during cell line 
development.  
The cell line development process has afforded the transformation of the host cells 
which secrete almost no protein, to become professional secretors. The cells produce 
almost 50 pg/cell/day which is equivalent to the productivity of high secretors in the human 
body like plasma cells or liver cells. Even after three decades following the development 
of this method, we do not fully understand the mechanisms of this transformation of non-
producers into hyper-producers. 
With the increasing number of drug candidates, especially in past few years, it has 
become necessary to accelerate the time required to develop a cell line. A better 
understanding of the transformation can enable us not only to speed up the process of cell 
line development, but also to develop more rational methods to screen cells with hyper 
productivity traits.  
2.1.3 Processes for Recombinant Protein Production 
The stable clone selected after the cell line development process is typically grown 
in bioreactors under controlled environmental conditions of pH, temperature, dissolved 
oxygen and CO2 for producing high amounts of therapeutic protein for clinical use. The 
cells are usually cultured in fed batch mode or perfusion mode. In fed batch mode, the cells 
are inoculated at a low concentration in the bioreactor and grown to high concentrations. 
Concentrated feed medium is fed regularly, typically once a day to make up for the 
consumed nutrients. The volume of the reactor increases through the course of the culture. 
To accommodate for the increasing volume, these cultures are usually initiated at volumes 
lower than the capacity of the bioreactor (reviewed in (Wlaschin & Hu, 2006)). The cells 
are grown to the maximum cell density after which cell growth is inhibited because of the 
accumulation of toxic metabolites like lactate and ammonia (Ozturk et al, 1991; Zhou et 
al, 1997). The high cell density is maintained until the viability drops to low levels because 
of high osmolality and reactive oxygen species (ROS). Since the protein quality is affected 
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at low viabilities of the culture (Yang & Butler, 2002), the culture is terminated at a certain 
predetermined viability, usually between 50% and 80%. The product is harvested at the 
end of the culture. A fed batch culture typically lasts for 14 days and routinely yields titers 
of up to 5 g/L (Whitford, 2006). The product titer largely depends on the specific 
productivity of the cells, the peak cell density, and the culture duration. 
Some processes in fed batch bioreactors employ additional productivity enhancing 
conditions such as exposure to low temperature, or addition of sodium butyrate in the late 
stage of the culture after the cells reach maximum cell density. Other ways to increase 
productivity in the stationary phase are increasing osmolality or a pH shift       (Baik et al, 
2006; Birzele et al, 2010; De Leon Gatti et al, 2007; Fogolin et al, 2004; Jiang & Sharfstein, 
2008; Kantardjieff et al, 2010a; Kaufmann et al, 1999; Klausing et al, 2011; Moore et al, 
1997; Oh et al, 1993; Rodriguez et al, 2005; Shen et al, 2010; Shen & Sharfstein, 2006; 
Trummer et al, 2006; Yee et al, 2008; Yoon et al, 2004; Yoon et al, 2003a; Yoon et al, 
2003b).  Sodium butyrate is a histone deacetylase inhibitor (Candido et al, 1978; Davie, 
2003; Sekhavat et al, 2007), and may play a role in increasing transgene accessibility in 
the stationary phase, leading to higher expression and productivity of the recombinant 
gene.  
In contrast to fed batch modes, in continuous culture, the cells are cultivated in a 
bioreactor with the feed media being added continuously. Simultaneously, an equivalent 
volume of reactor slurry is withdrawn, keeping the reactor volume constant. The product 
is extracted from this efflux continuously. One of the disadvantages of continuous culture 
is that the flow rate is limited by the growth rate of the cells. Continuous cultures cannot 
be operated at higher rates than the cellular growth rate, or else the cells will be washed 
out. Overcoming this shortcoming, in perfusion culture, the cells are separated from the 
slurry by filtration and then recycled back from the retentate into the reactor (Abu-Absi et 
al, 2014). One of the disadvantages of continuous culture is that the flow rate is limited by 
the growth rate of the cells. Continuous cultures cannot be operated at higher rates than the 
cellular growth rate, or else the cells will be washed out. One way of overcoming this 
shortcoming, is the filtration of cells followed by recycling them to the reactor (Abu-Absi 
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et al, 2014). The cell concentration in the reactor remains constant at usually 60 to 100 
million cells/mL. The product is harvested continuously from the filtrate. Since the spent 
media is continuous withdrawn from the reactor it prevents the buildup of toxic metabolites 
like lactate and ammonia. This allows the bioreactor to be run for much longer durations. 
Perfusion cultures can achieve 1-2 g/L/day titers (Bonham-Carter & Shevitz, 2011). 
The fed batch and perfusion modes are by far the most commonly used processes 
for commercial production. Among them, though fed batch culture is the dominant 
industrial practice. The choice of production format also depends on characteristics of the 
product and the production scale. For example, for an unstable product, a perfusion process 
maybe more suited due to much lower residence time. The average residence time is in the 
order of hours in the perfusion process compared to days in a fed batch process (Kadouri 
& Spier, 1997). 
2.2 Genomics and Transcriptomics 
The number of genomes being sequenced around the world is exponentially 
increasing (Liolios et al, 2010) fuelled by the plummeting costs of high throughput 
sequencing. With the sequencing of the CHO-K1 and Chinese hamster genomes, genomic 
resources for CHO cells have piled up significantly over the past few years (Brinkrolf et 
al, 2013; Lewis et al, 2013; Xu et al, 2011). Genomics takes a holistic approach for the 
investigation of the cellular properties as opposed to the traditional individualistic approach 
of studying a small portion of the genome in detail. Genomic investigations generate large 
amounts of data containing a wealth of information. A major challenge lies in finding 
intelligent ways of sifting through these vast amounts of data to obtain relevant 
physiological information. The availability of genomic resources for Chinese hamster has 
facilitated the use of genomics to characterize the CHO cells. 
Transcriptomics is the study of the expressed region of the cells’ genome including 
mRNA, rRNA, tRNA and other non-coding RNA. The most widely studied form of 
transcriptome is the mRNA. In a transcriptomics study, the expression level of all the genes 
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within a cell is measured in a single experiment. The most common tools for transcriptome 
analysis are microarray or RNA-Sequencing. 
2.2.1 Microarray 
Microarrays are used for global profiling of gene expression. Oligonucleotide 
microarrays are the most common form of microarrays that have evolved from cDNA 
microarrays. Each transcriptome microarray chip contains several spots, where each spot 
is a probe for the gene expression of a gene.  
 
Figure 0-4: An illustration of the working principle of an oligonucleotide 
microarray 
Usually, there are multiple probes per gene. The spot contains many copies of the 
reverse strand of a portion of the cDNA of the gene to be probed. The selective unique base 
pairing of nucleic acids of DNA is exploited to probe the expression levels of all the genes. 
Total RNA extracted from cells is converted to cDNA using oligo-dT primers for enriching 
mRNA from the sample. The cDNA is either directly hybridized to the microarray or 
converted to cRNA prior to hybridization. The cRNA nucleotides are labelled with 
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fluorochores to enable the measurement of gene expression level via fluorescence intensity. 
Spots on the chip are scanned to quantify the gene expression levels of all the genes in a 
single experiment (Figure 0-4). 
To take advantage of the microarray technology, it is imperative to have a 
comprehensive coverage of the transcriptome along with a good quality of annotation for 
most of the genes. With newly sequenced draft genomes, it is difficult to secure such high 
quality annotation. Over the years, our lab has invested a lot of resources in expanding the 
genome and transcriptome sequence annotation for Chinese hamster and CHO cells (Jacob 
et al, 2010; Kantardjieff et al, 2009; Wlaschin & Hu, 2007b; Wlaschin et al, 2005). The lab 
has designed, constructed and validated several different microarrays for CHO cells, a few 
of which will be referred to in this thesis. 
Several different commercial platforms are available for constructing 
oligonucleotide microarrays. While the working principle is the same, the manufacturing 
technologies and feature properties may vary quite a bit across different platforms. Each 
probe maybe 25 bp or 60 bp in length depending on the platform used. In our lab, we have 
designed and validated microarrays in both Affymetrix (25 bp probes) and Nimblegen (60 
bp probes) platforms. In this dissertation, I have used the Nimblegen microarray for the 
work described in Chapter 4 and the Affymetrix microarray for the work described in 
Chapter 5. 
Microarrays can also be used to probe genome copy number variation. These 
microarrays usually have probes either tiling the entire genome, or evenly spaced across 
the genome where the copy number of the genomic region is probed. Such arrays are called 
comparative genomic hybridization (CGH) arrays. 
For transcriptome analysis, our lab has generated several generations of 
microarrays, continuously validation.  
2.2.2 RNA-Sequencing 
RNA sequencing based transcriptome quantification methods is a powerful method 
that has gained acceptance and popularity in the past few years. Often referred to as RNA-
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Seq, it involves direct sequencing of RNA using high throughput sequencing methods. The 
short sequencing reads are aligned to the reference genome or transcriptome. The number 
of reads mapping to a gene is a measure of the expression level of that gene (Figure 0-5). 
With the decreasing cost of high throughput sequencing, the costs of conducting an RNA-
Seq experiment has reduced leading to its increase in popularity. 
 
Figure 0-5: Transcriptome analysis by RNA-Seq. The total RNA is converted to 
cDNA which is fragmented and sequenced. The sequencing reads are mapped to all 
the genes, and the depth of coverage of the genes is used to quantigy gene expression 
level. 
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Similar to the microarray experimental procedure, the total RNA is extracted from 
the cells and converted to cDNA using oligo-dT primers, thereby enriching for mRNA 
from total RNA. The cDNA is fragmented into approximately 200 – 500 bp size fragments. 
The fragments are sequenced by high throughput sequencing. Each sequencing output 
reads out the first 50 – 100 bp of the fragment depending on the experimental design. This 
output is called a read. The read sequences are usually preprocessed to remove low quality 
sequence and adaptor sequences after which they are mapped to the reference genome or 
transcriptome. Mapping is the process of identifying the genomic source of the read by 
simply matching or aligning the reads to the reference. As shown in Figure 0-5, the gene 
expression is quantified from the depth gene coverage. 
In addition to transcript quantification, RNA-Seq can provide additional 
information of novel transcript expression, or unique alternatively spliced forms, or even 
single nucleotide variants. 
  
  17 
Chapter 3: Transcriptomics in Bioprocess Development 
3.1 Summary 
Global survey of transcriptome dynamics can provide molecular insights into cell 
physiology. In the past few years, DNA microarray for transcriptome analysis has been 
augmented by high-throughput sequencing methods, extending the reach of transcriptome 
analysis to species of biotechnological importance, for which the development of genomic 
tools has been lagging. The rapid accumulation of sequencing data for these species 
highlighted the need of more evidence-based annotation. Recent findings in epigenetic 
regulation in human and mouse will inspire similar research in CHO and BHK cells. 
Transcriptome studies in these recombinant cells will likely lay the foundation for systems 
based genome engineering for develop superior producing cell lines. Herein, we 
summarized recent findings and advances in transcriptome studies of cell culture 
bioprocesses. The potential impact of transcriptomics on biopharmaceutical process 
technology is also discussed. 
3.2 Introduction 
Transcriptomics is a powerful tool providing a global view of cellular biological 
activities. Tens of thousands of different variables are simultaneously measured. Even 
proteomics or metabolomics cannot match the magnitude of quantitative information that 
can be obtained from a single transcriptomic assay. 
Recent advances in DNA sequencing technology have made global exploration at 
the transcriptome and genome levels feasible and affordable. This article reviews what 
have been accomplished in transcriptome analysis in the past few years and the possibility 
of its reach in the near future. 
3.3 Transcriptomic Tools 
Until a decade ago, global assessment of transcriptome was accomplished by 
sequencing expressed sequence tags (ESTs) or similar methods such as serial analysis of 
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gene expression (SAGE). Those decade long efforts in the 1990s and early 2000s collected 
a large number of EST sequences derived from different tissues in either healthy or disease 
states from various species. For human and mouse, over ten million of EST sequences were 
accumulated by 2006 (Nordstrom et al, 2006). Different ESTs with overlapping sequences 
were then assembled into contiguous sequences (contigs) or even full-length transcripts. 
More importantly, those early efforts in sequencing and assembling for human and mouse 
were accompanied by arduous efforts in annotation to give them the physiological context 
that paved the way for later genome annotation. The early work on ESTs demanded a large 
amount of resources (for a review on EST annotation, see (Kawai et al, 2001)). In ensuing 
sequencing effort in other mammalian species, including Chinese hamster and Syrian 
hamster used in biopharmaceutical production, the scale of sequence information and 
annotation effort is dwarfed by those in human and mouse. 
Through EST sequencing, especially methods like SAGE, one can also assess the 
transcript abundance level through the frequency of E. coli clones (each clone contains one 
EST species) that was sequenced. However, the expenditure of such an effort prevented it 
from being used routinely. Synthetic oligo DNA arrays and cDNA microarrays made 
transcriptome analysis more accessible. However, these microarrays were possible only for 
species for which EST sequence information was available. Nevertheless, transcriptome 
analysis was soon applied to antibody producing cell lines to explore gene expression 
changes under different metabolic states in a continuous culture (Korke et al, 2004). 
The versatility of expression microarrays spurred some early efforts to sequence 
ESTs of Chinese hamster tissues and CHO cells using the conventional Sanger sequencing 
method on phage libraries (Kantardjieff et al, 2009; Wlaschin et al, 2005). The 
development and the rapidly decreasing cost of high-throughput sequencing prompted its 
use to sequence transcripts of the industrially important CHO cell lines and Chinese 
hamster tissues (Becker et al, 2011; Birzele et al, 2010; Jacob et al, 2010; Rupp et al, 2014). 
However, compared to human or mouse, the number of Chinese hamster or CHO ESTs 
available is still very small. More recently, a transcriptome reference of Syrian hamster 
tissues and BHK cell lines (derived from Syrian hamster) was established using a 
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combination of Sanger and Illumina platforms (Johnson et al, 2013). Next-generation 
sequencing technologies also ushered the sequencing of the CHO-K1 cell line genome (Xu 
et al, 2011) and Chinese hamster genome (Lewis et al, 2013), and later, chromosome sorted 
Chinese hamster genome (Brinkrolf et al, 2013). An initial effort to sequence the Syrian 
hamster genome is currently underway (2013). From the genome sequence, in silico 
prediction of gene coding regions can be made. 
While millions of ESTs are sequenced for mouse and human, only 860 and 12 ESTs 
are available for Syrian and Chinese hamster, respectively, in the NCBI dbEST database. 
The availability of EST sequences enabled the construction of expression microarray for 
transcriptome surveys from early custom cDNA (De Leon Gatti et al, 2007; Wong et al, 
2006; Yee et al, 2009) to oligoDNA custom and commercial arrays (Jayapal & Goudar, 
2014; Kantardjieff et al, 2009; Melville et al, 2011), although the depth of sequence 
coverage varied over a range in those arrays (Baik et al, 2006; Ernst et al, 2006; Trummer 
et al, 2008).  
3.3.1 RNA-Seq 
High-throughput sequencing of ESTs is not only used to assemble transcript coding 
sequence of genes but also to assay the abundance distribution in a transcriptome (RNA-
Seq) even in a species without prior genome or transcriptome sequence information. These 
high-throughput sequencing methods generate sequences of short fragments of a transcript 
(called “reads”) (Jacob et al, 2010). A general procedure is to assemble those reads into 
contigs, or map those reads into a previously assembled reference transcriptome. Since the 
transcript length varies widely, the number of reads mapped to each contig (or gene) is 
normalized to its length. The abundance level of different contigs is indicated by number 
of reads per unit contig length. Unlike fluorescence intensity-based expression arrays, for 
which the detection of rare transcript is limited by sensitivity of fluorescence detection and 
the quantification of highly abundant genes suffers from intensity saturation, RNA-Seq is 
relatively free from those biases. By sequencing to a great depth (i.e., increasing the total 
number of reads sequenced), RNA-Seq can reveal any transcriptome in greater detail over 
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a wider dynamic range than DNA microarray. Through RNA-Seq, the abundance level of 
transcripts in CHO cells was shown to vary up to of five orders of magnitude. As expected, 
the transcripts of heavy chain and light chain IgG genes in the high producing recombinant 
CHO cell line were among the most abundant transcripts (Jacob et al, 2010). 
Along with providing a very high sequencing depth for abundantly expressed genes 
(Birzele et al, 2010), RNA-Seq also offers a high sensitivity in detecting sequence variants, 
i.e., more than one type of nucleotide is represented in the same position of a transcript 
(Johnson et al, 2013). These sequence variants may be caused by heterozogosity or by the 
accumulation of mutations. Interestingly, the frequency of variants with a high statistical 
confidence in CHO and BHK cell lines examined was not high, considering that mutations 
could possibly accumulate in each individual cell within the population. In spite of 
extensive culture of the cell lines, no sequence variant in the product transcript was 
detected. 
3.3.2 Challenges 
The ideal way of annotating a genome is based on evidence of transcription and 
biological functional studies. Among all mammals, human, mouse and to a much lesser 
extent, rat, have large EST repertoires. The data on mutation loci and genetic studies 
accumulated over years greatly facilitate evidence-based annotation for human and mouse 
genes. For example, the manually annotated mouse database of the FANTOM consortium 
(Kawai et al, 2001), the repertoire of the ENCODE project, (Bernstein et al, 2012) and the 
Cancer Atlas project for human (2008) are great resources for relating genes to their 
expression and functions. 
For Syrian hamster and Chinese hamster, such data are meager or even nearly non-
existent in comparison. Like all recently sequenced genomes, genes in the Chinese hamster 
genome have been identified through de novo, homology-based, and transcriptome-aided 
prediction (Lewis et al, 2013). The EST data can be assembled separately and may be 
annotated by homology to other species (Becker et al, 2011; Birzele et al, 2010; Rupp et 
al, 2014). Using next-generation sequencing technology as the primary means of 
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sequencing, the resulting EST assemblies are often fragmented contigs, except for very 
abundant genes. Many transcripts are not full-length sequences of the transcribed genes. In 
general, a reasonably large fraction (~30%) of genes can be annotated by homology with a 
high degree of confidence. But many are poorly annotated for lacking highly homologous 
orthologs in other better annotated species (Becker et al, 2011). RefSeq IDs for CHO-K1 
genome are not yet accepted by functional analysis modules such as IPA, GSEA, or 
GenMAPP. To utilize the resources available for human and mouse, one currently still 
relies on tagging CHO and BHK genes to the Ensembl IDs of their human or mouse 
orthologs. The focus of transcriptome research in recombinant cells therefore needs to shift 
from sequencing to annotation in order to converge with those performed in human and 
mouse. 
3.3.3 Data Analysis 
Another challenge to transcriptome analysis in biopharmaceutical industry is that 
the degree of differential expression in the host and production cell lines is relatively small. 
Upon differentiation or developmental events, many genes change their expression by 
several orders of magnitude. In contrast, gene expression changes in cell lines under 
different culture conditions or different treatments are relatively moderate. Given that cells 
under somewhat different culture conditions may have different total RNA and mRNA 
contents and the inevitable experimental variations, the identification of differential 
expressed genes is easily affected by the method of normalization used in data analysis. It 
might be prudent to perform analysis on biological replicates to estimate the extent of 
systematic errors for genes expressed at different abundance levels to assist making 
differential expression calls. 
RNA-Seq based transcriptome analysis will be increasingly used because of its 
independence from a prefabricated expression array. RNA-Seq data, represented by 
discrete read count, often follow a Poisson, binomial, or multinomial distribution (Fang et 
al, 2012). Because of this drastic difference in data nature, normalization and statistical 
analysis methods are different from conventional DNA microarrays. Instead of using t-test 
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or ANOVA, which are based on normal distribution assumption, it is more appropriate to 
apply Fisher’s exact test with or without an estimation of the conditional maximum 
likelihood. RNA-Seq normalization methods take sequencing depth and transcript length 
into consideration to account for intrinsic variance prior to analysis (reviewed in (Dillies 
et al, 2013)). Among them, fragments per kilobase per million mapped reads (FPKM) are 
commonly used metric. Recently, a new normalization method based on expected uniquely 
mappable area of genes or isoform models (NEUMA) has been shown to produce better 
consistency with qRT-PCR compared to other methods (Lee et al, 2011). 
Furthermore, like other biochemical variables, transcript levels change dynamically 
in bioprocesses. Instead of static comparison, or finding genes whose transcript levels 
change at the same time point, it is more revealing to identify genes whose time profiles 
are altered under different culture conditions. Because cultures are not synchronized, time 
alignment may be necessary before dynamic differential expression call, hierarchical 
clustering, or pathway analysis can be performed (for review see (Castro-Melchor et al, 
2011)). 
3.4 Transcriptome Dynamics and Regulation in Cell Line Development and 
Bioprocessing 
3.4.1 Transcriptome Dynamics in Recombinant Cell Culture 
Because of the limited availability of microarrays for species of cell lines used in 
biopharmaceutical industry except for human and mouse, and perhaps also the cost 
associated with microarray assays, the research literature on transcriptome analysis in 
bioprocessing of biologics is still relatively thin and mostly from a few research groups. 
As expected, the early work often addressed the issues of productivity of recombinant 
proteins by comparing cell lines of different productivities or culture conditions that elicit 
different productivities. A common thread in the findings from those studies was that the 
degree of differential expression among samples was small and the number of replicates 
needed to obtain a low false discovery rate was often too large to be affordable. Instead of 
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focusing on differential expression at individual gene levels, gene functional class analysis 
was performed. These methods use pathway analysis tools to identify groups of 
functionally related genes with statistically significant changes. Even though individual 
genes may incur only relatively minute changes in expression, if a large number of such 
genes in a cellular functional class (or gene set) incur such changes, the functional class 
can be identified as differentially expressed by those methods. 
Gene functional class analysis on transcriptome data upon sodium butyrate 
treatment and/or temperature shift (Baik et al, 2006; Birzele et al, 2010; De Leon Gatti et 
al, 2007; Kantardjieff et al, 2010a; Klausing et al, 2011; Wippermann et al, 2014; Yee et 
al, 2008; Yee et al, 2009) revealed that gene sets involved in protein processing and 
secretion, signaling pathways, and cell cycle were differentially expressed. Similar 
pathways are observed to be altered in high and low producer comparison (Clarke et al, 
2011; Nissom et al, 2006; Seth et al, 2007b; Vishwanathan et al, 2013), methotrexate 
(MTX) treatment for gene amplification (Grillari et al, 2001) and productivity-enhancing 
conditions such as osmotic stress (Shen et al, 2010; Shen & Sharfstein, 2006). Instead of 
having one or a small number of master regulator(s) differentially expressed, a set of genes 
in a few functional class were found to alter their transcript levels. 
Transcriptomic data have been exploited to identify targets for cell engineering. 
From CHO microarray data, genes differentially expressed with temperature were 
identified and a representative promoter region isolated (Thaisuchat et al, 2011). This 
promoter was shown to induce expression of a luciferase reporter gene upon temperature 
shift. The system may be used to control the expression of a toxic protein or to induce anti-
apoptosis genes. In a similar vein, endogenous CHO promoters which drive transcripts in 
different dynamic patterns throughout fed-batch cultures were identified. One of them, the 
promoter of Thioredoxin-interacting protein (Txnip) which has a lower expression level in 
the exponential growth stage but a high level in the late stage, was used to express a sugar 
transporter in a dynamic fashion  to manipulate glycolytic flux in the late stage (Le et al, 
2013). 
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3.4.2  Transcriptomics and Hyper-productivity in Cell Line Development 
A recent study examined changes in transcriptome during cell line development 
using methotrexate-induced amplification of dihydrofolate reductase (DHFR) gene 
(Vishwanathan et al, 2013). An interesting finding was that the transcripts of product genes 
(the heavy chain and light chain of immunoglobulin G) were already at high levels upon 
the selection of cells bearing the vector and increased little after amplification. This is 
contrary to the conventional notion that amplification serves to increase the copy number 
of the transgene and its transcript level. It was hypothesized that the amplification step may 
select for surviving cells that have developed cellular machineries to cope with the surge 
of secretory protein synthesis. This transcriptome data set was combined with previous 
meta-data compiled from comparison of high and low producers and high- and low-
productivity culture conditions (Charaniya et al, 2009; De Leon Gatti et al, 2007; 
Kantardjieff et al, 2010a; Seth et al, 2007b; Yee et al, 2008; Yee et al, 2009) in an attempt 
to generate a hyper-productivity gene set. The majority of these genes are involved 
primarily in protein synthesis, metabolism, cell cycle, and transcription regulation. With 
the extremely large number of dimensions, and with the possibility of alternative routes to 
give rise to the hyper-productivity trait, the development of a hyper-productivity gene set 
will require a very large set of data of cell lines and processes of different productivities, 
and will likely be accomplished only through a large scale and collaborative effort (Figure 
0-6 and Table 0-1). 
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Table 0-1: Pathways correlated to the hyper-productivity trait compiled from studies studying the hyper productivity trait in 
different aspects of bioprocessing mentioned in Figure 0-6. 
Pathways 
affected 
Temperature 
Shift (TS) 
Sodium butyrate 
treatment (SB) 
TS and SB Osmotic 
shock 
Cell line 
development- 
selection 
Cell line 
development - 
amplification 
High versus Low 
producer comparison 
Cell cycle (Barron et al, 
2011) 
(Birzele et al, 
2010; De Leon 
Gatti et al, 2007; 
Klausing et al, 
2011; Yee et al, 
2008) 
(Kantardjieff 
et al, 2010a) 
(Shen et al, 
2010; Shen & 
Sharfstein, 
2006) 
(Vishwanathan 
et al, 2013) 
(Vishwanathan 
et al, 2013) 
(Charaniya et al, 2009; 
Nissom et al, 2006; 
Seth et al, 2007b; 
Trummer et al, 2008; 
Vishwanathan et al, 
2013) 
Cell 
proliferation 
(Barron et al, 
2011) 
(Birzele et al, 
2010) 
 (Shen & 
Sharfstein, 
2006) 
  (Nissom et al, 2006; 
Seth et al, 2007b) 
Cell 
adhesion 
(Barron et al, 
2011) 
      
Apoptosis (Barron et al, 
2011; 
Wippermann 
et al, 2014) 
(De Leon Gatti et 
al, 2007; Klausing 
et al, 2011; Yee et 
al, 2008) 
 (Shen et al, 
2010; Shen & 
Sharfstein, 
2006) 
  (Seth et al, 2007b) 
Lipid, fatty 
acid, steroid 
metabolism 
(Barron et al, 
2011) 
(De Leon Gatti et 
al, 2007) 
(Kantardjieff 
et al, 2010a) 
(Shen & 
Sharfstein, 
2006) 
  (Clarke et al, 2011; 
Trummer et al, 2008) 
Protein 
synthesis, 
processing, 
trafficking 
and secretion 
(Baik et al, 
2006; Yee et 
al, 2009) 
 
(De Leon Gatti et 
al, 2007; Yee et 
al, 2008) 
(Kantardjieff 
et al, 2010a) 
(Shen et al, 
2010; Shen & 
Sharfstein, 
2006) 
(Vishwanathan 
et al, 2013) 
(Vishwanathan 
et al, 2013) 
(Charaniya et al, 2009; 
Clarke et al, 2011; 
Seth et al, 2007b; 
Trummer et al, 2008; 
Vishwanathan et al, 
2013) 
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Pathways 
affected 
Temperature 
Shift (TS) 
Sodium butyrate 
treatment (SB) 
TS and SB Osmotic 
shock 
Cell line 
development- 
selection 
Cell line 
development - 
amplification 
High versus Low 
producer comparison 
Proteolysis (Yee et al, 
2009) 
    (Vishwanathan 
et al, 2013) 
(Charaniya et al, 2009) 
DNA 
replication 
 (Birzele et al, 
2010) 
  (Vishwanathan 
et al, 2013) 
(Vishwanathan 
et al, 2013) 
(Seth et al, 2007b; 
Vishwanathan et al, 
2013) 
Oxidative 
stress 
(Yee et al, 
2009) 
(De Leon Gatti et 
al, 2007; Yee et 
al, 2008) 
    (Trummer et al, 2008) 
Cellular 
assembly and 
organization 
(Yee et al, 
2009) 
(Birzele et al, 
2010) 
(Kantardjieff 
et al, 2010a) 
(Shen & 
Sharfstein, 
2006) 
 (Vishwanathan 
et al, 2013) 
(Charaniya et al, 2009; 
Seth et al, 2007b; 
Trummer et al, 2008; 
Vishwanathan et al, 
2013) 
DNA Repair (Wippermann 
et al, 2014) 
  (Shen & 
Sharfstein, 
2006) 
  (Seth et al, 2007b) 
Nucleotide 
metabolism 
(Barron et al, 
2011) 
(De Leon Gatti et 
al, 2007) 
 (Shen & 
Sharfstein, 
2006) 
  (Nissom et al, 2006) 
Transcription 
and 
Translation 
(Wippermann 
et al, 2014) 
(De Leon Gatti et 
al, 2007; Klausing 
et al, 2011) 
(Kantardjieff 
et al, 2010a) 
(Shen et al, 
2010; Shen & 
Sharfstein, 
2006) 
  (Charaniya et al, 2009; 
Clarke et al, 2011; 
Grillari et al, 2001; 
Nissom et al, 2006; 
Seth et al, 2007b; 
Trummer et al, 2008) 
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Pathways 
affected 
Temperature 
Shift (TS) 
Sodium butyrate 
treatment (SB) 
TS and SB Osmotic 
shock 
Cell line 
development- 
selection 
Cell line 
development - 
amplification 
High versus Low 
producer comparison 
Histones  (De Leon Gatti et 
al, 2007) 
    (Charaniya et al, 2009; 
Nissom et al, 2006) 
Signaling (Baik et al, 
2006) 
 (Kantardjieff 
et al, 2010a) 
(Shen et al, 
2010; Shen & 
Sharfstein, 
2006) 
(Vishwanathan 
et al, 2013) 
(Vishwanathan 
et al, 2013) 
(Charaniya et al, 2009; 
Nissom et al, 2006; 
Seth et al, 2007b; 
Vishwanathan et al, 
2013) 
Growth 
factor 
signaling 
  (Kantardjieff 
et al, 2010a) 
 (Vishwanathan 
et al, 2013) 
(Vishwanathan 
et al, 2013) 
 
MAPK 
signaling 
(Wippermann 
et al, 2014) 
      
Wnt β-
catenin 
signaling 
(Wippermann 
et al, 2014) 
      
TGF-β 
signaling 
pathway 
 (Birzele et al, 
2010) 
     
Golgi   (Kantardjieff 
et al, 2010a) 
   (Charaniya et al, 2009; 
Clarke et al, 2011) 
Carbohydrate 
Metabolism* 
(Baik et al, 
2006; Barron 
et al, 2011; 
Yee et al, 
2009) 
(De Leon Gatti et 
al, 2007; Yee et 
al, 2008) 
 (Shen et al, 
2010; Shen & 
Sharfstein, 
2006) 
  (Nissom et al, 2006; 
Seth et al, 2007b; 
Trummer et al, 2008; 
Vishwanathan et al, 
2013) 
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Pathways 
affected 
Temperature 
Shift (TS) 
Sodium butyrate 
treatment (SB) 
TS and SB Osmotic 
shock 
Cell line 
development- 
selection 
Cell line 
development - 
amplification 
High versus Low 
producer comparison 
Ion 
transport* 
(Yee et al, 
2009) 
(Birzele et al, 
2010; De Leon 
Gatti et al, 2007; 
Kantardjieff et al, 
2010a) 
 (Shen et al, 
2010; Shen & 
Sharfstein, 
2006) 
  (Nissom et al, 2006; 
Seth et al, 2007b) 
Amino acid 
or protein 
metabolism* 
(Barron et al, 
2011) 
(Yee et al, 2008)  (Shen et al, 
2010; Shen & 
Sharfstein, 
2006) 
(Vishwanathan 
et al, 2013) 
(Vishwanathan 
et al, 2013) 
(Grillari et al, 2001; 
Nissom et al, 2006; 
Trummer et al, 2008; 
Vishwanathan et al, 
2013) 
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Figure 0-6: Towards generating a hyper-productivity gene set from meta-analysis of 
historical transcriptome data 
3.4.3 Transcriptomics and Product Quality 
The increasing accessibility of transcriptome survey has spurred interest in 
employing transcriptome analysis in help steering the glycosylation pattern of the product. 
The repertoire of glycosylation genes in mammals is large, but their expression is tissue 
specific. Among the 300 genes related to glycosylation identified in CHO genome, 159 are 
expressed in CHO K1 cell as revealed by transcriptome sequencing. Among those not 
expressed is α(2,6) sialyltransferase (Becker et al, 2011; Xu et al, 2011). Since α(2,6) sialic 
acid is present in many glycoproteins of human, de-silencing of this gene may lead to the 
synthesis of glycans closer to those of human origin, mitigating the need of cloning in 
α(2,6) sialyltransferase to accomplish the same glycan alteration. A sub-array of 79 
glycosylation related genes was used to study the cells genetic response to addition of 
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nucleotide sugar precursors (Wong et al, 2010).The addition of sodium butyrate is known 
to alter sialic acid content of the protein and was reported to  cause a decrease the 
expression levels of sialic acid transferase St3gal3 and cytosolic sialdiase neu2 and an 
increase of lysosomal sialdiase neu1 and membrane sialdiase neu3 (Lee et al, 2014). Unlike 
the tissue specific glycosylation enzyme, most glycosylation enzymes and transporter 
expressed in CHO and other industrially important cells are subjected to only relatively 
small changes of a couple fold. The glycosylation pattern of a product protein is affected 
by a large number of factors, including the metabolic state of the cell and the supply of 
nucleotide sugar, the extent that other cellular proteins are also being processed through 
Golgi apparatus and thus competing for the glycosylation machinery and the abundance 
level of other components of the secretory pathway. To harness the power of transcriptome 
analysis and to use changes in the expression profile of genes in glycosylation for steering 
glycosylation patterns a systems analysis approach using a kinetic model as a predictive 
tool will be necessary. 
3.5 Transcriptomics and Epigenetics for Process Enhancement 
During development, the genome is reprogrammed to segregate into regions highly 
accessible to transcriptional machinery (transcriptionally active) or inaccessible 
(transcriptionally silent) through chemical modifications of DNA and histone. Such 
epigenetic alterations are also hallmarks of cancer transformation. Recent findings from 
the ENCODE consortium studies (Bernstein et al, 2012) have shown the immense impact 
of epigenetics on gene regulation. The conversion of host cells to a hyper-producer in a 
short two to three week period during cell line development may also involve genomic 
reprogramming. While the studies were on human tissues and human cells, the findings are 
highly relevant transcriptional regulation in recombinant CHO and mouse cells. Here, we 
highlight a few important findings that may impact biomanufacturing. 
The transcript expression level of a gene can be altered through the methylation of 
CpG (cytidine and guanine dinucleotide)–rich region in its promoter. Methylation of CG 
sites on the CMV promoter that drives the expression of the product gene was reported to 
  31 
result in a decrease in productivity in a few cases (Kim et al, 2011; Osterlehner et al, 2011; 
Yang et al, 2010). In an early application of mouse expression array to cell culture 
bioprocessing, it was shown that cholesterol auxotrophy in NS0 cells was caused by 
silencing of the hsd17b7 gene involved in cholesterol synthesis (Seth et al, 2006b). Normal 
and tumor cells have an inverted methylation patterns. Repetitive DNA regions, usually 
silenced in normal cells, are hypomethylated in tumors. Overall, there is 20-60% lesser 
DNA methylation in cancer cells (De Carvalho et al, 2012). How the methylation status of 
recombinant cell lines used in bioprocessing as compared to normal diploid cells is not 
known. 
3.5.1 Histone Modification 
Histones facilitate the packaging of DNA and influence the accessibility to DNA 
by transcription regulators. Typically, acetylated histone lysines are associated with active 
chromatin, whereas some methylated histones mark repressed chromatin. Profound 
changes in histone modification pattern in the pluripotent (and many other) genes upon 
reprogramming of differentiated cell to iPSC was revealed by Chromatin-
immunoprecipitation sequencing (ChIP-Seq) (Mikkelsen et al, 2008). Cancer cells also 
exhibit a global loss of H4 acetylation and trimethylation (Fraga et al, 2005). Histone 
modification aberrations in cancer cells result in abnormal gene expression, cell cycle 
checkpoint instability, and impaired DNA repair (reviewed in (Fullgrabe et al, 2011)). 
Since these aberrations are also of great concerns in cell biomanufacturing, a better 
understanding of histone modification in cell line generation and over long-term cultivation 
is important. 
3.5.2 ncRNA 
A surprise finding of the ENCODE project is the extensive role played by non-
coding RNAs (ncRNA). Although only 2-3% of the genomes encodes for proteins, (i.e., 
are exons), about 80% of the genome is actively transcribed (Bernstein et al, 2012). While 
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there are many kinds of non-coding RNA (ncRNA), we will highlight micro RNA 
(miRNA) and long non-coding RNA (lncRNA).  
miRNA are 22 nt long oligonucleotides that associate with the 3’-UTR of its target 
protein coding genes and inhibit their translation. miRNAs are “global” regulators - one 
miRNA affects many different transcripts. In cancer, miRNAs can be tumor suppressing 
(e.g., Let-7 down-regulation increases Ras oncogene expression) or oncogenic (reviewed 
in (Zhang et al, 2007)). Deep sequencing has been used to identify CHO miRNAs (Hackl 
et al, 2011; Hammond et al, 2012; Johnson et al, 2011), and more recently, piRNAs (Gerstl 
et al, 2013). CHO miRNA profiling shows the diversity of expression in different culture 
phases (exponential or stationary) (Hernandez Bort et al, 2012), growth characteristics 
(Hackl et al, 2014), conditions such as temperature shift (Barron et al, 2011; Gammell et 
al, 2007) or nutrient stress (Druz et al, 2011). miRNAs have been reported to delay 
apoptosis and improve culture performance (Druz et al, 2013; Lim et al, 2006). 
lncRNAs (> 200 bp) are usually expressed at lower levels than mRNAs. While a 
very large fraction of protein coding mRNAs are expressed in all cell types, many lncRNAs 
are expressed only in a few cell types. They are conserved but seem to evolve faster than 
protein-coding regions. Recent studies have indicated a wide range of functions for 
lncRNAs from regulation of gene expression and splicing to imprinting (Derrien et al, 
2012). The role of lncRNA has not been reported in cells used in biomanufacturing.  
3.6 Transcriptome as a Guide for Cell Engineering 
An aim of establishing a hyper-productivity gene set is to devise a highly efficient 
transcriptome-based cell line development process (Vishwanathan et al, 2013). To achieve 
a high level of predictability, a very large sample set will be required due to the high 
dimensionality of the transcriptome data involved. The samples for such studies will likely 
include cells in the course of transiting from non- or low-producing cells to the final high 
producing cells. Because of the quantities of cells needed for transcriptome analysis, the 
cell samples that have been studied in cell line development all had undergone further cell 
expansion and passed the transient stage of being transformed to become a high producer. 
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Using microfluidic based RNA-Seq or single-cell transcriptomics (Tang et al, 2009), one 
will able to discern the transcriptome dynamics during the transformation of host cells to 
hyper producers. 
Transcriptomics may provide insights into cell line screening for specific gene 
expression levels. Mammals often have different isoforms of the same enzymes that are 
expressed differently in different tissues to serve various physiological needs. Those 
isozymes often have different catalytic characteristics and are subjected to different 
regulations. Cells from different tissues, differentiation and oncogenic transformation 
states express different isoforms. Different clones of the same cell line, especially those 
under extensive selection as seen in cell line development for biopharmaceutical 
production, express different isoforms at different proportions. The role of isozyme 
variation on the wide range of different behaviors seen in various producing cell lines is 
not yet studied. They may account for the different metabolic characteristics and the 
different glycosylation patterns seen in different production lines.  A transcriptome-
assisted cell line development can, possibly lead to more robust bioprocess development 
and a better profile prediction of glycosylation or other post-translational modifications. 
One can envision screening for clones that express fucosylation enzymes at low levels to 
minimize fucosylated glycans in IgG production for applications relying on antibody 
dependent cellular cytotoxicity (ADCC) (Niwa et al, 2004; Shields et al, 2002; Shinkawa 
et al, 2003). In short, the application of transcriptome for biopharmaceutical production 
will extend from enhancing the productivity to betterment of process robustness as well as 
product quality and consistency.  
With the increased use of transcriptomic tools in cell culture bioprocessing, one 
will be able to identify more potential targets for cell engineering to enhance process and 
product characteristics. The advances in genome engineering in the past few years, 
including zinc finger nuclease (ZFN), transcriptional activator like effector nuclease 
(TALEN) and CRISPR/Cas9 (reviewed in (Gaj et al, 2013)), will facilitate the 
transformation of insights from transcriptome analysis to tangible benefits for 
biopharmaceutical production. ZFN has been applied in CHO cells to create homozygous 
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deletion of the dhfr gene (dhfr-/-) (Santiago et al, 2008), knockouts of fut8 (Malphettes et 
al, 2010), mgat1 (Sealover et al, 2013), pro-apoptotic genes bak and bax (Cost et al, 2010) 
and triple bi-allelic knockout of dhfr, fut8 and glul (Liu et al, 2010). 
3.7 Conclusion 
Transcriptomic studies in conjunction with genome engineering tools have greatly 
facilitated the development of cell lines for biopharmaceutical production. Microarray and 
RNA-Seq tools are used increasingly for revealing dynamics and hyper-productivity trait 
in these cells. Exploration of the epigenetic space will lead to deeper understanding of 
transcriptome regulation affecting the cells’ productivity and stability. With the increasing 
accessibility and affordability of transcriptomic tools and genomic resources, we can 
anticipate an increased interest in using such tools for advancement of the 
biopharmaceutical industry. 
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Chapter 4: Insights from the Chinese hamster and CHO cell 
transcriptomes 
4.1 Context statement 
This chapter is attempt to create a repertoire of transcriptome sequence and 
expression data for CHO cells. This data will be useful in providing estimates of enzyme 
expression levels for systems analysis approaches. Systems approaches aid in painting a 
holistic picture of the cells’ state and also help predict their response to different 
environments. This enables a rational approach to manipulate cellular behavior and 
enhance their performance for protein production. 
Parts of this work are a results of several collaborations and contributions from 
previous students. Historical RNA sequencing data from Sanger, 454 and Illumina 
technologies were generated by Katie F. Wlaschin, Cornelia T. Bengea and Nitya M. Jacob, 
respectively. To the best of my knowledge, earlier versions of the transcriptome assembly 
were constructed by KFW, followed by NMJ with assistance from Kathryn C. Johnson. 
Terk Shuen Lee and NMJ annotated the transcriptome assembly used in this section. Even 
though the latest version of the transcriptome assembly is described in Chapter 7, this 
assembly was not available to use at the time of writing this manuscript. I collected the 
data and performed the analysis described in this chapter. I have retained only those 
sections of work to which I contributed significantly. 
4.2 Summary 
Systems approaches towards understanding cellular processes have gained 
popularity in past few years. Especially for CHO cells, a major biotechnology resource, the 
rich genome and transcriptome information has provided great impetus to such systems-
based approaches. Approaches such as modelling the central carbon metabolism or the 
glycosylation pathway or even building genome-scale models, need estimates for gene 
expression levels in CHO cell lines to make the models realistic. Our work attempts to 
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create such a resource in which the range of expression levels for many genes in several 
different CHO cell lines along with the expression Chinese hamster tissues was collected. 
This rich information revealed genes that are highly variable in gene expression levels 
across the CHO cell lines surveyed. Such genes, especially those involved in the energy 
metabolism and glycosylation are highly relevant for bioprocessing. The comparison of 
expression levels in CHO cells to that in Chinese hamster tissues, we find that the 
preference of CHO cells for glycolytic isozymes corresponding to high glycolytic flux. The 
isozyme expression profile in CHO cells is more similar to brain than liver, and also has a 
striking similarity to the expression pattern in ovary tissue. A few of the variable genes in 
glycosylation belonged to the ER glycan processing pathways, Golgi mannosidases and a 
few sugar transferases. Potential implications of the variability in gene expression is 
discussed. 
4.3 Introduction 
Cell lines derived from Chinese hamster ovary (CHO) cells are widely used for the 
production of recombinant protein therapeutics (Aggarwal, 2014; Kantardjieff & Zhou, 
2014). To generate those recombinant protein producing cell lines, transgenes are 
introduced into a host CHO cell line, such as CHO K1 or CHO DG44, and allowed to 
integrate into the host chromosome. Subsequent amplification increases the copy number 
of the transgene and the level of product formation. Finally, clones of cells are isolated for 
the assessment of their productivity, and the production cell lines are selected after further 
characterization. For over three decades, the process of developing the production cell lines 
for a given product has been relatively empirical. To enhance our physiological 
understanding of cell line development, many have resorted to transcriptome based global 
survey of producing cell lines and production processes (Kantardjieff et al, 2010a; Korke 
et al, 2004; Seth et al, 2005; Seth et al, 2007b). EST sequencing projects were also initiated 
since a decade ago aiming to develop annotated EST sequences and expression microarrays 
for this economically important species (Becker et al, 2011; Birzele et al, 2010; Jacob et 
al, 2010; Rupp et al, 2014; Wlaschin et al, 2005).  
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The rapid advances in DNA sequencing technology in the past decade transformed 
biomedical research and imparted very notable impact to bioprocess technology. Following 
the de novo sequencing of the genomes of Chinese hamster and CHO cell lines (Lewis et 
al, 2013; Xu et al, 2011) and supplementary chromosomal information (Brinkrolf et al, 
2013), perhaps dozens of industrial cell lines have been sequenced.  The new generation of 
high throughput DNA sequencing technologies have also made direct sequencing of 
transcripts, or RNA-seq, readily affordable and applicable to cell line and process 
investigation (Birzele et al, 2010; Johnson et al, 2013). Over the past decade, through a 
number of stages of EST sequencing efforts, started with Sanger sequencing, then 454 
technology and finally Illumina sequencing, we have accumulated a data set that has a 
broad range of gene coverage. We have assembled those sequences into contigs and 
annotated using the homology to mouse and human. With EST and genome sequence data 
we can also expect increasing applications of proteomic studies on CHO cells since the 
peptide sequences identified in mass spectrometry can now be validated through sequences 
translated from EST or genomic data.   
The post genomic era in cellular bioprocessing research and development will 
increasingly adopt a systems approach, integrating genomic, transcriptomic, proteomic and 
metabolomics data. The recently available Chinese hamster and CHO genomes are likely 
to play an important role in genome editing for improving protein quality (reviewed in 
(Baik & Lee, 2014; Steentoft et al, 2014)). Also likely to play an increasing important role 
are system-wide cellular models, as the complexity of the cellular system will require the 
aid of mathematical formulation of biochemical and regulatory networks to facilitate our 
understanding of cellular behavior. In the analysis of the glycosylation pattern of 
glycoproteins, modeling has been employed to reveal possible alterations under different 
environmental constrains (Hossler et al, 2007; Jimenez del Val et al, 2011; Krambeck & 
Betenbaugh, 2005). Using a mathematic model of energy metabolism in mammals it was 
shown that different combinations of isozymes in glycolysis give rise to very different flux 
behaviors in glycolysis; with the high flux behavior being the hallmarks of cancer cells 
(and fast growing cell lines like CHO cells). Glycosylation is a key attribute to the quality 
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of therapeutic proteins (reviewed in (Gramer, 2014; Jefferis, 2009)).  The metabolic 
behavior of cells in fed batch cultures has been reported to greatly influence the process 
outcome (Burleigh et al, 2011; Chee Furng Wong et al, 2005; Ha & Lee, 2014; Liu et al, 
2014; McAtee et al, 2014; Nyberg et al, 1999; Seo et al, 2014). A systems biotechnology 
approach employing models that describe various cellular dynamics, will greatly enhance 
our ability to modulate the glycosylation profile of therapeutic proteins or to control 
cellular metabolism for increased process robustness. 
In developing a mechanistic model and in undertaking a systems approach, one 
frequently encountered hurdle is the estimation of the abundance level of the involved 
proteins (enzymes, transporters, binding proteins etc.). When multiple isoforms are 
involved in a reaction step, it is required to identify the isozymes expressed in the cell type 
to be studied, and their abundance levels. Given that the makeup of isozymes in a pathway 
and the level of enzymes in a network affects the behavior of biochemical systems 
profoundly, an evidence (or experimental data) based estimate of the expression levels of 
those key proteins will help in establishing systems tools for CHO cells. 
Herein we compiled the transcript expression data from RNAseq and DNA 
microarray studies on the genes in a number of pathways in CHO cells lines to allow for 
an order-of-magnitude estimate of their corresponding protein levels. We highlighted their 
characteristic isoform expression by comparing their expression levels to liver and brain 
tissues. The compiled data shows a high degree of variability of gene expression levels 
among different cell lines. Such variability may contribute to the phenotypic variability 
among different cell lines or cell clones. Another possible source of variability in cellular 
response in culture is mutation, especially in the gene coding region. Cells in culture may 
accumulate mutations in the population. CHO cells have been cultured extensively since 
their isolation decades ago (Puck et al, 1958; Tijo & Puck, 1958). The RNAseq data 
covered a large number of genes at the transcript level to very high depth. Sequence 
variants, even at low levels, can thus be detected. We thus also analyzed the frequency of 
sequence variants among the seven cell lines for which RNA-seq data are available. 
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4.4 Materials and methods 
4.4.1 Source of Transcripts and EST Sequencing 
Complementary DNA (cDNA) libraries from Chinese hamster tissues and different 
CHO cell lines were constructed for sequencing using 454 and Illumina sequencing 
technologies. The average read length of 454 sequencing was 210 bp and for Illumina 
sequencing was 90 bp. A total of 40 Gbp of sequencing data was used in this study 
(Appendix Table 0-3). 
4.4.2 De novo Assembly of CHO Transcriptome 
The sequencing data was supplemented with Sanger sequencing reads reported 
previously (Jacob et al, 2010; Wlaschin et al, 2005). The redundant reads were removed 
by mapping to the assembly of the Sanger reads. Using a combination of assemblers like 
Velvet (Zerbino & Birney, 2008) and MIRA (Chevreux et al, 1999) to assemble the diverse 
nature of sequencing reads, Illumina and 454, respectively. We therefore used Phrap, a 
long read assembler, to integrate these contigs together to obtain longer sequences of 
transcripts. The final CHO EST collection consists of 194,450 sequences, with a median 
length close to 600 bp (Figure 0-7).  
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Figure 0-7: Chinese hamster and CHO transcriptome assembly. Final transcriptome 
assembly statistics-distribution of length of contigs. Inset shows the contig length 
distribution for the contigs greater than 1000 bp. Table shows more detailed 
statistics. 
4.4.3 Annotation of the CHO Transcriptome 
Functional annotation of the assembled CHO ESTs was based on the identification 
of orthologs in closely related species.  We employed a tier-based annotation strategy and 
used several public databases for this process, including ENSEMBL (Mouse, Rat, Human) 
(www.ensembl.org), FANTOM3 (Carninci et al, 2005), NONCODE and GenBank. 
Repeat-masked ESTs were first aligned to ENSEMBL Mouse, FANTOM3, ENSEMBL 
Rat, ENSEMBL Human and NONCODE (Figure 0-8) using NCBI BLAST. Those that did 
not align to any sequence in these databases were searched against the GenBank and 
RefSeq nucleotide repositories. The details of the pipeline are described in Chapter 7.1. 
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Figure 0-8: Transcriptome annotation schema showing homology-based annotation 
strategy. The annotation was divided into tiers based on the strength of the 
annotation. 
Finally, any transcripts which could not be annotated via this pipeline were 
searched for the presence of open reading frames and protein motifs from the PFAM 
database. 
4.4.4 RNA-Seq based quantification of gene expression 
The transcriptome sequencing data from six cell lines and two tissues were mapped 
to the annotated transcriptome using Bowtie software (Langmead et al, 2009) allowing for 
3 mismatches per 90 bp read. The number of reads mapping to a contig were summed up 
to generate counts for each contig. The counts were then normalized across nine libraries 
to adjust the expression values for variability in sequencing depth using the upper quantile 
normalization procedure (Bullard et al, 2010). The upper quantile normalized values were 
further adjusted for variability in contig lengths. For each Ensembl-annotated gene, the 
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contig with the maximum number of reads mapped was considered representative of that 
gene for further analysis. 
4.4.5 Microarray 
Based on the assembled and annotated transcriptome, a microarray was constructed 
using the NimbleGen platform.(Jacob, 2011). Liver, brain and ovary tissues and parental 
CHO cell lines K1, DXB11 and DG44 along with 6 recombinant cell lines (four derived 
from DXB11, two from DG44). Three of these produced IgG, two produced a TNF-alpha 
Fc fusion protein derived from DXB11 and one remaining expressed only DHFR gene. 
Three of these lines were additionally treated with methotrexate, one was treated with 2 
mM sodium butyrate for 24 hr prior to sourcing the RNA. All RNA samples were taken 
from cells at exponential growth stage, except one was in late stage. A total of 14 samples 
from cell lines in addition to three from Chinese hamster tissues were used for RNA 
extraction (Appendix Table 0-3). RNA was extracted from samples using the RNeasy Mini 
kit (Qiagen) using standard manufacturer-recommended protocols. cDNA was synthesized 
from the samples, labeled, and hybridized to the custom microarray. Data obtained was 
linearly normalized to a mean expression value of 500.  
4.4.6 Hierarchical clustering 
The linear normalized data was clustered using UPGMA (un-weighted average) 
clustering method in Spotfire DecisionSite (TIBCO, Somerville, MA). The Euclidean 
distance metric was used to estimate the inter-cluster distance. 
4.5 Results 
4.5.1 The CHO Transcriptome 
We have performed RNAseq on the mRNA samples from liver and brain tissues of 
Chinese hamster and nine CHO cell lines, assembled them into contigs (see Materials and 
Methods, Figure 0-7) and subsequently annotated them based on homology to mouse and 
human sequences (Figure 0-8). Approximately half of the EST contigs were annotated 
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using the two mouse databases (ENSEMBL Mouse, FANTOM3) with a stringent E-value 
cutoff of 1e-25.  Furthermore, another 20% of the total sequences could be confidently 
annotated against the other databases.  When the E-value cut off was relaxed to 1e-4, a 
further 27% of the ESTs in our collection could be assigned annotation. Overall, 63% of 
the sequences were assigned tier 1 annotation, of which ~70% have ENSEMBL mouse 
annotation (Figure 0-9A). 
 
Figure 0-9: (A) Distribution of contig annotations among the reference databases. (B) 
Coverage of genes in major pathways. 
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Comparing the EST collection to the 22,036 Chinese hamster/CHO sequences 
present in RefSeq, 77% of the RefSeq sequences are represented with an E-value < 1e-22.  
The sequences are covered by 77,244 out of 194,450 EST contigs in our collection. The 
coverage of major pathways was assessed. The list of genes in each pathways was obtained 
from the Kyoto Encyclopedia of Genes and Genomes (KEGG) database. Most of the 
pathways that are relevant in the context of bioprocessing, such as N-glycosylation, energy 
metabolism glycolysis, tricarboxylic acid cycle or apoptosis, are almost completely 
covered. A few pathways involved in signaling, MAPK pathway, phosphatidylinositol 
pathway have a larger number of genes not yet assembled or annotated. Other pathways 
with lower coverage are from the taste transduction pathway and olfactory transduction 
pathways (Figure 0-9B).  
4.5.2 Comparative Analysis Of Gene Expression Between Chinese Hamster Tissue 
and CHO Cell Lines 
 
 
Figure 0-10: Distribution of expression levels in (A) RNA-seq and (B) Microarray. 
Arrows indicate 25%, 50%, 75% and 90% of the data from the cumulative 
distribution. 
The annotated transcriptome sequences were then used as a reference for 
quantification of the expression levels of genes in Chinese hamster liver, brain and that of 
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the six cell lines using RNA-Seq reads. Using the microarray constructed with the 
assembled contigs, the expression levels of genes in major pathways for fourteen samples 
consisting of nine cell lines under different conditions was assessed (Appendix Table 0-3). 
The use of these rather diverse samples was intended to give a representative view of the 
range of transcript level for genes that are relevant for bioprocessing. To give a context of 
relative expression levels the distributions of RPKM value and microarray intensity value 
are shown in Figure 0-10. The values for each quartile, and top 10% are also marked in the 
graph. In the section below we will first compare the expression level of enzymes in energy 
metabolism in CHO cells and tissues. We will next describe the divergence of transcript 
levels among CHO cells in other pathways bioprocess significance. 
4.5.2.1 Glycolysis Enzymes 
The transcript level of enzymes in glycolysis, in liver and brain tissues as well as 
the average of all cell lines as determined from RNA-seq are shown in Figure 0-11A. In 
this study RNA-seq was not performed on RNA sample of Chinese hamster ovary. 
However, we performed microarray transcriptome analysis on ovary tissue. The transcript 
expression levels of glycolysis genes of ovary tissue along with three CHO cell lines are 
shown in Figure 0-12. Several enzymes in glycolysis, hexokinase (HK), 
phosphofructokinase (PFK1), 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 
(PFKFB), enolase (Eno), pyruvate kinase (PK) and lactate dehydrogenase (LDH), have 
isoforms that have different kinetic behaviors and are subject to different allosteric 
regulations. The combination of isozymes expressed in different tissues gives each tissue 
its metabolic characteristics.  
The dynamic range of transcript levels of glycolysis genes spans over 30 fold in 
brain, liver and CHO cells. As is well known GAPDH is the highest expressed in all cells 
and tissues. In fact, it is among the top 1 % highest transcripts in every tissue and cell line 
surveyed. In liver adolase (aldo) and fructose bisphosphate phosphatase (FBP) are also 
expressed at very high levels, approaching that of GAPDH. In all other samples, a group 
of enzymes are expressed at levels of 1/5 to 1/10 of GAPDH, including enolase, pyruvate 
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Figure 0-11: Glycolysis gene expression levels from (A) RNA-Seq expression levels of cell line average, liver and brain. The bar 
indicates the range of expression in cell line. (B) Box-plot of microarray expression data for 14 cell line samples. 
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kinase pfk, pgk, pgm, tpi and ldh. Glucose transporter and glucose-phosphate isomerase 
(gpi) levels in brain and cell lines are lower than all other enzymes. In liver, these two 
genes are expressed at higher levels. Pfkfb, being an enzyme playing primarily a regulator 
role, has a wide range of expression levels in different samples. 
 
Figure 0-12: Expression levels of glycolysis enzymes in parental CHO cell lines 
compared to ovary expression level measured by microarray. 
As is expected the pattern of isozyme expression in CHO cells is very distinct for 
tissues. Four isoforms involved in gluconeogenesis, glucokinase (gck), glucose 6-
phosphatase (g6pc), phophoenolpyruvate carboxykinase (PCK) and pyruvate carboxylase 
(PCX) are expressed at high levels only in liver. Liver also expresses liver isoform of 
pyruvate kinase (pkl) and pfkfb1 almost exclusively (the other isoforms are expressed at 
least ten times lower level), however these liver isoforms are also expressed in brain and 
CHO cell as minor isoforms, Pfkfb1 is a bifunctoinal enzyme that catalyzes the formation 
of fructose 2,6-bisphophate from fructose 6-phosphate (the kinase activity) and the reverse 
reaction of hydrolysis of f26p to f6p (phosphatase) has a higher kinase to phosphatase 
activity. The high expression level of pfkfb1 in liver gives it the capability of rapidly 
changing glycolysis flux, even to revert it to gluconeogenesis.  
Ldhb is uniquely expressed in brain. Brain expresses the platelet form of 
phosphofructokinase (pfkp), while liver and CHO expressed predominantly the muscle and 
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liver forms (pfkm and pfkl). Pfkl and pfkm are subjected to activation by fructose-1,6-
bisphosphate, however, this interaction is almost absent for pfkp. CHO cells and liver have 
high levels of pfkm/pfkl. They thus have a high glycolytic rate as a result of F16P 
activation. Hexokinase isozymes, hk1 and hk2, are highly expressed in CHO cell lines and 
brain. Both hk1 and hk2 have a low Km and have the ability to physically bind to the outer 
membrane of mitochondria. This association with mitochondria confers hk1 and h2 direct 
access to ATP generated by mitochondria and provide driving force for high rate of 
glycolysis as seen in both brain and CHO cells.  
Overall the isoenzyme pattern of CHO cells is closer to brain than to liver. Notable 
differences between CHO cell and brain are ldh (ldha isoform in CHO cell while ldhb in 
brain) and pfk (pfkl in CHO cell and pfkp/pfkm in brain). Interestingly from the microarray 
data the isozyme expression pattern between CHO cell line and ovary are rather similar 
except that ovary also expresses Eno3 (Figure 0-12). Pkm1 and pkm2 are alternatively 
spliced forms differing in only one exon, originating from the pkm gene, with a difference 
in 23 amino acids. Pkm2 is activated by fructose-1,6-bisphosphate, but not pkm1. Pkm1 is 
expressed in majority of adult tissues, while pkm2 is restricted to embryonic tissues and 
transformed cells. CHO cells express pkm2 as the dominant isoform. The microarray data 
show that ovary express pkm also, however, the microarray probe design does not allow 
for differentiation of pkm1 and pkm2.  
4.5.3 Variability of transcriptome profiles among cell lines 
4.5.3.1 Glycolysis genes 
To examine the variability of the expression level of genes of glycolysis in different 
cell lines, a box plot of the transcript level obtained from microarray on all fourteen cell 
lines are shown in Figure 0-11B. All the cell lines surveyed express the same dominant 
isoforms of the glycolysis isozymes. However the transcript level of individual enzymes 
and the ratio of different isoforms of a given enzyme vary rather widely among cell lines. 
This is seen in enzymes which play major regulatory roles, such as pfkfb, pk, as well as in 
other enzymes. CHO cell lines often behave differently in their metabolic profile in terms 
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of their consumption of nutrients and production of metabolites. The variability of enzymes 
involved in glycolysis may play a role in the metabolic diversity. 
4.5.3.2 N-Glycosylation genes 
The glycosylation pattern of the therapeutic protein products produced by CHO 
cells is a defining parameter of product quality. The expression of glycosylation enzymes 
can impact on the glycosylation profile of the product proteins. We examined the transcript 
levels of about fifty N-glycosylation enzymes expressed in CHO cells as assayed with 
microarrays in fourteen samples (Figure 0-14). The pathway starts from adding the first 
two GlcNAc residues to the dolichol phosphate and growing by transferring mannose to 
form the initial oligosaccharide precursor (Man5GlcNAc2) in the cytosolic side of the ER 
membrane. This is followed by flipping the oligosaccharide into the ER lumen, and 
subsequent growth to 9-mannose (Man9Glc3GlcNAc2) oligosaccharide precursor. The Alg 
family of enzymes play key roles in the synthesis of the oligosaccharide backbone. The 
glycan precursor is transferred to nascent protein molecule and subsequently to Golgi 
apparatus for further glycoprocessing as N-linked glycan (Figure 0-13). The microarray 
intensity data indicates that most of the genes involved in the glycan precursor formation 
(Alg family and Dpm genes) are expressed at moderate levels (ranging from 200-2000 with 
a median intensity of 500 of all transcripts). The transcript levels are variable among cell 
lines, but not particularly varying over wide ranges compared to other genes. The 
Oligosaccharyl transferase (OST) complex consisting of stt3a, stt3b subunits, and 
associated protein tusc3 are involved in the transfer of the oligosaccharide to the nascent 
protein molecule. The enzymes involved in the glycan translocation to nascent proteins are 
all expressed at higher levels of about five fold higher than the Alg family proteins. Many 
of those enzymes also have a wide range of expression level (Figure 0-14).  
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Figure 0-13: Protein N-glycosylation pathway. The genes that are variable in 
expression level are indicated in red font on the pathway. 
Subsequently the glucose and mannose residues in the oligosaccharide are trimmed. 
The glucose trimming enzyme, Ganab, is also expressed at a rather high level, but not the 
mannose trimming α-(1,2)-mannosidases Man1a1, Man1a2, Man1b1 and Man1c1 (Figure 
0-14). Members of the mannosidase family have been reported to be among the 
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hyperproductivity gene set in the study of high producing cell lines (Charaniya et al, 2009). 
Some of those enzymes (Man1a2, Man1b1) have very wide range of transcript levels 
among cell lines, spreading over 10 fold. 
 
Figure 0-14: Expression levels of glycosylation enzymes in 14 cell lines represented as 
a box plot. Top panel are ER localized enzymes, and bottom panel has the Golgi 
localized enzymes. 
Most of the Golgi glycosyltransferases in CHO cells are expressed at levels 
comparable to those in brain or liver with three exceptions of beta-1,4-mannosyl-4-beta-
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N-acetylglucosaminyltransferase (Mgat3), and two sialyltransferases (St6gal1 and 
St6gal2). Mgat3 adds the bisecting GlcNAc to the oligosaccharide and showed extremely 
low expression in all the CHO cells (Figure 0-14). The presence bisecting GlcNAc 
enhances antibody dependent cellular cytotoxicity (ADCC) of recombinant 
immunoglobulin G and is potentially a desirable feature for some therapeutic antibodies.  
 
Figure 0-15: RNA-Seq expression levels of glycosylation genes for cell lines, and brain 
and liver tissues. The bar on the cell line (average of 6 samples) represents the range 
of expression. 
The α-(2,6)-sialyltransferase genes St6gal1 and St6gal2 show almost no expression 
in CHO cells, but St6gal1 is very at a very high level in liver (Figure 0-15). In contrast, the 
α-(2,3)-sialyltransferase genes (St3gal family) are highly expressed in CHO, liver and brain 
tissues. This transcript pattern is reflected in the low 2,6-sialyl and high 2,3-sialyl glycan 
content in recombinant proteins produced in CHO cells. St3gal1 is the dominant α-(2,3)-
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sialyltransferase (Figure 0-15), however, its expression level is highly variable, spanning 
over five fold, from a moderately high level (intensity 2000) to very high level (intensity 
almost 12000). 
The expression level of Fut8 in CHO cells, in the range of moderate level of 500-
1000, is higher than that in liver Figure 0-15. Lower expression of Fut8 has been shown to 
correlate with increased recombinant IgG therapeutic performance.  
4.5.3.3 Heritability of transcriptome signatures 
The transcript profiles of all cell lines and tissues obtained from RNA-seq and from 
microarrays were subjected to hierarchical clustering using the Unweighted Pair Group 
Method with Arithmetic Mean (UPGMA) algorithm. As can be seen in Figure 0-16, cell 
lines from the same lineage or derived from the same parental source were clustered 
together, using both microarray data and the RNAseq data. With microarray data cell lines 
which originated from the same parental lineage also cluster together; those derived from 
DG44 formed a cluster in spite of their having been subjected to highly stressed conditions 
of transgene amplification as in the cell lines. One DG44-derived recombinant cell line did 
not cluster together along with its group. One of the DXB11-derived cell lines that was 
treated with methotrexate, also did not cluster with the DXB11 cluster. At a higher level, 
the cell lines are clustered together with ovary tissue, forming a distinct group from brain 
and liver.   
In a separate study in our lab, the SNVs that have sufficient depth of coverage in 
all cell line libraries were also analyzed for tracing cell lineage. The resulting tree grouped 
cell lines derived from the same parent together. Cell lines derived from the same parent 
retain the common variant markers in their population. It is interesting that both the 
transcriptomes, and the profile of transcript expression levels of all genes, and nucleotide 
variants allowed for tracing of lineage of cell lines. 
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Figure 0-16: Hierarchical clustering of expression data from (A) RNA-seq samples 
and (B) microarray samples. 
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4.6 Discussion  
Since the beginning of transcriptomic exploration in CHO cells a decade ago an 
increasingly large size of transcriptomic data has been accumulating. In the past few years 
the pace of accumulation has greatly accelerated due to the rapidly decreasing cost of high 
throughput DNA sequencing. The RNA-seq data that were acquired in our previous studies 
were first assembled and annotated before the transcript levels for different genes or contigs 
could be obtained. The annotated ESTs were then used to construct a transcription gene 
expression microarray for this study. The two transcriptome surveying methods employed 
are complementary. RNA-seq allows for higher accuracy of transcript identification by 
mapping the reads to the entire transcript. We thus employed RNA-seq data to identify 
isozymes, even those which are alternatively spliced, expressed in CHO cells. We then take 
advantage of the broad gene coverage of microarray to obtain a comprehensive gene 
expression data on a diverse cell lines economically. 
The global nature of transcriptome has demanded a more complex and systematic 
means of transforming the data into physiological information. Increasingly the 
understanding of cell’s behavior is hinged upon the development of models for systematic 
analysis. Notable examples are the metabolism and glycosylation pattern in the production 
of recombinant proteins. The stability behavior of energy metabolism and the flux 
distribution in glycan biosynthesis cannot be prescribed without resorting to a systems 
approach. Important to establishing a descriptive model, is the estimation of the enzyme or 
other protein levels for model analysis. Many kinetic constants can be measured, or 
obtained from literature, or estimated from reactions of similar nature. However, protein 
levels for a biochemical reaction system often cannot be easily assessed. With the 
transcriptome data compiled from RNAseq and from microarrays we identified the 
isozymes and their range of expression in pathways. These values can be used as a first 
order estimate of the relative protein levels for systems analysis. In the above section we 
described glycolysis and glycosylation pathways. Data of other major pathways important 
to CHO cell physiology are given as supplementary data.  
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The composition of isozymes in glycolysis has a profound effect on the metabolism 
of tissues and cells. It was shown recently that, depending on make-up of isozymes, cells 
may reside in a high flux or a low flux state at the given glucose concentration,(Mulukutla, 
2012; Mulukutla et al, 2012). The glycolytic isozyme profile of CHO is closer to brain than 
to liver. It is not surprising that pkm2 is the dominating isoform of PK. What is unexpected 
is the very high level of the isoform and the wide margin of expression levels among 
different cell lines. Overall the variability of gene expression level in glycolysis is high. 
Pfkfb, that plays an important role in regulating glycolysis flux, also shows variable 
expression among cell lines. Different isozymes of pfkfb exert different stimulatory effect 
on glycolysis flux, while different levels of the same isoforms of pfkfb affect the speed at 
which metabolism responds to changing environment especially glucose levels. The 
variability in the expression levels of pkm2 and pfkfb may contribute to the diversity in 
metabolism among cell lines.  
Most glycosylation enzymes are expressed at levels comparable to native tissue 
expression level. However, the expression levels of α-2,6-sialyltransferases St6gal1 and 
St6gal2, and bisecting GlcNAc transferase Mgat3 are at lower levels than native tissue. 
Interestingly, the region upstream of the St6gal1 gene has four CpG islands. On 
interrogation of the methylation status of the CpG islands, and found that most of those 
four CpG islands in CHO cells are methylated (unpublished work). In contrast, those in 
liver are not methylated. The methylation status is thus consistent with the transcript 
expression profile. It is thus possible that St6gal1 in CHO cells can be de-silenced to 
produce product proteins with sialic acid more similar to human form. Elimination of 
expression of Mgat5 can reduce the dimensions of the Golgi apparatus (Dong et al, 2014), 
suggesting that glycosyltransferases may have functions other than participating in the 
building of the glycan. 
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Figure 0-17: Long noncoding RNA expression levels among CHO cell lines. 
A number of non-coding RNA were among the transcripts profiled in RNA-seq and 
microarray assays. The roles of long ncRNA in regulating cellular physiology are only 
beginning to be revealed even in the better studied human (Derrien et al, 2012) and mouse. 
Only a few of transcript are annotated as ncRNA in our Chinese hamster transcriptome. 
Non coding RNAs adapt15 and adapt 33, that were earlier shown to be associated with 
oxidative stress response in hamster fibroblasts (Crawford et al, 1996a; Crawford et al, 
1996b; Wang et al, 1996; Wang et al, 2003), are found to be highly expressed in all CHO 
cells (Figure 0-17). Xist, a non-coding RNA that regulates X-chromosome inactivation for 
dosage compensation in mammalian females, is also found to be expressed significantly in 
CHO cells. Ntt (non-coding transcript in T cells), BC1, DISC2 (disrupted in schizophrenia 
2), BORG (BMP/OP-responsive gene), His-1 and Air (antisense Igf2r) are a few other non-
coding RNAs expressed in CHO cells. Apart from these, there are a lot of unannotated 
ncRNAs found to be expressed in CHO cells. What role those ncRNA may play in CHO 
cells is an area open for future investigation. 
The RNA Seq sequenced the transcripts to varying depth depending on the 
abundance level of each gene. While in genome sequencing the sequencing depth ranges 
from a few fold in depth for re-sequencing to 60-100 fold for de novo sequencing, the 
RNAseq performed in our study reach thousands to tens of thousands fold in depth for 
  58 
abundant genes. The RNAseq data can thus be exploited to examine the sequence diversity 
to a greater detail. The recombinant CHO cell lines have undergone selection, even 
transgene amplification and single cell cloning that at some point of their derivation refined 
each line’s clonality. When a population of cells undergo single cell cloning, the mutations 
accumulated in the population is potentially drastically trimmed in size. The cell lines we 
examined in RNAseq involves both parental cell lines as well as recombinant cell lines that 
were once cloned.  
In conclusion, an order of magnitude estimate of the gene expression levels in CHO 
cells will be a great aid in systems biology approaches. The systems biology experiments 
give a holistic understanding of the system. This will enable more rational process 
interventions and cell engineering efforts. The knowledge of the variation in gene 
expression, can be used for screening cell lines and to identify the host cell most suited to 
the product being produced. 
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Chapter 5: Transcriptome dynamics during cell line development in 
CHO cells 
5.1 Context statement 
Reproduced with permission from Vishwanathan, N., Le, H., Jacob, N. M., Tsao, Y.-S., 
Ng, S.-W., Loo, B., Liu, Z., Kantardjieff, A. and Hu, W.-S. (2014), Transcriptome 
dynamics of transgene amplification in Chinese hamster ovary cells. Biotechnol. Bioeng., 
111: 518–528. doi: 10.1002/bit.25117. 
License Number: 3392010734552 
© 2013 Wiley Periodicals, Inc. 
 
The cell line development process for creating a high producing cell line for 
recombinant protein production, is very time consuming and labor intensive. A study of 
the molecular changes in the cells during this process will enable us to rationally engineer 
or screen the cells which may lead to the shortening of the time scale for cell line 
development. This chapter presents such a global view of CHO cells transcriptome as they 
transition from non-secretory host cells to hyper secretors during the process of cell line 
development.  
This project was a collaborative effort between Merck & Co., Bioprocessing 
Technology Institute and University of Minnesota. YST carried out the experiments at 
Merck & co. The cell pellets were transported to the lab, where NMJ and HL carried out 
the RNA extraction. NV extracted the DNA. The RNA samples were shipped to 
Bioprocessing Technology Institute, where SN hybridized the samples to the microarray 
chip. NV and HL synthesized the cDNA and conducted the qRT-PCR studies for transcript 
expression quantification. NV conducted qRT-PCR for genomic DNA copy number 
quantification. The data from the fed batch cultures were analyzed by NV and HL. NV and 
HL conducted the all the data analysis for this manuscript. The text and figures for the 
manuscript was developed by NV and WSH. 
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5.2 Summary 
Dihydrofolate reductase (DHFR) system is used to amplify the product gene to 
multiple copies in Chinese Hamster Ovary (CHO) cells for generating cell lines which 
produce the recombinant protein at high levels. The physiological changes accompanying 
the transformation of the non-protein secreting host cells to a high producing cell line is 
not well characterized. We performed transcriptome analysis on CHO cells undergoing the 
selection and amplification process. A host CHO cell line was transfected with a vector 
containing genes encoding the mouse DHFR (mDHFR) and a recombinant human IgG 
(hIgG) and subjected to selection and amplification. Clones were isolated following 
selection and subcloned following amplification. Control cells were transfected with a 
control plasmid which did not have the hIgG genes. Although methotrexate (MTX) 
amplification increased the transcript level of the mDHFR significantly, its effect on both 
hIgG heavy and light chain genes was more modest. The subclones appeared to retain the 
transcriptome signatures of their parental clones, however, their productivity varied among 
those derived from the same clone. The transcript levels of hIgG transgenes of all subclones 
fall in a narrower range than the product titer, alluding to the role of many functional 
attributes, other than transgene transcript, on productivity. We cross examined gene 
functional class enrichment during selection and amplification as well as between high and 
low producers and discerned common features in them. We hypothesize that the role of 
amplification is not merely increasing transcript levels, but also enriching survivors which 
have developed the cellular machinery for secreting proteins, leading to an increased 
frequency of isolating high-producing clones. We put forward the possibility of assembling 
a hyper-productivity gene set through comparative transcriptome analysis of a wide range 
of samples. 
5.3 Introduction 
In the past quarter century, we have witnessed a two order of magnitude increase 
in product titer (Wurm, 2004). Critical to attaining a high productivity process is the 
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establishment of a high producing cell line which can secrete the product to a high level in 
a timely fashion. 
Many of the high producing CHO cell lines were obtained using the dihydrofolate 
reductase (DHFR)-based amplification system developed three decades ago. DHFR 
catalyzes the conversion of dihydrofolic acid to tetrahydrofolic acid, a precursor for the 
synthesis of glycine, thymidine phosphate, and purine. CHO cell lines, such as DG44 and 
DXB11, which are mutated to be deficient in DHFR activity, require supplementation of 
hypoxanthine and thymidine (HT-media) for growth. Upon co-introduction of the 
exogenous DHFR gene with the product transgene, cells that express the transgene can be 
selected in HT-deficient media (Urlaub & Chasin, 1980). By including in the medium a 
high level of methotrexate (MTX), a DHFR inhibitor, one can further select for cells which 
have elevated levels of DHFR. The selected cells typically have multiple copies of an 
approximately 100 kilo base region of the chromosomal region containing the DHFR gene 
locus (Kim et al, 2001; Kim & Lee, 1999; Milbrandt et al, 1981). This increased copy 
number of the DHFR gene sequence often increases its transcript and protein levels, 
enabling them to survive a high concentration of MTX. Since the product transgene is 
introduced along with the DHFR gene, the product gene is co-amplified with the DHFR 
gene, leading to an increase in the product gene copy number (Kaufman et al, 1983). 
Upon transgene introduction and amplification, parental CHO cells, which do not 
naturally secrete protein at an appreciable level, can be transformed into secretors. 
However, the resulting cells often exhibit a wide range of productivity (Jun et al, 2005; 
Kim et al, 2001; Kim et al, 1998a; Kim et al, 1998b). A screening process thus follows 
amplification to look for cells which secrete a high level of the product initially; and the 
selected clones are then subjected to more detailed characterization of production under 
process conditions. 
Despite its widespread use in cell line development over the last quarter century, 
the transgene amplification and selection of high producing cell lines are still not 
understood at a mechanistic level. With the arrival of transcriptome analysis and genomic 
tools, a global survey of the impact of gene amplification on cell line development is called 
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for. Herein, we report changes in transcriptome during the processes of selection and 
amplification and deliberate about the functional classes which may contribute to the 
hyper-productivity trait on a production cell line. 
5.4 Materials and Methods 
5.4.1 Cell Line Development 
5.4.1.1 Transfection and Selection 
CHO DUXB-11 cells were maintained at 37oC and 7.5% CO2 in the MEMα 
medium with ribonucleosides and deoxyribonucleosides (Gibco#12571) containing 10% 
v/v Characterized Fetal Bovine Serum (Hyclone#SH30071). The cells were grown to 80% 
confluence and transfected using the Lipofectamine reagent (Invitrogen, Carlsbad, CA) 
with 8 µg of an expression vector containing (1) hIgG heavy and light chain cDNAs driven 
by constitutive Cytomegalovirus (CMV) promoters, (2) hygromycin resistance marker 
under a Thymidine Kinase (TK) promoter and (3) mouse DHFR gene under a retroviral 
long terminal repeat (MMTV-LTR) promoter. In addition, a control transfection was 
performed using the backbone of the expression vector, but without the cDNA of hIgG 
heavy chain and hIgG light chain. 
Following transfection, the cells were sub-cloned in 96-well plates in the MEMα 
medium without ribonucleosides and deoxyribonucleosides (Gibco#12561) and 
supplemented with 10% v/v Dialyzed Fetal Bovine Serum (Hyclone#SH30079) and 400 
µg/mL hygromycin B. After three weeks, the supernatant of wells containing single-cell 
colonies was collected, and the hIgG concentration was measured using the enzyme-linked 
immunosorbent assay (ELISA). Three clones, with highest titers namely P1, P2 and P3, were 
selected for further analyses. A control cell line (C0) was also developed, by transfecting 
similar vectors with all selection marker, but without hIgG cDNA. 
5.4.1.2 Methotrexate Treatment and Subcloning 
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The three clones (P1, P2 and P3) and the control (C0) were expanded to about 40% 
confluence in T-75 flasks and further treated with 20 nM methotrexate (MTX) (Sigma 
Aldrich, St. Louis, MO) for 15 days.  The concentration of MTX was optimized by 
conducting a kill curve on the parental cells. Following MTX treatment, the cells were 
grown to 80% confluence for sample collection. After MTX treatment, the cell pools 
obtained from P1, P2, P3 and C0 were denoted as P1M, P2M, P3M and CM, respectively. Two 
biological replicates were used for MTX treatment from each clone. Cell samples for RNA 
extraction were collected for both biological replicates prior to and following MTX 
treatment. 
Following MTX treatment, the three hIgG producing cell lines P1, P2 and P3, were 
sub-cloned in 96-well plates using MEMα medium without ribonucleosides and 
deoxyribonucleosides (Gibco#12561)  and supplemented with 10% v/v Dialyzed Fetal 
Bovine Serum (Hyclone#SH30079) and 400 µg/mL hygromycin B. The antibody 
concentration in the supernatants of wells with single-cell colonies was measured using 
ELISA. Two sub-clones each derived from P1M and P2M and five sub-clones derived from 
P3M were selected for further study. 
5.4.1.3 Adaptation of Sub-clones to Suspension and Fedbatch Culture 
The sub-clones were adapted to growth in suspension in an in-house modified 
serum-free Excell ACF CHO medium (Sigma C5467) for two weeks by gradual serum 
reduction. The cells were then cultivated in fedbatch cultures at 70 mL scale maintained at 
37oC and 7.5% CO2 for 12 days with feeding performed at day 3 and day 6. Cell samples 
were collected during exponential growth phase (day 4) and stationary phase (day 7) for 
RNA extraction. 
5.4.2 RNA Extraction, cDNA Synthesis, and Hybridization 
Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA) following 
the manufacturer’s recommended protocols with on-column DNase I digestion to remove 
any genomic DNA. The quality of the extracted RNA was examined using the Agilent 
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RNA 6000 Nano chip. cDNA and labeled cRNA were prepared from the RNA extracted  
for hybridization onto an in-house Affymetrix microarray customized for CHO cells 
containing 61,223 probe sets representing 26,227 unique gene IDs and 14,657 unique 
Ensembl mouse genes. cRNA was synthesized from cDNA using the 3’-IVT Express kit 
(Affymetrix, Santa Clara, CA). Subsequent hybridization onto the custom microarray in 
the GeneChip Hybridization Oven 640 (Affymetrix, Santa Clara, CA) and processing was 
done using the GeneChip Fluidics Station 450 (Affymetrix, Santa Clara, CA).  
5.4.3 Microarray Data Processing and Analysis 
The raw image files were processed using the Expressionist software (GeneData, 
Basel, Switzerland) for preliminary data filtering. The Affymetrix MAS5 algorithm was 
used to estimate and correct for background and also to remove and mask defects. The data 
were then linearly scaled to a mean value of 500 per array. Probe sets with a detection p-
value ≤ 0.04 and an intensity ≥ 40 in at least one sample were retained for further analysis. 
Hierarchical clustering was performed using the UPGMA (un-weighted average) 
clustering method in Spotfire DecisionSite (TIBCO, Somerville, MA). Euclidean distance 
was used to represent the difference in gene expression of the samples under consideration. 
Significance Analysis of Microarray (SAM) (Tusher et al, 2001) was used to determine the 
statistical significance of differentially expressed genes. The differential expression of gene 
classes with related functions (known as gene sets) was analyzed using Gene Set 
Enrichment Analysis (GSEA) (Subramanian et al, 2005). 
  65 
 
Figure 0-18: Experimental design of selection, amplification, and sub-cloning. Host cells (H0) were transfected with rIgG 
heavy chain, light chain, mDHFR, and hpt (hygromycin phosphotransferase) genes, and selected in hygromycin and HT-minus 
media They were single cell cloned to give rise to three clones P1, P2 and P3. A control transfectant (C0) was developed by 
transfection of mDHFR and hpt genes into host cells (H0), and selected in the same media. Each of the three selected clones (P1, 
P2, and P3) along with the control transfectant (C0), were subjected to amplification using methotrexate for 15 days. Following 
MTX treatment, the samples for the three hIgG-producing clones was named P1M, P2M and P3M, respectively. The post-
amplification control sample was named CM. P1M, P2M and P3M were further sub-cloned to give rise to two (P11, P12), two (P21, 
P22), and five (P31-35) sub-clones, respectively. Each of these sub-clones were cultured in fedbatch mode and assayed for growth 
and titer. Samples for RNA extraction were collected from day 4 and day 7 of the fedbatch culture. 
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5.4.4 Quantitative Real Time PCR (qRT-PCR) 
qRT-PCR assay was conducted in triplicate using 1 µL of cDNA in a 12.5 μL 
reaction volume using the Brilliant II SYBR Green master mix (Agilent, Santa Clara, CA) 
on a MxPro3000P (Stratagene, Santa Clara, CA) machine using standard cycling 
conditions. hIgG heavy chain, hIgG light chain, mDHFR and beta actin (for normalization) 
were assayed using qRT-PCR. The primers used for the assay are listed in Table 0-1. 
5.4.5 DNA Extraction 
5.4.6 Quantification of DNA amplification by qRT-PCR  
5.5 Results 
5.5.1 Effect of Amplification Process on hIgG Titer and Transcript Level 
CHO host cells were transfected with hIgG heavy chain and light chain genes. In 
addition, a control transfection was carried out using a control plasmid derived from the 
same construct but without the hIgG genes. Following selection, three clones were obtained 
in 96 well-plates (P1, P2, and P3) (Figure 0-18). After further cultivation to expand the cells, 
these three clones were subjected to amplification using MTX. The resulting populations 
are denoted as P1M, P2M, and P3M, respectively. 
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Figure 0-19: Microarray intensity of hIgG upon selection and amplification. (A) 
Heavy chain upon selection. (B) Light chain upon selection. (C) Heavy chain upon 
amplification. (D) Light chain upon amplification. 
The transcript levels of both the hIgG heavy and light chain genes, after selection 
and prior to amplification, were rather high, on the order of 10,000 as compared to the 
mean intensity of 500 for the entire array. Upon amplification with MTX, the transcript 
levels of the hIgG heavy and light chains in P1, P2, and P3 increased moderately, from an 
average intensity value of 25,000 to 32,000 for the heavy chain and from an average value 
of 38,000 to 44,000 for the light chain (Figure 0-19). 
To quantify the effect of selection, the transcript level of mDHFR, hIgG heavy 
chain and light chain were also assayed using qRT-PCR (Figure 0-21). The transcript level 
of the reference gene beta-actin is shown as a dashed line (i.e., fold-change of 1). mDHFR 
was expressed at a moderate level upon selection, much lower than that of the reference, 
beta-actin. In contrast, the expression levels of the hIgG genes were significantly higher 
post-selection, in agreement with microarray results (Figure 0-19). 
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Figure 0-20: Quantification of copy number change of (A) mRNA and (B) DNA post 
amplification for the control cell line and each of the clones. R1 and R2 are 
biological replicates. 
The amplification process resulted in a 4- to 8-fold increase in mDHFR transcript, 
which however is still at a level lower than that of beta-actin. In contrast, only a modest 
change in the transcript level of the hIgG heavy chain and light chain was observed in all 
three clones P1, P2, and P3 after amplification. However, the hIgG genes were already 
expressed at higher levels than mDHFR gene, thus even a small fold increase would 
represent a large number of mRNA molecules (Figure 0-21). 
The extent of transgene amplification duplication after MTX amplification for the 
control clone and each clone and its derived pool is measured compared to its 
corresponding transcript level increase. After amplification with a moderate level of MTX, 
a small copy number increase was observed in six pools while two others did not have 
significant variation.  Overall, the extent of increase was higher for mDHFR than for hIgG 
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genes. The corresponding change in mRNA levels was much higher than the change in 
copy number of the transgenes, including in the pool that showed no copy number change 
(Figure 0-20). 
 
Figure 0-21: Expression level relative to beta-actin upon selection and amplification. 
(A) hIgG heavy chain. (B) rIgG light chain. (C) mDHFR for clones Control (), P1 
(), P2 () and P3 (). 
5.5.2 Characterization of Amplified Sub-clones 
A total of nine sub-clones were isolated from P1M, P2M, and P3M (two, two, and five 
sub-clones, respectively) and denoted as (P11, P12), (P21, P22), and (P31-35) for further 
analysis. Duplicate fedbatch cultures for each sub-clone were performed and their growth 
curves are shown in Figure 0-22. Samples from two time points at the exponential and 
stationary phases (approximately day 4 and 7, shown with dotted vertical lines) of each 
sub-clone were used for microarray study. mDHFR transcript level was measured by qRT-
PCR. 
Following MTX treatment and sub-cloning, a wide range of the antibody titer was 
seen among the sub-clones at the 96-well stage (Figure 0-23A). However, the hIgG 
concentration measured in the fedbatch cultures at day 4 and day 7 was not clearly 
correlated to those observed in 96-well plates (Figure 0-23B). Among the three high-titer 
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sub-clones, P12 showed a high productivity in fedbatch cultures while P21 and P22 did not 
exhibit high productivity as seen in 96-well culture. Two sub-clones, P34 and P35, which 
had a moderate productivity in the 96-well plate stage, continued to showed a moderate 
productivity in fedbatch cultures. Notably, two sub-clones, P33 and P31, which showed a 
low titer in 96-well plates, had a moderate productivity in fedbatch cultures. Overall, the 
final hIgG titer spread over a 4-fold range. A similarly wide span was also observed for 
specific productivity (Figure 0-23C). 
 
Figure 0-22: Viable cell density in the fed batch cultures of all the nine sub-clones 
(two replicates each). Replicate 1 is shown in solid line, and replicate 2 is shown in 
dotted line. Data points for each sub-clone are represented by the same symbol. (A) 
P11 () and P12 (). (B) P21 () and P22 (). (C) P31 () and P32 (). (D) P33 (), P34 
(), and P35 (). 
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Figure 0-23: hIgG titer in 96-well plate stage, hIgG titer levels in fedbatch culture, 
specific productivity in fedbatch culture, hIgG heavy chain, hIgG light chain, and 
mDHFR transcript levels in fedbatch culture are shown in panels (A), (B), (C), (D), 
(E) and (F), respectively. The solid bars represent day 4 and the dashed bars 
represent day 7 of fedbatch culture. The Pearson correlation coefficient (r) and 
normalized root mean square error (ε) for the relationship between the specific 
productivity and rIgG heavy chain expression, rIgG light chain expression, mDHFR 
expression, and light to heavy chain expression ratio for all the sub-clones in 
fedbatch culture are shown in (G), (H), (I) and (J), respectively. Data from day 4 is 
shown with black symbols and data from day 7 is shown with red symbols. 
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In contrast to the wide range of productivity, the transcript levels of the light chain 
and heavy chain hIgG fell into a relatively narrow range for all sub-clones (Figure 0-23D 
and 5E). The microarray intensities for the heavy and light chain genes spanned from 
19,000 to 34,600 and 38,200 to 48,400, respectively. The ratio of light chain to heavy chain 
transcript ranged from 1.2 to 2, a ratio that has been commonly observed (Schlatter et al. 
2005). The mDHFR transcript levels among different sub-clones spanned over nearly an 
8-fold range (Figure 0-23F). Compared to hIgG, the variability of the mDHFR transcript 
levels among different sub-clones was substantially larger. 
The transcript level of the hIgG heavy chain showed a positive correlation to 
specific productivity (𝑟 =  0.72) (Figure 0-23G). For the hIgG light chain, no apparent 
correlation between specific productivity and the transcript level was seen (𝑟 =  0.19) 
(Figure 0-23H). Surprisingly, the mDHFR transcript level was somewhat negatively 
correlated to specific productivity (𝑟 = –  0.59) (Figure 0-23I). The ratios of light chain 
and heavy chain transcripts were also examined, and a negative correlation was discerned 
(𝑟 = –  0.76) (Figure 0-23J). The root mean square errors (𝜀) are also shown (Figure 
0-23G-J). Except for mDHFR expression (𝜀 =  1.7), the expression trends do not deviate 
much from the fitted trend (𝜀 =  0.3 − 0.4). 
5.5.3 Overall Transcriptome Changes During Selection and Amplification 
The three clones and all nine sub-clones isolated were further analyzed for 
transcriptome profiling. We were constrained in both time and materials necessitating a 
trade-off between processing more samples with a small set of replicates and fewer samples 
with more replications for each sample. We opted for a larger number of clones while 
limiting the number of replicates. For the microarray assays, replicate cultures for all clones 
were performed. Replicate cultures were also performed for the sub-clones with maximum 
productivity derived from each clone; while for the rest of the sub-clones, only one of the 
replicate cultures was assayed. 
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Figure 0-24: Dendrogram from hierarchical clustering of microarray data 
5.5.3.1 Investigation of Clonal Variation 
Transcriptome data from the host cell and the derived clones and sub-clones (data 
from fed batch cultures) were clustered using hierarchical clustering (Figure 0-24). The 
clustering results indicate two major contributions. Among the host and clones, except for 
P3M, all the other clones clustered together, whereas the host cell and the unamplified 
control also clustered together. Among all the sub-clones isolated after amplification, those 
derived from the same clones clustered together. It suggests that significant clonal signature 
at the transcriptome level is carried forward to the offspring cells regardless of their 
productivity. 
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Table 0-2: Generation and enrichment of hyper-productivity gene sets comprising 
differentially expressed genes from different comparisons. 
Process Selection 
(S) 
Amplification 
(A) 
High vs. Low 
Producer 
(H) 
Logic 
[(
𝐏𝐢
𝐇𝟎
) 𝐍𝐎𝐓 (
𝐂𝟎
𝐇𝟎
)] [(
𝐏𝐢𝐌
𝐏𝐢
) 𝐍𝐎𝐓 (
𝐂𝐌
𝐂𝟎
)] [(
𝐇
𝐋
)
𝐃𝟒
𝐀𝐍𝐃 (
𝐇
𝐋
)
𝐃𝟕
] 
Criteria  
(
𝐏𝐢
𝐇𝟎
) : 𝐪 < 5; 
(
𝐂𝟎
𝐇𝟎
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𝐏𝟎
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𝐂𝐌
𝑪𝟎
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𝐇
𝐋
)
𝐃𝟒
: 𝐪 ≤ 𝟏𝟎; 
(
𝐇
𝐋
)
𝐃𝟕
: 𝐪 ≤ 𝟏𝟎 
Number of 
genes after 
filtering  
𝒏(𝑺) = 𝟏𝟗𝟗𝟔 𝒏(𝑨) = 𝟗𝟖𝟖 𝒏(𝑯) = 𝟑𝟒𝟗 
Hyper-productivity gene set enrichment 
 Set I Set II  
Criteria 𝑺⋂𝑯 𝑨⋂𝑯 - 
Number of 
genes after 
enrichment 
58 13 - 
 
5.5.3.2 Transcription Variation in Reference to Selection, Amplification, and 
Productivity 
In setting out to construct a gene set pertinent to hyper-productivity, we compared 
the transcriptome of various cells/clones/sub-clones before and after selection as well as 
before and after amplification (Table 0-2). The transcriptome of three groups of cells – the 
host (H0), the selected clones (P1, P2, P3), and the amplified clones (P1M, P2M, P3M) were 
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compared using Significance Analysis of Microarray (SAM) (Tusher et al, 2001). The 
same analysis was also performed on the selected (C0) and amplified control transfectant 
(CM). A q-value of < 5% was used as the criterion to identify differentially expressed genes 
among producing cells during selection (Pi vs. H0) and amplification (PiM vs. Pi). These 
sets of genes were considered responsive to either selection or amplification, but might not 
be directly related to the production of hIgG antibody. To further limit these gene sets to 
include only those which are likely to be related to hIgG production, we set out to identify 
genes which were not significantly differentially expressed in the control transfectant. A 
q-value criterion of > 10% was used to determine genes not differentially expressed 
significantly in the comparisons to the control (C0 vs. H0 and CM vs. C0).  
 
Figure 0-25: The division of high and low producing clones for comparative analysis 
is shown. (A) shows titer and (B) shows specific productivity of the subclones 
cultured in fedbatch mode. The dark bars correspond to the sub-clones that are 
classified as high producers, the white bars correspond to the sub-clones classified 
as low producers and the grey bars are sub-clones that were mid-producers. 
Various sets of genes which were differentially expressed in the producing cell 
comparison but not significantly differentially expressed in the control were identified: 
1996 genes (Set S) are specifically differentially expressed upon selection and 988 genes 
(Set A) are specifically differentially expressed during amplification. These genes have a 
high likelihood of being related to the production of hIgG in the course of selection and 
amplification. The genes which contribute to productivity in high-producing cells have a 
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high propensity to be in this group. However, not all of these genes are correlated to high 
productivity because the sub-clones derived from those three producers yielded both high 
and low product titers. 
To further deduce the set of genes which are pertinent to high productivity, we 
utilized the data which differentiate high- and low-producing cells. The sub-clones fall into 
three groups (high producers: P12, P34, P33, P35; middle producers: P31, P11; and low 
producers: P32, P21, P22) in terms of their titer (Figure 0-25A) and specific productivity 
(Figure 0-25B) observed in fedbatch cultures. The distinction between high and low 
producers was made such that the high producers show both high titer and high specific 
productivity. Four and three sub-clones were assigned into high producer and low producer 
groups respectively. Two sub-clones that do not have consistent pattern in their titer and 
specific productivity were not included in the high productivity gene set analysis. SAM 
was performed on fedbatch culture data of the sub-clones of high-productivity and low-
productivity groups. Genes differentially expressed between high- and low-producers in 
day 4 and day 7 of fedbatch cultures were identified. 349 genes were consistently 
differentially expressed in both day 4 and day 7 with a q-value of less than 10%; these 
genes were denoted as Set H. 
Genes that are common between Set S and Set H possibly represent the high 
productivity genes which attain their expression levels through selection (Set I). Those in 
the intersection of Set A and Set H are possibly related to hyper-productivity and are 
accorded in the amplification (Set II). A total of 58 and 13 genes are in those two gene sets, 
respectively. 
5.5.3.3 Functional Analysis of Differential Expression 
To understand the physiological functions possibly conferred by the changes in 
gene expression in the course of selection and amplification, Gene Set Enrichment Analysis 
(GSEA) (Subramanian et al, 2005) was performed on the set of data used for the 
identification of differentially expressed genes. The gene sets used for the analysis were 
obtained from the Molecular Signatures Database, Broad Institute (v2.5 MSigDB). The  
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Table 0-3: Functional enrichment during selection, amplification, and high vs. low producers in exponential and stationary 
phase by Gene Set Enrichment Analysis (GSEA). 
Gene sets changed during Selection Amplification High vs. Low Producers 
Exponential Phase Stationary Phase 
Direction  p-value  Direction  p-value  Direction  p-value  Direction  p-value  
Signaling Pathways 
EDG1 signaling pathway Up * 0.015 * Up * 0.029 * Down 0.0385   
PDGF signaling pathway Up * 0.047 * Up * 0.042 *     
mTOR signaling pathway Up * 0.055 *       
Toll-like receptor signaling pathway  Up  0.039        
Cytokine-cytokine receptor interaction  Up  0        
RAS pathway    Up  0.069      
Extracellular matrix receptor interaction   Up * 0.048 * Down 0.0045 Down 0 
PIP3 signaling       Up 0.064 
IGF1R pathway     Down 0.0042 Down 0.089 
TNFR1 pathway     Down 0.0346 Down 0.02 
JAK STAT signaling pathway     Down 0.0188   
Gene Expression and Protein Synthesis 
Aminoacyl tRNA biosynthesis  Down 0 Down 0.020  Up 0.0213   
mRNA processing Up * 0.068 *       
Ribosome  Up 0.080   Up 0.0593   
Proteasome   Down 0.003      
Cell Cycle 
Cell cycle Up  0.05  Down 0  Down 0.0056 Down 0 
DNA replication Up  0.008  Down  0  Up 0.0076   
CDK5 pathway     Up 0.0503   
Energy Metabolism 
Glutathione metabolism  Down * 0 *       
Amino acid metabolism  Down  0-0.081  Down  0.003-0.080  
Up 
0.0098-
0.0846 
  
Glycolysis and TCA cycle   Down * 0 *     
Mitochondria       Down 0.04 
Others 
Cytoskeleton function     Down 0.0165 Down 0.003 
ABC transporters     Down 0.035 Down 0.053 
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gene sets that were significantly enriched (nominal p-value < 0.1) after selection or 
amplification as compared to the control were identified. The enriched gene sets fall into 
two categories: one is enriched in both producing clones and control transfectant, the other 
is enriched in producing cells but not in the control transfectant. The identified enriched 
gene sets are listed in Table 0-3. These gene sets are likely to be related to the production 
and secretion of the product protein since they were enriched only in producing clones but 
not in the control transfection. We then proceeded to perform GSEA on transcriptome data 
of high and low producing cells to identify gene sets enriched in the high-producing sub-
clones as compared to the low producing sub-clones. These gene sets represent biological 
functions that are likely to contribute to enhancing productivity. 
Interestingly, there is a significant overlap between gene sets which are enriched in 
the process of cell line generation (i.e., upon selection and amplification) and in 
productivity enhancement (i.e., high vs. low producing cells), suggesting that high-
producing cells may have more enhanced enrichment than the low producing cells in 
functions which enable a cell to produce and secrete products. Prominent among the gene 
sets that were enriched between the transfected clones and the parental host during 
selection were the EDG1, PDGF, mTOR, Toll-like receptor, and Cytokine signaling 
pathways. Of these, the EDG1, PDGF pathways were also up-regulated following the 
amplification process, as were Ras, and extracellular matrix (ECM) receptor interaction. 
Interestingly, the EDG1 pathway and ECM receptor interaction pathways were down-
regulated in high producing clones compared to low producing ones. Most of these 
pathways contain genes from the MAPK signaling pathway (e.g., Mapk1, Mapk3), the 
PI3K signaling pathway (e.g., Pik3ca, Pik3r1), and the AKT signaling pathway (e.g., Akt1, 
Src, and Smpd1). Furthermore, several other signaling pathways, including IGF1R, 
TNFR1, and JAK-STAT, were down-regulated in high vs. low producers whereas the PIP3 
signaling pathway was up-regulated under such comparison. 
Aminoacyl tRNA biosynthesis and amino acid metabolism were enriched 
following selection and amplification as well as in high vs. low producers although the 
direction of change was not the same. Genes involved in mRNA processing and ribosomes 
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were up-regulated following selection, but unchanged by amplification. The ribosomal 
elements were further up-regulated in high vs. low producers. Proteasome activities were 
down-regulated upon amplification and unchanged under other conditions, whereas amino 
acid metabolism was up-regulated in high vs. low producers. 
Genes involved in cell cycle, DNA replication, and CDK5 pathways also showed 
various enrichment trends upon amplification, selection, and comparison of high vs. low 
producers. Glutathione metabolism was down-regulated during selection in the producing 
clones but unchanged in the control transfectant. Glycolysis and TCA cycle were 
unchanged during selection but down-regulated following amplification. Other gene sets 
which were enriched in high vs. low producers included cytoskeleton function, 
mitochondria, and ABC transporters. 
5.6 Discussion 
Through DHFR-based transgene amplification a non-secretory host cell can be 
transformed into a hyper-producer. We employed transcriptome analysis to gain insights 
into the mechanism of this process. A relatively low concentration of MTX was used for a 
moderate degree of amplification. This protocol was adopted to minimize the emergence 
of a large number of unstable clones seen when a high MTX concentrations was used (Fann 
et al, 2000; Kaufman et al, 1985; Pendse et al, 1992). After amplification, the transcript 
level of mDHFR increased about 4-fold. However, the change in the level of hIgG heavy 
chain and light chain was only moderate (Figure 0-21A and 3B). This moderate change 
was still seen in the sub-clones after single cell cloning (Figure 0-23D and 5E). Given the 
long held notion that amplified gene copy number would give rise to higher transcript level, 
thereby enhancing productivity, this absence of a large increase in the transgene transcript 
level was surprising. 
The small change in copy number of transgene is consistent with the low 
concentration of MTX used in this study. The amplification thus only caused a rather 
moderate change at the transgene copy number level (Figure 0-20B). However, the change 
in transcript levels, was much higher than the change in the copy number (Figure 0-20A). 
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Thus, increasing the transgene copy number is potentially not the only role of MTX 
amplification in selecting hyper productive cells.  
 
Figure 0-26: Scatter plot showing correlation between specific productivity and (A) 
specific growth rate in growth phase, (B) specific growth rate in death phase and (C) 
peak cell concentration in fedbatch culture for high-, low- and mid-producers. The  
( ) symbols correspond to the sub-clones that are classified as high producers, the     
( ) symbols correspond to the sub-clones classified as low producers and ( ) 
symbols are sub-clones that were mid-producers. 
Although there was only a small variation in expression level of IgG genes among 
the sub-clones, a wide range of specific productivities was observed among them. A weak 
positive relationship between productivity and the transcript level can be seen in heavy 
chain, but not in light chain (evidence also shown in (McLeod et al, 2011)). The lack of a 
strong direct correlation between the transgene transcript level and the product titer has 
also been observed before (Fann et al, 2000; Flickinger et al, 1992; Leno et al, 1992). All 
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clones and sub-clones had a light chain transcript to heavy chain transcript ratio larger than 
1, as has been reported for both transcript and protein levels (Bibila & Flickinger, 1991; Li 
et al, 2007; O'Callaghan et al, 2010; Schlatter et al, 2005). However, the high producing 
sub-clones only had a smaller degree of excess level of light chain transcript, while low 
producers tend to have a light chain to heavy chain transcript levels above 1.5.  
High producing subclones show lower specific growth rate and lower specific death 
rate (Figure 0-26A & B).  However, the data set is insufficient for asserting a firm 
correlation between growth rate and productivity. Two fast growing sub-clones which also 
gave high maximum cell concentrations were both lower producers (Figure 0-22). It is 
worth noting that similar observations of a weak correlation between growth behavior and 
productivity characteristics have been reported previously (Chusainow et al, 2009; Fann et 
al, 2000). Functional analysis also revealed that the cell cycle progression functional class 
is significantly down-regulated in high producers compared to low producers (Table 0-3). 
The maximum cell concentrations seen in the high producing clones spanned over 
a range, but did not bear any relation to the productivity of the subclones (Figure 0-26C). 
In this study and in industrial practice, a high producer is judged by a high product 
concentration at the end of production. The product titer is affected by both growth and 
specific productivity. Thus, it is not surprising that among clones of similar product titer, a 
range of growth behavior is seen. 
Hierarchical clustering of transcriptome data showed that, except P3M, all hIgG 
producing clones (P1, P2, P3) and amplified subclones cluster together, suggesting that the 
production and secretion of IgG (as a result of selection) has a profound effect at the 
transcriptome level that is discernable in all secreting clones. Sub-clones derived from the 
same parental clone retained similar transcriptional signature and clustered together. Sub-
clones of similar productivity did not show a high similarity in clustering. The results thus 
suggested that the hyper-productivity related gene expression profile may not be 
sufficiently distinctive in genome wide transcriptome analysis. 
It was postulated previously that the hyper-productivity is likely to entail relatively 
small expression level changes in a large number of genes in many functionalities, rather 
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than profound and readily discernible alterations in a small set of genes (Seth et al, 2007b). 
Different high producing clones may acquire the same characteristics through different 
gene expression alterations. 
We next focused on those genes whose expression was significantly altered in the 
producing cells during selection and amplification but not in the control. It is not surprising 
that the number of genes identified (sets I and II) is relatively small. We employed Gene 
Set Enrichment Analysis (GSEA) (Subramanian et al, 2005) to compare the functional 
classes that have been enriched during the process of selection and amplification, as well 
as between low and high producing cells. In performing GSEA genes with related 
biological significance, such as the same pathway or imparting the same consequence (e.g. 
correlated to the occurrence of a particular disease) are grouped into “gene sets”. By 
comparing the transcript levels of genes in a gene set of two groups of samples, GSEA 
makes a statistical call whether the changes (called enrichment) in this gene set is above 
that caused by random events. The enrichment call is thus affected by the gene composition 
in a gene set. 
A number of gene sets enriched in selection and amplification are related to growth 
control, including mTOR, PDGF, and RAS signaling pathways (Table 0-3). Given the 
toxicity of selective markers used in selection and amplification, it is not surprising that 
growth control-related functional classes were enriched. This was consistent with the 
enrichment of cell cycle related functional classes, also observed in another transcriptome 
study (Doolan et al, 2013). The enrichment of the general functional classes related to cell 
cycle, cytokine signaling, energy metabolism and redox balance (e.g., glutathione 
metabolism) finds parallel in the gene expression changes seen in the development of non-
secreting B cells to immunoglobulin secreting plasma cells (Bertolotti et al, 2010; 
Underhill et al, 2003; Vene´ et al, 2010). The detailed list of genes is presented in the 
Appendix Table 0-2. 
This study represents a first attempt to systematically study the mechanism behind 
the transformation of a non-secretory host cell into a high producer of recombinant protein. 
A surprised finding is the modest change of transgene transcript level imparted by 
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amplification, making one wonder the role of amplification. A possible explanation is that 
the high transcript level of the transgene after selection may have surged to an even higher 
level during the 15 day exposure of high level of MTX for amplification, which would 
have caused a surge in the translation of IgG. As a result, cells with an insufficient secretory 
capacity would have excessive accumulation of intracellular product protein and 
encountered death. Only those which develop the necessary machinery to allow for high 
level of IgG synthesis and secretion would have survived. Hence, the amplification process 
increases the frequency of the isolation of hyper-producing clones. The unfolded protein 
response (UPR) pathway may play an important role in this process (reviewed in (Hussain 
et al, 2014; Prashad & Mehra, 2014)).  
The small number of cells in culture and the extensive cell death during 
amplification does not permit a comprehensive transcriptome analysis. The transcription 
array assay was performed on the amplified cell pools after a period of cell recovery. It did 
not capture the transient dynamics at the transcriptome level. Nevertheless, the results of 
GSEA analysis on the selection and amplification process revealed the enrichment of 
signaling pathway, aminoacyl tRNA synthesis, mRNA processing and ribosome 
machinery. These changes may be the remnants of the amplification process. 
The process of selection and amplification would have set of gene expression 
profile changes related to increased productivity. The transcriptome comparison between 
high and low producers would also have highlighted those genes entailed in increasing the 
productivity. The results of our attempt of integrating those two transcriptome analysis 
indicate that the road to hyper-productivity does involve colossal changes in gene 
expression across a wide range of functional classes. This is largely consistent with other 
reported transcriptome analysis on recombinant CHO (Grillari et al, 2001; Nissom et al, 
2006) and mouse myeloma cells (Charaniya et al, 2009; Seth et al, 2007b) of different 
productivities as well as on recombinant CHO cells under culture conditions which 
enhance productivity (Kantardjieff et al, 2010a; Yee et al, 2008; Yee et al, 2009). 
GSEA studies on cell lines of bioprocess interest, have provided some insight, 
however, the results have not been very revealing. The gene sets employed were based on 
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biological function classes, or were collections of genes which were reported to be related 
to a disease (such as a cancer) or a biological event (such as a developmental process). 
Ideally, genes which have a high probability of being differentially expressed between high 
producing and low producing cells or host cells should be collected as a hyper-productivity 
gene set. An enrichment of such a gene set will be indicative of a clone’s propensity to 
become a high producer during cell line development. 
One may hypothesize that the generation of a hyper-producing cell line and the 
culture conditions which increases the productivity share similar pattern of gene expression 
changes. Furthermore, such hyper-productivity features may be shared across cell line 
derived from different tissues and different species, such as CHO and mouse myeloma 
cells. With that premise one may proceed to assemble a hyper-productivity gene set by 
comparative analysis of transcriptome data from different sources. 
The assembly of a hyper-productivity gene set will certainly require a large number 
of cell and culture samples across a wide range of conditions. The data presented in this 
study are very small in comparison to what is needed; considering that alternative genes 
may give rise to the same trait, the sets of genes generated in this study may be only 
tentative. Nevertheless, we compared the combined list of the genes which were reported 
to be differentially expressed in previous transcriptome studies (Charaniya et al, 2009; 
Kantardjieff et al, 2010a; Seth et al, 2007b; Yee et al, 2008; Yee et al, 2009) with the genes 
identified from our analyses. From among a total of 451 genes reported in these previous 
studies, 15 were identified as differentially expressed in the high vs. low producing sub-
clones (Set H) in this study. These 15 genes have function related to cell cycle (Ncapd2, 
Tfdp1), regulation of transcription (E2f6), chromatin organization (H2afy), lipid 
metabolism (Hmgcr, Acs14, Hsd17b12), protein processing (Dnpep, Fn1, Timp2), protein 
secretion (Arfrp1, Ckap4), protein synthesis (Rps20) and signaling pathways (Sar1b, Pask) 
(Listed as Set III in Table 0-2).  A gene set of 15 genes is too sparse, while that of 451 is 
too large (Subramanian et al, 2005). With the increasing availability and affordability of 
RNA seq analysis, the data set available will increase and the establishment of a hyper-
productivity gene set may be feasible.  
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Chapter 6: Engineering dynamic nutrient uptake for improved CHO 
cell culture performance 
6.1 Context statement 
Reproduced with permission from Le H., Vishwanathan, N., Kantardjieff A. Doo I., 
Srienc M., Zheng X., Somia N.and Hu, W.-S. (2013), Dynamic gene expression for 
metabolic engineering of mammalian cells in culture. Metabolic Engineering, 20: 212–
220. 
License Number: 3392010980731 
© 2013 Elsevier 
 
This chapter demonstrates the utility of a dynamic promoter which enables the 
expression of a transgene in a dynamic fashion. The transgene exhibits low expression in 
the lag and exponential growth stages, but a high expression in the stationary phase. Such 
a dynamic promoter was identified by mining a large amount of time-series microarray 
data. The microarray data was collected and processed by AK. HL reorganized and 
analyzed the data to identify dynamic genes. HL isolated the dynamic promoters from 
Chinese hamster genomic DNA and conducted verification in GFP system. NV constructed 
plasmids for mGLUT5 overexpression and constructed stable cell lines for experiments. 
All the characterizations in fed batch culture were conducted by NV with the assistance of 
XZ. Data analysis was conducted by NV. The portions to which I have contributed 
significantly have been retained. The remaining sections were condensed and replaced with 
a summary to provide adequate context for the following sections. 
6.2 Summary 
Cell engineering efforts in mammalian cells are conventionally performed using 
constitutive expression systems. However, cells respond to various environmental cues and 
cellular events dynamically according to the cellular needs. The use of inducible systems 
allows for time dependent expression, but it also requires external manipulation. Ideally, a 
transgene’s expression should be synchronous to the host cell’s own rhythm, and its 
expression level should be adjusted to the cellular process and manipulated according to 
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the transgene’s function. To that end, we surveyed the transcriptome profiles over different 
stages of fed-batch cultures operated under different conditions and identified genes with 
different expression dynamics and intensity ranges. The promoters of these genes are likely 
to drive the expression of the transgenes following patterns similar to those of the 
endogenous genes. To illustrate their potential utility for conferring dynamic responses, a 
representative promoter of the Thioredoxin-interacting protein (Txnip) gene was used to 
drive expression of a blasticidin resistance (BSD) gene and an enhanced green fluorescent 
protein (EGFP) gene in concert with cell growth. We further employed this Chinese 
hamster promoter to engineer dynamic expression of the mouse GLUT5 fructose 
transporter in Chinese hamster ovary (CHO) cells, enabling them to utilize sugar according 
to cellular needs rather than in excess as typically seen in culture. Under these conditions, 
less lactate was produced, resulting in a better growth rate, which in turn prolonged culture 
duration, and increased product titer. This approach illustrates a novel concept in metabolic 
engineering which can potentially be used to achieve dynamic control of cellular behaviors 
for enhanced process characteristics. 
6.3 Introduction 
A producing cell line is developed by the introduction of a transgene encoding for 
the protein product into the host cells, usually followed by gene copy number amplification 
to increase its transcript level (Kantardjieff et al, 2010b; Seth et al, 2006a). Subsequently, 
extensive screening and testing are performed to isolate producing cell lines that give rise 
to high levels of the product in the production culture conditions (Freshney, 2005; Hu, 
2012; Wirth & Hauser, 2008). However, high transcript level of the product gene is not 
sufficient for high productivity and consistency of product quality. The combination of 
many superior characteristics that collectively confer the complex trait of hyper-
productivity (Chapter 5 and (Meleady et al, 2011; Seth et al, 2007a)).  In cell line 
development, a large effort is typically devoted to screen for cell clones which confer major 
attributes which collectively give the desired characteristics of a hyperproducer. 
  87 
A possible faster route for cell line development is via cell engineering to endow 
cells with the desired characteristics, especially on host cell lines that can be used for 
product transgene introduction. The engineering of metabolic, secretory, and growth 
control pathways in producing cells to enhance their growth and product secretion trait 
have all been attempted (reviewed in (Datta et al, 2013; Kim et al, 2012) (Kaufmann & 
Fussenegger, 2003; Seth et al, 2006a; Vallee et al, 2014)). For instance, down-regulation 
of lactate dehydrogenase A (LDH-A) and pyruvate dehydrogenase kinases (PDHK) to 
reduce lactate production (Zhou et al, 2011); over-expression of the transcription factor X-
box binding protein 1 (Xbp1) to enhance secretory capacity (Tigges & Fussenegger, 2006); 
and over-expression of the anti-apoptotic genes E1B19K and Aven to delay the onset of 
apoptosis (Figueroa et al, 2007) have all been reported. 
The expression of these genes is typically driven by a constitutive promoter, such 
as those derived from cytomegalovirus (CMV), Simian virus 40 (SV40), or elongation 
factor 1 (EF1). Such strong and constitutive expression may not be suitable for all genes 
(Figure 0-27). In some cases, it is desirable to express the transgene only in a particular 
time or condition of the culture, especially when the gene confers a negative effect, such 
as growth inhibition, on cellular behavior. The use of inducible promoters allows for 
possible dynamic expression to mitigate the negative effects. However, depending on the 
inducible system employed, external addition of an inducer such as tetracycline, isopropyl-
-D-thio-galactoside (IPTG), or a hormone is necessary. The use of such inducers, 
especially antibiotics, is undesirable at a manufacturing scale. Furthermore, gene 
expression is a dynamic process by nature, which is constantly adjusting to cope with 
various perturbations. Consequently, endogenous promoters with intrinsic dynamic 
activities represent attractive tools to control the expression dynamics of the transgenes 
(Figure 0-27). 
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Figure 0-27: Schematic of transgene expression patterns in a typical fed batch 
culture of engineered mammalian cells. Viable cell density curve shows exponential 
phase stationary phase and death phase of the fed batch culture. Most cell 
engineering is constitutive where the transgene is expressed at continuously high 
levels throughout the course of the culture. In contrast, inducible cell engineering 
strategies, make use of an inducer molecule to induce gene expression at a desired 
stage of the culture, and the high expression level is maintained for the period that 
the cells are exposed to the inducer. Dynamic cell engineering involves using 
promoters whose natural transcriptional response is dynamic. 
The endogenous promoter can be used for similar cell engineering strategies, 
especially in engineering the metabolism of mammalian cells because such engineering 
often requires a dynamic control on gene expression. For example, it is well known that 
cellular metabolism is very different in the growth and stationary stages of the culture 
(Wahrheit et al, 2014). Lactate accumulation is major obstacle in achieving high 
productivity, and hence, higher titers (Glacken et al, 1986; Hu et al, 1987). However, high 
lactate is essential for good growth (reviewed in (Mulukutla et al, 2010)) akin to the 
Warburg effect in cancer cells. Therefore, an ideal process would involve high lactate 
accumulation in the initial culture stages to boost growth, and lower lactate concentrations 
at the stationary stage to enhance productivity. Data mining studies on industrial 
bioreactors have indicated lactate consumption phenomenon to be the most correlated with 
better reactor yields (Le et al, 2012). This is usually achieved by introducing metabolic 
shifts, i.e., inducing the consumption of lactate at the stationary stage to lower lactate 
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concentrations. Metabolic shifts can be introduced by lowering glucose concentration in 
the stationary phase of the culture to extremely low levels, ~ 0.04 g/L (Cruz et al, 1999; 
Mulukutla, 2012; Zhou et al, 1997) in order to maintain low glycolytic flux. Since the 
glucose transporter glut1 has a high affinity for glucose, the enzyme attains saturation 
kinetics at very low glucose concentrations (Figure 0-28). Maintaining such low glucose 
levels in large bioreactors is difficult because they require precise control of glucose 
feeding with a continuous estimate of glucose concentration. In addition, insufficient in 
mixing can create localized pockets of starved cells where the glucose concentration can 
drop quite rapidly at high cell densities. 
 
Figure 0-28: Kinetic behavior of sugar transporters glut1 and glut5. Glut5 
preferentially transports fructose and has a much higher Km value for fructose 
compared to the Km value that glut1 has for glucose. Km values are indicated by the 
dashed vertical lines. 
Cell engineering can provide a solution to this problem. One can knockdown the 
glucose transporter conditionally in the late stage of the culture to enforce lower transport 
flux. However, the cells overexpress other glucose transporters glut4 and glut8 to overcome 
this restriction (Bengea, 2008). Another possibility is to switch the sugar source to a 
substrate that is not taken up by the glucose transporters. For example, fructose is taken up 
  90 
by the glut5 transporter, which has a much lower affinity for fructose than that glut1 has 
for glucose (Figure 0-28). Since, glut5 is not expressed in CHO cells, they can easily be 
engineered to consume fructose by knocking in the glut5 gene. Moreover, a dynamic 
promoter can be used to express the glut5 gene to ensure low expression in the growth 
stage, and higher expression in the stationary phase when lower glycolytic flux needs to be 
engineered. 
The identification of genes and their promoters with the desired expression 
dynamics necessitates the use of time profiles of transcript levels to discern unique 
expression patterns. Major expression trends of hundreds of regulatory motifs or genes 
were distinguished from the background noise either by model fitting or by principal 
component analysis (PCA). These trends could be subsequently classified into several 
groups by clustering based on their similarity. 
The next challenge to be addressed is the isolation of the corresponding promoter 
region because the precise locations and boundaries of the DNA binding region of 
regulatory elements are not easily identifiable. Most mammalian core promoters are 
associated with either a TATA box or a CpG island within a few hundred basepairs from 
the putative transcription start sites (Carninci et al, 2006). The proximal promoter regions, 
however, can extend to several kilo basepairs and comprise binding sites of different 
transcription factors, many of which are not known. The core promoter often contributes 
to the basal expression level of the downstream gene, whereas different regulatory elements 
in the proximal promoter region typically confer transcriptional responses of that gene to 
various stimuli. Due to this fuzzy boundary of promoters, a relatively long fragment of at 
least one thousand basepair is often isolated (Minn, 2005; Thaisuchat et al, 2011; Wang et 
al, 2005). Serial deletion and other modifications are performed subsequently to identify 
cis-regulatory elements within the isolated promoter fragment. 
A survey of historical time-course microarray data from multiple fed-batch cultures 
were used to identify genes with time dynamic expression trends in CHO cells. The 
promoter of a candidate gene (Txnip) was used to drive the expression of a fusion gene 
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(BSD_EGFP) following the expected dynamic manner. Furthermore, dynamic expression 
of the GLUT5 fructose transporter under the control of this Txnip promoter resulted in 
more moderated sugar consumption, less lactate production, better growth characteristics, 
and higher product titer. Thus this study represents the first proof-of-concept in dynamic 
cell engineering. 
6.4 Materials and Methods 
6.4.1 Construction of Expression Vectors 
The pTet_BSD_EGFP  plasmid with the tetracycline inducible promoter, pTet, in 
this plasmid replaced by the Chinese hamster Txnip promoter via the restriction sites of 
AatII and EcoRI to generate the pTxnip_BSD_EGFP plasmid (Figure 0-29B). A similar 
vector, pCMV_BSD_EGFP, wherein the human CMV promoter was used to drive the 
expression of the fusion gene, was created similarly using sequential digest of NaeI and 
EcoRI. The mouse GLUT5 cDNA was amplified from the pcDNA3.1-GLUT5 plasmid 
(Wlaschin & Hu, 2007a) using the two primers GLUT5_L 
(GTACCGAGCTCGGATCCACTAGTCC) and GLUT5_R 
(AACGGGCCCTCTAGAATCGATCGGCCGCCC).  
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Figure 0-29: Cloning of Txnip promoter from Chinese hamster liver genomic DNA.  
(A) Isolated fragment of Txnip promoter with approximate locations of the putative 
transcription start site (TSS), the TATA box, the carbohydrate response element 
(ChoRE), the CAT boxes, the FOXO binding site, and other transcription factor 
binding sites (TFBSs).  Approximate location of the start codon (ATG) was shown 
for reference.  (B) Map of the expression vector pTxnip_BSD_EGFP.  Txnip 
promoter was used to drive the expression of a fusion gene composed of a blasticidin 
resistance marker (BSD) and an enhanced fluorescent protein (EGFP) gene.  (C) 
Map of expression vector pTxnip_mGLUT5.  The plasmid includes the mouse 
GLUT5 gene driven by the Txnip promoter and an SV40 polyA site for 
transcription termination. 
The expected PCR product of ~2100 bp was cloned in the pTxnip_BSD_EGFP 
plasmid to generate the pTxnip_mGLUT5 plasmid, in which the complete fusion gene 
(blasticidin S resistance and EGFP genes), was replaced by the mGLUT5 cDNA using 
EcoRI and ClaI restriction enzymes (Figure 0-29C). 
6.4.2 Generation and Characterization of Stable Pools and Clones 
All plasmids constructed above were linearized with ScaI prior to transfection into 
the host cells. 24 hr prior to transfection, CHO cells expressing a recombinant protein were 
seeded in duplicate wells per transfection at 5 x 105 cells/mL in 2 mL of DMEM-F12 
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medium in a 6-well plate. A DNA – cation lipid complex containing 3.6 g of the linearized 
pTxnip_mGLUT5 plasmid and 0.4 g of the linearized pCMV_BSD_EGFP plasmid was 
used. After incubation for 20 min at room temperature, the complex was added drop by 
drop into the cells. 6 hr after transfection, the transfected cells were centrifuged at 700 rpm 
for 5 min at room temperature and re-suspended in 2 mL of fresh DMEM-F12 medium. 
Twenty-four hours following transfection, the cells transfected with 
pTxnip_BSD_EGFP were diluted in 96-well plates at 1000 cells/well in 0.2 mL of the 
selective medium comprising DMEM-F12 supplemented with 5 g/mL Blasticidin S 
(InvivoGen, San Diego, CA), 5% (v/v) fetal bovine serum (Atlas Biologicals, Fort Collins, 
CO), and 20% (v/v) conditioned medium. The conditioned medium was collected during 
the mid-exponential growth phase of the non-transfected cells in a batch culture in DMEM-
F12, and was filtered through a 0.45 m pore size filter (Fisher Scientific, Pittsburgh, PA). 
In parallel, the pools were spun down and resuspended in DMEM-F12 medium containing 
2 g/L fructose and no glucose 24 hours following transfection. The cells were maintained 
in this medium for 14 days and then further selected in 10 g/mL Blasticidin S (Invivogen, 
San Diego, CA) for 4 days. The selected stable pool (TSGP) was cultured in fed-batch 
mode using this fructose medium. The expression level of mGLUT5 was characterized 
over the course of the fed-batch culture using qRT-PCR. 
The cloning plates were incubated for approximately two weeks in a 37oC, 5% CO2 
environment. Single clones in 96-well plates were picked and transferred to new wells, 
each containing 150 L of fresh selective medium. As cell density increased, the culture 
was gradually expanded to 1 mL in 24-well plates, 4 mL in 6-well plates, 8 mL in T-25 
flasks, and 25 mL in T-75 flasks for cryopreservation and subsequent characterization in 
the selective medium.  
6.4.3 Fed-batch Cultures 
The cultures were initiated by inoculating cells at 0.5 x 106 cells/mL, in 20 mL of 
DMEM-F12 medium in a 125 mL shaker flask (Thermo Scientific, Rochester, NY). The 
flasks were then incubated at 37oC on a shaker rotating at 130 rpm in a humidified incubator 
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with 5% CO2. One mL of a ten-fold concentrated feed medium (10 X) was added daily 
starting from day 2. In the bi-substrate culture, the cells were given glucose feed medium 
in the growth stage until day 5 or 6 when the cell reached maximum cell density, after 
which they were fed fructose feed media to adjust the concentration of fructose to 1 g/L. 
The bi-substrate cultures with switch back to glucose were fed twice a day to avoid glucose 
depletion.  
Cell concentration and viability were determined by counting with a 
hemacytometer using trypan blue staining. One million cells were withdrawn each day for 
RNA extraction starting from day 2. For hexose measurements, samples were preheated at 
65oC for 20 min. to inactivate phosphoglucoisomerase (PGI) released from dead cells. 
Glucose was measured using Infinity Glucose Hexokinase Method (Thermo Fisher 
Scientific, Dubuque, IA), and total hexose was measured similarly with the addition of 
phosphoglucose isomerase (PGI) (Roche Applied Sciences, Basel, Switzerland) at 35 
U/mL and an incubation time of 20 min. Fructose concentration was estimated by 
subtracting glucose concentration from total hexose concentration. Lactate concentration 
was measured using the YSI Model 2700 industrial analyzer (Yellow Springs Instruments, 
Yellow Springs, OH). 
6.4.4 Quantitative Real Time Polymerase Chain Reaction (qRT-PCR) 
Total RNA was isolated using the RNeasy Mini kit (Qiagen, Valencia, CA) 
according to the manufacturer’s protocol with on-column DNase I treatment for removal 
of genomic DNA. Reverse transcription was performed with 2.5 g of total RNA using 
Superscript III Reverse Transcriptase (Invitrogen, Carlsbad, CA) with 1 mM oligo dT 
primers in a total volume of 50 L. A no reverse transcriptase control was performed in 
parallel to assess genomic DNA contamination. 
qRT-PCR primers listed in Table 0-1, were designed using Primer3 
(http://frodo.wi.mit.edu/). The mRNA levels of these genes were quantified using the 
Brilliant II SYBR Green qPCR Master Mix (Agilent, Santa Clara, CA). Each 12.5 L 
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reaction mixture contained 6.25 L of the master mix, 50 ng of the cDNA template, and 
0.2 M of each primer (forward and reverse). qRT-PCR was performed using the 
Stratagene Mx3000P instrument (Agilent, Santa Clara, CA). The thermal cycling profile 
was set as follows: initial denaturation at 950C for 10 min., followed by 40 cycles of 95oC 
for 10 sec., 57oC for 1 min., and 72oC for 30 sec. The dissociation curves of the PCR 
products were generated by ramping from 57oC to 95oC after a denaturation step at 95oC 
for 1 min. and an annealing step at 57oC for 30 sec. All cDNA samples were run in 
triplicates alongside a no reverse transcriptase control and a no template control. -actin 
was used as a reference for comparison across samples. 
6.5 Results 
6.5.1 Identification and Characterization of Dynamic Promoters 
Archived time-series microarray data obtained from multiple fed-batch culture 
conditions were used to identify genes with reproducible dynamic behaviors in a typical 
fed-batch culture. Principal component analysis was used to identify major expression 
trend followed by k-means clustering to separate the genes into different dynamic 
categories. Among approximately 1000 genes selected, 15 genes with available 5’-end 
sequence in our repertoire and showing an upswing dynamic expression pattern were 
chosen (Figure 0-30). 
Among these 15 genes, three genes exhibited upswing dynamics in another cell 
line. Out of these three genes, the txnip gene was selected because its expression level was 
shown to increase by 23-fold between exponential and stationary phases in another study 
(Kantardjieff et al, 2010a). 
An 800 bp fragment upstream of the translated region of the Txnip gene was 
isolated from genomic DNA of Chinese hamster liver. The isolated fragment contains 
approximately 280 bp of the 5’-untranslated region (5’-UTR) and 520 bp of the upstream 
region of the putative transcription start site (TSS) (Figure 0-29A). The upstream region 
contains a number of classic elements such as a TATA box and two inverted CAT boxes. 
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In addition, it also contains other regulatory elements including a carbohydrate response 
element (ChoRE) and binding sites of FOXO and several other transcription factors. 
 
Figure 0-30: Flowchart summarizing the procedure of identify dynamic promoters 
from time-series microarray data 
6.5.2 Engineering dynamic expression of mouse Glut5 
CHO cells do not natively express the glut5 transporter. The expression level of the 
transporter in CHO cells is at least 5-fold lower than the median expression level of 500 
from microarray data. The Chinese hamster tissues brain and liver express high levels of 
the transporter. In contrast the expression level in ovary tissue is also absent similar to 
CHO cells. 
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Figure 0-31: Microarray expression level of glut5 transporter (Slc3a5) in several 
CHO cell lines and Chinese hamster tissue. 
In addition to this, the parental cells also failed to grow in completely fructose 
media. Since the background expression level of the transporter is low, the effects seen in 
culture can be interpreted as solely resulting from the expression of the transgene. 
6.5.2.1 Characterization in mono-substrate culture 
The Txnip promoter was further used to drive the expression of a fructose 
transporter isolated from mouse cDNA, mGLUT5. We have shown previously that CHO 
cells do not utilize fructose as a nutrient and that the introduction of an exogenous GLUT5 
enables them to use fructose (Wlaschin and Hu 2007). CHO cells were transfected with the 
vector pTxnip_mGLUT5 (Figure 0-29C) and selected in fructose medium followed by 
selection with blasticidin. Fed-batch culture of the stably transfected pool was performed 
using either glucose or fructose as the sole carbohydrate source. The cultures were 
characterized for growth, lactate production, hexose consumption, mGlut5 expression and 
rIgG production, results are summarized in Figure 0-32. Data from the control glucose 
culture are shown in open triangles and that from fructose culture are shown in open circles. 
The cells grow to a higher cell density in fructose culture compared to glucose culture 
(Figure 0-32A), consistant with what was observed before (Wlaschin and Hu 2007). The 
glucose consumption rate is high in the growth stages of the culture and steeply reduces in 
the late stage (Figure 0-32C).  The mGLUT5 gene exhibited the dynamic profile as 
expected, with an approximately 5-fold increase in transcript level on day 10 compared to 
day 4 as measured by qRT-PCR (Figure 0-32D). 
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Figure 0-32: Metabolic characterization of TSGP pool stably expressing mGLUT5 gene in a dynamic fashion. Symbols represent data from glucose culture 
() or fructose culture (). (A) Viable cell concentration of TSGP in glucose and fructose culture showing improved growth and higher maximum cell 
concentration in fructose culture compared to glucose. (B) Lactate concentration revealing lower rate of lactate accumulation in fructose culture. (C) Specific 
hexose uptake rate of TSGP. (D) Expression level of mGLUT5 over the course of the fed-batch culture shows dynamic behavior, as well as dynamically 
increasing specific fructose uptake rate, shown in bar chart. The expression was measured by qRT-PCR. (E) Stoichiometric ratio of mole of lactate produced 
per mole of glucose or fructose consumed in glucose culture. Cells produced less lactate per mole substrate consumed in fructose culture compared to glucose 
culture. (F) Titer of TSGP cells in glucose and fructose culture, showing higher titer in fructose culture.
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The consumption of fructose and the production of lactate was also measured. The 
specific fructose consumption rate stayed relatively constant but then increased toward the 
end of culture period following the increase in the transcript level of mGlut5. 
The lactate concentration increased to 30 mM in the glucose culture, whereas the 
lactate concentration only increased to 19 mM in the fructose culture (Figure 0-32B). The 
final titer was about 70 mg/L in glucose culture and 119 mg/L in fructose culture, 
increasing the titer by 40% (Figure 0-32F). Similar to the resulted reported previously, the 
stoichiometric ratio of lactate to sugar consumption observed was lower than that typically 
seen when glucose was used as the carbohydrate source (Figure 0-32E). Even though the 
titer from the glucose culture was higher, the specific productivity is lower (Figure 0-32F). 
However, it must be noted that all the above data was obtained from culturing a 
pool, which is genetically heterogeneous. A few clones of this pool were obtained by 
dilution cloning. One of the clones was characterized in fed batch culture. These cells also 
showed growth to higher cell densities in fructose culture and switch to lactate consumption 
in late stage when low fructose levels were maintained (data not shown). 
6.5.2.2 Characterization in mixed substrate culture 
To demonstrate the potential utility of dynamic expression, the transfected cells 
were cultivated in the presence of both glucose (25 mM) and fructose (5mM). 
It has been shown previously that at a low expression level of mGLUT5, the 
consumption rate of fructose is low unless fructose is present at 30 mM or higher (Wlaschin 
and Hu 2007). Under the culture condition used in this current study, glucose was expected 
to be consumed quickly by the cells as the main sugar source while fructose would be 
consumed only at a rather low rate. Such differential consumption between glucose and 
fructose was seen in Figure 0-33 during the exponential growth stage. Glucose was further 
added intermittently as shown in Figure 0-33 to sustain a high growth rate. 
It has been reported previously that a switch from lactate production in the early 
stage to lactate consumption in the late stage is a desirable feature in many cultures (Le et 
al, 2012). Such a switch of metabolism occurs when both sugar consumption rate and 
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glycolytic flux are low. One way to achieve a low glycolytic flux is to reduce the sugar 
concentration to such a low level that allows glucose to become almost depleted. However, 
such a strategy of allowing near depletion of glucose may also trigger apoptosis due to 
starvation. 
 
 
Figure 0-33: Fedbatch culture of transfectants expressing GLUT5 driven by Txnip 
promoter symbols: concentrations of cells (), glucose (), fructose (), lactate 
(), and antibody (), and relative transcript level of mGLUT5 () represented as 
-log2 (fold change in mGLUT5 expression relative to β-actin). 
In this culture, we employed a strategy of switching to fructose consumption at a 
low rate to avert apoptosis. As can be seen, glucose was allowed to be depleted when the 
culture reached stationary phase. The increased expression of mGLUT5 in the late stage 
and the presence of fructose at 5 mM enabled the cells to utilize fructose and sustain 
glycolysis at a low flux. As anticipated, lactate was consumed along with fructose upon 
glucose depletion. 
6.5.2.3 Investigating the memory effect in metabolic shift 
Metabolic shift has been speculated to have a memory effect, i.e. once it is initiated, 
even if we switch back the sugar to glucose the cells should continue to consume lactate. 
In order to test this hypothesis, the cells cultured in glucose medium were switch to fructose 
medium in order to initiate lactate consumption, as shown in the previous section. After a 
5-10 mM reduction in lactate concentration, the cells were then transferred back to glucose 
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feeding at different levels. When the cells were maintained at 3 g/L, 1.5 g/L or 1 g/L of 
glucose, the cells continued to produce lactate. Only when the cells were maintained at 0.5 
g/L, the cells marginally continued to consume lactate (Figure 0-34). 
 
Figure 0-34: Mixed substrate culture with switch back to glucose after lactate 
consumption. Concentration of cells (), glucose (), fructose () and lactate () 
for cells switched to glucose after a 5-10 mM reduction in lactate concentration and 
then cells were switched to (A) 3 g/L, or (B) 2 g/L (C) 1 g/L (D) 0.5 g/L glucose 
concentration. Open arrowhead shows time point for switch to fructose and solid 
arrowhead shows time point at which cells were switched back to glucose.  
  102 
Also, for maintaining the lower glucose concentrations (1 g/L and 0.5 g/L) the cells 
had to sampled and fed twice a day to avoid glucose starvation. Despite that effort, glucose 
was completely depleted by the time the cells were fed, It was also observed that the pH of 
the culture increased (became more basic) considerably after lactate consumption. The pH 
was not controlled in the shake flasks. 
6.6 Discussion 
Time-series transcriptome data to identify dynamic promoters in CHO cells whose 
expression is dependent on culture stage. We contended that these promoters can be used 
for the expression of transgenes in cell engineering. 
 Gene expression in cultured mammalian cells is typically not highly dynamic. For 
a given gene, the transcript levels in culture usually only changes by a few folds. In the 
fed-batch cultures investigated in this study, the number of genes whose transcript level 
changes more than 5-fold on average is fewer than 200. This is in contrast to what is often 
observed during tissue development in vivo, for example in adipogenesis (Soukas et al, 
2001); and in stem cell differentiation in vitro, where drastic transcription pattern change 
is not uncommon (Takahashi & Yamanaka, 2006; Ulloa-Montoya et al, 2007). 
Based on the identified transcription patterns, 15 dynamic promoters that give 
similar upswing dynamics under different fed-batch conditions were selected. Among 
them, three genes (Mmp12, Txnip, and Serpinf1) showed similar profiles in a different 
producing cell line. Even though both lines were derived from CHO-K1, minute 
differences in culture conditions and mutations accumulated over long term culturing may 
have resulted in drastic difference in transcriptional responses. 
Since Txnip was also shown to be dynamically expressed in another CHO cell line 
undergoing temperature shift and sodium butyrate treatment (Kantardjieff et al, 2010a), it 
was selected for subsequent promoter isolation. A fragment of approximately 800 bp 
upstream of the putative start codon of Txnip was isolated and used for further analysis. 
Sequence comparison to the mouse homolog revealed the presence of a TATA box, a 
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carbohydrate response element (ChoRE), a CAT box, and the binding sites of several 
transcription factors such as FOXO (Figure 0-29A). The equivalent region in mouse has 
been shown to harbor a promoter activity at least 5-fold higher than the SV40 promoter 
(Wang et al, 2005). 
It is conceivable that the isolated promoter fragment, albeit capable of conferring 
essential transcriptional activities, may not harbor all necessary regulatory elements to fully 
mimic the endogenous expression profile of Txnip. 
The approach taken in this study was through random integration of transgene 
driven by the promoter. A different approach is to insert the transgene in the locus under 
the control of the endogenous promoter. Such targeted transgene integration has been 
greatly facilitated by the advanced in various genome targeting methods, including Zinc 
finger nuclease (ZFN) (Keeler et al, 1996; Urnov et al, 2005; Urnov et al, 2010), 
transcriptional activator-like effector nuclease (TALEN) (Boch et al, 2009; Christian et al, 
2010; Miller et al, 2011; Mussolino et al, 2011) and clustered regulatory interspaced short 
palindromic repeats (CRISPR)/Cas-based technologies ((Cong et al, 2013; Mali et al, 2013; 
Ronda et al, 2014); reviewed in (Gaj et al, 2013)).  
The employment of cell’s promoter to engineer the dynamic expression of 
transgenes presents a novel approach to enhance cell’s characteristics. Most cell 
engineering studies use strong, constitutive promoters originated from bacteria and viruses 
such as CMV or SV40 to drive the transgenes (Seth et al, 2006a; Wurm, 2004). For 
example, the expression of mGLUT5 gene driven by a constitutive promoter was shown to 
reduce lactate accumulation (Wlaschin & Hu, 2007a). The expression levels of these genes 
are almost always high irrespective of the culture conditions or cellular states. 
Nevertheless, strong and constitutive expression of a transgene is not always ideal; for 
some transgenes inopportune expression can even be deleterious. The use of an inducible 
promoter minimizes the unwanted transcription and permits the transgene expression only 
in the stage during which it is desired (also discussed in (Weber & Fussenegger, 2007). It 
may also provide a wider range of gene expression. In contrast, for dynamic expression in 
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sync with cell’s cultural rhythm, one may have to select a number of promoters and test a 
number of clones to achieve the desired dynamic range of gene expression. Several 
promoter engineering methods have been addressed to achieve high expression ((Brown et 
al, 2014; Mariati et al, 2014) and reviewed in (Ho & Yang, 2014)), but only a few aim for 
such dynamic expression. However, the use of an inducible system may not be desirable 
in large-scale manufacturing due to cost and regulatory considerations. The use of a native 
dynamic promoter has potential advantages as it provides a more controllable and stable 
means for modulating the expression of the transgenes with regard to timing and dose.  
We employed a pTxnip-driven mGLUT5 to demonstrate the concept. Fructose 
consumption remained low in the transfected culture in the early stage in spite of the excess 
of the sugar. The consumption increased only in the late stage of cultivation when the 
expression of mGLUT5 was high. This surge of fructose uptake led to an increased influx 
of sugar into glycolysis, however at a lower rate than glucose, and thus averted apoptosis 
caused by glucose depletion and enabled the culture to switch from lactate production to 
lactate consumption. 
A direct application of this approach in the industry requires other additional 
characterizations, most importantly that of protein quality. Glycosylation is the most 
important of the critical quality attributes of a recombinant protein therapeutic (Abu-Absi 
et al, 2010). The glycosylation precursors UDP-N-acetylglucosamine and UDP-N-
acetylgalactosamine are much lower when cultured in fructose medium compared to 
glucose medium culture (Ryll et al, 1994), and may potentially affect glycosylation status 
and hence, the protein quality. However, it is speculated that metabolic shift has a memory 
effect, i.e., after switching to lactate consumption, the cells may continue to consume 
lactate even if fructose replaced by glucose. In that case, the cells will be exposed to 
fructose only for a short time period which may not impact the product quality 
significantly. Unfortunately, we find that the cells actually switch back from lactate 
consumption to lactate production stage after replacing fructose to glucose (Figure 0-34). 
It must be noted that the experiment was not conducted with adequate pH and DO control. 
When lactate consumption occurs, the pH of the culture media goes down considerably 
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(more basic). During the switch back to glucose, it is important to maintain more neutral 
to acidic environment in the culture to enable the lactate symporter (with H+) on the cell 
membrane to drive the lactate into the cell. 
The concept of dynamic expression in sync with culture stage may also be applied 
to control apoptosis for process enhancement. Many apoptotic genes are expressed at high 
levels only when under stress conditions, such as heat shock or addition of histone 
modification agents, or at the late stage of a fed-batch culture. Over-expression of anti-
apoptotic genes has been shown to delay the decline of culture viability. However, over-
expression of some anti-apoptotic genes during the exponential phase may impair rapid 
proliferation, as reported in the case of high-level expression of anti-apoptotic genes 
retarding cell growth (Dorai et al, 2009; Nivitchanyong et al, 2007). Anti-apoptosis 
strategies, such as over-expressing anti-apoptotic genes or siRNAs against pro-apoptotic 
genes may be best carried out using dynamic promoters. 
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Chapter 7: Developing Genomic Resources for CHO Cells 
7.1 Summary 
This chapter summarizes the results of the collaborative efforts initiated by our lab 
to develop and enhance genomic resources for CHO cells. The first part of this chapter 
describes the assembly and annotation of the Chinese hamster and CHO cell transcriptome. 
The second part describes our efforts to enhance the Chinese hamster genome assembly. 
The final part of this chapter discusses the evaluation of two methods for the high-
throughput identification of the transgene integration sites in CHO cell lines. 
7.2 Context statement 
A collaborative effort funded by the Consortium for CHO Systems Biotechnology 
was initiated for developing and applying genomic resources for Chinese hamster and CHO 
cell lines by my advisor, Prof. Wei-Shou Hu. Thiruvarangan Ramaraj and Joann Mudge 
from the National Center for Genome Resources; Faraaz Noor Khan Yusufi from the 
Bioprocessing Technology Institute; Getiria Onsongo and Kevin Silverstein from the 
Minnesota Supercomputing Institute at the University of Minnesota; Adam Hauge and 
Kenneth Beckmann at the University of Minnesota Genomics Center; Mohit Sharma and 
Prof. George Karypis from University of Minnesota played important roles in the success 
of this project. Kathryn C. Johnson and Arpan Bandyopadhyay from Prof. Wei-Shou Hu’s 
lab assisted on the transcriptome annotation and the genome quality assessment, 
respectively. Postdoctoral associates Mingyong Xiong and Hsu-Yuan Fu assisted me in the 
integration site analysis project. 
The transcriptome assembly was done by FNKY using the Trinity assembler, while 
the genome assembly was done by MS. Gapclosing was done by TR, while NV conducted 
the re-scaffolding steps. NV and MS conducted quality assessments of the genome and 
transcriptome. The transcriptome annotation pipeline was automated by GO and executed 
by NV and KCJ. Genome annotation, genome assembly and the annotation statistics and 
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figures for transcriptome and genome annotation were generated by NV. GK, WH, KS and 
JM provided guidance for many of these efforts. 
The integration site analysis methods were conceptualized by WH and NV. Initial 
experiments for integration site analysis were conducted by NV and MX. The pipeline for 
data processing was developed by NV and executed by HF and MX. The figures for this 
section were generated by MX, HF and NV. 
7.3 Assembly and annotation of the Chinese hamster and CHO cell 
transcriptome 
7.3.1 Introduction 
The past few years have seen a major expansion in the genomic resources that are 
publically available for CHO cells. The Chinese hamster genome and transcriptome have 
been sequenced, and there is continued interest in studying different genomic aspects of 
CHO cells using sequencing technologies. While plenty of information is available, it is 
still not directly usable for omic analyses, mainly because of the lack of useful annotation. 
Most softwares for functional analysis only accept mouse or human gene symbols. There 
are also no Chinese hamster-specific ids that can be used for such analyses. For example, 
the Chinese hamster genome in NCBI has 22,036 CHO transcripts, of which only ~ 30% 
of annotations are usable for functional analyses. The remaining transcripts have been 
given ‘hypothetical’ or ‘predicted’ gene status. The accurate gene determination is 
extremely valuable, however, a small dataset of 8,000 genes cannot give us much 
functional insight from transcriptomic studies. 
Our lab initiated a collaborative effort to assemble and annotate the Chinese 
hamster and CHO cell transcriptome. Historical transcriptome sequencing data in Sanger, 
454 and Illumina sequencing platforms were used to assemble the transcriptome using the 
Trinity assembler (Grabherr et al, 2011). The capability of assembling large datasets while 
retaining alternative splicing information, made the Trinity assembler suitable for our 
purposes. A total of 353,445 transcriptome contigs were compiled in the final 
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transcriptome database. A rigorous annotation pipeline was developed in-house, and used 
to annotate the assembled transcriptome with homologous gene IDs from related species. 
The annotated transcriptome assembly has a comprehensive coverage of the CHO 
transcriptome which is a valuable resource for studying CHO cells. 
7.3.2 Results and discussion 
7.3.2.1 Transcriptome assembly 
Expressed Sequencing Tags (ESTs) with the Sanger sequencing technology were 
generated by Hu and coworkers in ca. 2005 (Kantardjieff et al, 2009; Wlaschin et al, 2005).  
An approach of sequencing diverse cell sources, culture conditions, and treatments was 
used. Several Chinese hamster tissue sources were added to increase the diversity of 
transcripts. Some of the libraries were normalized to remove redundant copies of highly 
expressed transcripts. 
Illumina sequencing allowed us to sequence to much greater depths and detect rare 
transcripts. The treatments used to maximize transcript detection included 5-azacytidine 
(DNA demethylation), tunicamycin (inhibition of N-glycosylation, induction of ER stress, 
cell cycle arrest), and sodium butyrate (histone deacetylation inhibitor). In total, more than 
40 Gbp of transcriptome data was obtained (Table 0-4). 
Since the sequencing error profiles in different sequencing platforms vary 
significantly, the data generated from each sequencing platform was compiled into separate 
bins. Each bin was assembled individually using the Trinity assembly pipeline (Grabherr 
et al, 2011).  The assembly from the three bins were pooled together as a combined 
assembly. 
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Table 0-4: Transcriptome sequencing reads used for the Trinity assembly. Reads 
from Sanger, 454 and Illumina sequencing technologies were used for the assembly. 
A total of more than 40 Gbp of transcriptome sequence was used for the assembly. 
Description (mRNA Source) No. of 
Reads/EST
s 
Average 
Read 
Length 
(bp) 
Total 
Output  
Sanger Sequencing 
CHO DXB11 105,141 ~ 800 84.1 
Mbp Recombinant CHO DXB11 producing IFNγ 
Recombinant CHO DXB11 producing IgG 
Recombinant CHO DG44 producing IgG 
 Sodium butyrate treated 
Recombinant CHO DG44 producing IgG 
 5-Azacytidine treated 
Recombinant CHO DG44 producing IgG 
 Tunicamycin treated 
Chinese hamster brain 
Chinese hamster spleen 
454 Sequencing 
Recombinant CHO-K1 (IgG) 
• Normalized library 
• Exponential growth phase, suspension  
• GsuI digestion of polyA 
399,744 212 84.75 
Mbp 
Recombinant CHO-K1 (IgG) 
• Normalized library 
• Exponential growth phase, suspension 
GsuI digestion of polyA 
262,059 219 57.39 
Mbp 
Illumina sequencing 
Recombinant DG44 (IgG) 
• Exponential growth phase, suspension  
• Serum independent 
55,807,972 46 2.57 
Gbp 
Recombinant DG44 (EPO)- High Producer 
• Exponential growth phase, suspension  
• Serum independent 
• Weak promoter, strong selection 
43,766,688 90 3.94 
Gbp 
Recombinant DG44 (EPO)- Low Producer 
• Exponential growth phase, suspension  
• Serum independent 
• Weak promoter, strong selection 
47,611,596 90 4.29 
Gbp 
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Description (mRNA Source) No. of 
Reads/EST
s 
Average 
Read 
Length 
(bp) 
Total 
Output  
Recombinant DG44 (IgG)- High Producer 
• Exponential growth phase, suspension  
• Serum independent 
• 5-azacytidine treatment 
49,712,048 90 4.47 
Gbp 
Recombinant DG44 (GFP)- Unamplified cell line 
• Suspension culture 
• 0 mM MTX treatment 
6,091,962 90 0.55 
Gbp 
Recombinant DG44 (GFP)- Unamplified cell line 
• Suspension culture 
• 50 mM MTX treatment 
6,832,790 90 0.61 
Gbp 
Parental DG44 
• Exponential growth phase, adherent  
• Serum dependent 
36,877,142 90 3.32 
Gbp 
Chinese Hamster Brain Tissue 
Brain mRNA from one late adolescent virgin 
female hamster 
47,225,174 90 4.25 
Gbp 
Chinese Hamster Liver Tissue 
Liver mRNA from one late adolescent virgin 
female hamster 
73,223,442 90 6.59 
Gbp 
Parental CHO cell line 
Untransfected 
183,992,242 50 9.20 
Gbp 
 
There is a finite possibility that the transcriptome sequences specific to certain 
tissues are missing in our dataset. In an attempt to include such data, other sources such as,  
a previous in house assembly (Jacob, 2011)  and the NCBI RefSeq database were 
considered. The sequences from these sources that are unrepresented in our transcriptome 
assembly were identified using BLAST (Altschul et al, 1990; Mount, 2007). In order to 
avoid adding spurious transcriptome sequences, a multiple evidence strategy was 
employed, i.e. only those unrepresented sequences with evidences from both the previous 
assembly and RefSeq database were added to the combined transcriptome assembly. The 
remaining sequences were aligned to the Chinese hamster genome to confirm their 
existence. In this way, 3657 sequences were identified and added to the transcriptome 
contigs (Figure 0-35). The final number of transcriptome contigs was 353,445. 
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The assembly statistics for the contigs assembled from each read library are shown 
in Table 0-5. 248 Mbp of the transcriptome sequence was assembled from Illumina reads 
alone. While the number of contigs generated was very high, 321,381 of these belonged to 
263,967 contig groups. A contig group contains all contigs that are similar in sequence and 
contain all possible variants of the transcripts. All the variants of the contigs were retained 
because of the possibility of alternative splicing. 
 
Figure 0-35: Workflow of the transcriptome assembly: The sequencing data 
obtained from three different sequencing technologies were assembled individually. 
Transcriptome information from other sources were identified by aligning to the 
assembly and subsequently included in the transcriptome. 
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Table 0-5: The number of contigs obtained from each of three sequencing platforms. 
Majority of the contigs are assembled from Illumina reads. The median contig 
length of the Illumina contigs is greater than the 454 and Sanger-sourced contigs. 
 EST contigs assembled from 
 Sanger Reads 454 Reads Illumina Reads 
Number of contigsa 9,720 18,533 321,381 
Number of contig groupsb 9,418 17,239 263,967 
Total sequence (Mb) 8.12 6.70 248 
Min contig length (bp) 201 201 201 
N50 contig length (bp) 889 369 1,597 
 
 
Figure 0-36: Contig length statistics of the final combined transcriptome contigs: 
Table shows basic statistics. The bar chart shows the contig length distribution. Bar 
chart in the inset shows contig length distribution for contigs greater than 1000 bp in 
length. 
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The assembly statistics of the transcriptome shows an average contig length of 769 
bp and an N50 contig length of 1563 bp. N50 is an estimate of the median contig length. It 
is calculated by sorting the contig lengths in descending order followed by calculating the 
minimum contig length representing half of the total assembly. The estimate of average 
mRNA length in humans is approximated to be 1400 bp. Hence, most of the genes 
represented in the assembly can be assumed to be near full-length. The chart illustrating 
the size distribution of the EST contigs shows that most of the contigs are small in length. 
However, the number of contigs more than 1,500 bp is significantly large (Figure 0-36).  
Even though the transcriptome contigs are not near full length, the number of 
contigs is still high enough to be alarming. The large amount (40 Gbp) of sequence 
information can potentially lead to the assembly of many variants that may have very low 
representation in the sequencing data. Since the sequencing was conducted in 2009 when 
the Illumina sequencing technology was not as mature as it is today, these sequences could 
have also arisen from reads that may have suffered PCR or ligation errors.  
7.3.2.2 Transcriptome annotation 
The transcriptome contigs were annotated using an in-house homology-based 
annotation scheme. The schema is explained in Figure 0-37. All the transcript contigs were 
repeat masked to remove sequences related to the known repetitive DNA elements. These 
repeat masked contigs were aligned using BLAST to the databases of annotated 
transcriptome sequences from other species, including Ensembl mouse, Fantom 3, 
Ensembl rat, Ensembl human, Noncode v3 (“a” in Figure 0-4). The annotation from the 
alignment is then assigned a tier based on the strength of the BLAST score. A higher 
BLAST score will result in the annotation being categorized within a high tier.  
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Figure 0-37: Detailed homology-based transcriptome annotation pipeline. Firstly, all 
the transcriptome contigs were repeat-masked to conceal the repetitive sequences. 
This repeat-masked sequence was then aligned to the complete dataset of 
transcriptome sequences from mouse, rat and human sources collected from Ensembl 
and Fantom databases. The sequences were also aligned to NONCODE database to 
annotate noncoding RNA. The blast hit scores were used to categorize the annotation 
by strength into three tiers. Contigs with the strongest tier 1 annotation were directly 
added to the final transcriptome annotation, and the annotation from the database 
showing the strongest hit was transferred to the contig. If the contigs hit to all the 
databases with almost equal scores, then the annotation was given according to a pre-
decided database priority shown in the figure. Tier 2, tier 3 and unannotated 
sequences were aligned to further lower priority databases- Genbank and RefSeq. If 
significantly better hits are obtained, then the respective annotation is transferred; 
otherwise the original annotation is retained. Based on the BLAST score, the 
annotation was given tier 2 or tier 3 status. The remaining unannotated sequences are 
unmasked and subjected to the same annotation pipeline. The final transcriptome 
annotation includes one annotation per contig along with a tier assignment. 
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A contig with blast score higher than 200 to a certain reference transcript was given 
a tier 1 status. A score between 100 and 200 was categorized as tier 2, and a score less than 
100 was assigned a tier 3 status. Within each tier, a higher priority was given to the 
annotation arising from Ensembl mouse. The priority list of databases is shown in Figure 
0-37. If the annotation score from a lower priority database was higher than that from a 
higher priority database, then the annotation from the lower priority database was assigned 
only if the difference between the scores is greater than 20. 
Tier 2 and tier 3 contigs along with the unannotated contigs were then aligned to 
the lowest priority database “b”, which contain sequences from GenBank (Benson et al, 
2014). The GenBank database is a publicly available database of sequence information 
deposited by individual laboratories. The sts, gss, refseq_rna, nt, est and patnt databases 
were used. A similar strategy was used to assign tiers to the annotations. Similar to the 
previously described case, a GenBank annotation was assigned only if the BLAST score 
to the GenBank sequence was significantly higher than the BLAST score to the databases 
in the group “a”. 
The sequences that remain unannotated were then unmasked, and aligned to all the 
databases. The annotation with the highest score was recorded for each of these contigs. 
Table 0-6: Distribution of contigs among the four annotation tiers. Most contigs 
have tier 3 annotation. Only a few contigs remain unannotated. 
Tier Number of contigs 
Tier 1 94,282 
Tier 2 84,422 
Tier 3 165,242 
Tier 4 9,321 
No Annotation 178 
Total 353,445 
 
The distribution of the contigs between the tiers is given in Table 0-6. More than 
25% of the contigs have tier 1 annotation. Majority of the contigs have tier 3 annotation. 
  116 
Only 178 contigs remained unannotated following the complete execution of the annotation 
pipeline. 
Most functional class analysis software use curated gene sets, pathways or 
interaction networks, which are only available for human or mouse genes. This can be 
attributed to their popularity in genomic research, and the fact that most of the interaction 
data has been generated for human and mouse genes. Often functional class analysis in 
CHO cells is conducted using mouse gene ids because it is closest relative to Chinese 
hamster among the rodents. Furthermore, we can avail of the vast amount of functional 
interactions and pathway information available for mouse. It is for this purpose that 
Ensembl mouse database was given the highest priority in the annotation pipeline. 
Table 0-7: Breakdown by database within the tier 1 contigs. Ensembl mouse was 
given the highest priority in the categorization, therefore most contigs have Ensembl 
mouse annotation.  
Database Number of 
sequences 
Number of unique Gene 
Ids 
Ensembl mouse 84,906 18,416 
Fantom3 4,168 2,725 
Ensembl rat 1,816 932 
Ensembl human 1,515 882 
NONCODEv3 1,254 459 
 
The distribution of the assigned annotations among the databases within the tier1 
contigs shows that close to 90% of the sequences have mouse annotation, representing 
18,416 mouse genes (Table 0-7). Second priority is given to Fantom3 which is a manually 
curated database of functional annotation in mouse generated by the RIKEN consortium 
(Carninci et al, 2005). Only a few tier 1 contig sequences were assigned to annotation from 
Ensembl rat and human and NONCODE databases. 
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Among the sequences in all the tiers, the most represented database is still Ensembl 
mouse, however, only ~60% of the sequences have Ensembl mouse annotation (Figure 
0-38A). The average nucleotide identity between mouse and Chinese hamster is 95% 
(Figure 0-38B). 24,652 Ensembl mouse genes were covered out of a total of 39,179 total 
mouse genes.  
 
Figure 0-38: (A) Distribution of annotation by database for all the contigs. Most 
contigs have been annotated to mouse. Only a few contigs show better hits to human 
and rat. Many contigs also have annotation to Genbank. (B) Distribution of percent 
identity to mouse transcripts. Most transcriptome contigs have high identity (95-
100%) to mouse. 
Most of the functional analysis tools also require that all the annotations are of the 
same type. For example, either all genes in mouse should be represented entirely by their 
gene symbols, or entirely by MGI ids or by Ensembl mouse gene ids. Therefore, all the 
annotations need to be condensed to one type of id. Ensembl mouse id was selected because 
linking information is more easily available from Ensembl ids to other databases. 
All the annotations from Ensembl human and rat databases were converted to the 
corresponding mouse annotations using orthology information. Further, Fantom3 gene ids 
were also converted to the corresponding Ensembl mouse id. Out of 39,179 total mouse 
genes, 24,932 mouse genes were finally covered in our database. The mouse gene database 
also includes pseudogenes that may or may not have an evidence of expression, as well as 
genes that are expressed in specific tissues that we do not have in our database.  
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Figure 0-39: Coverage of key pathways: The gene sets for some pathways curated 
by KEGG and REACTOME were collected for mouse. The corresponding mouse 
ids in the annotated transcriptome were used to estimate the coverage of the 
pathway. Most pathways relevant to bioprocessing were well covered in the 
transcriptome assembly. 
Exploring the coverage of major functional groups that are relevant for 
bioprocessing, we find that most functional classes are completely covered (Figure 0-39). 
The gene sets were obtained from KEGG pathway database (Kanehisa et al, 2014). The 
functional classes with lower coverage 60-80% are from pathways such as olfactory 
transduction, olfactory signaling, systemic lupus erythematosus and telomere maintenance. 
A few genes in these pathways are probably tissue specific or disease related, because of 
which they were not represented in our transcriptome assembly. 
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7.3.3 Conclusions and future outlook 
Resource poor species like Chinese hamster can greatly benefit from next-
generation sequencing. A large amount of transcriptome sequence data from diverse 
sources was used to assemble 353,445 transcriptome contigs. A major disadvantage of the 
high throughput sequencing approach is the large number of contig sequences generated 
by the assemblers. Even though they represent only a few genes, an ideal algorithm should 
be able to combine these sequences into longer and fewer contigs. 
Although sequencing and assembly methods are available in plentitude, the 
annotation of the assembled genome or transcriptome is a unique challenge. Annotation 
strategies are almost species-specific, so most of the tools have to be derived in-house.  The 
annotation pipeline developed for annotating Chinese hamster transcriptome can be easily 
extended to other resource-poor species with a few alterations. The automated feature of 
this pipeline enables easy updates as more data becomes available for the reference 
genomes.  
A good quality reference transcriptome assembly will prove to be valuable for using 
omic approaches to understand and improve the role of CHO cells as recombinant protein 
producers. 
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7.4 Assembly and annotation of Chinese hamster genome 
7.4.1 Introduction 
Transcriptomic studies can reveal immense information about the molecular 
changes occurring in a given process. Information can be gathered about the transformation 
of CHO cells from non-producers to hyper-producers with productivities equivalent to 
nature’s professional secretor cells like plasma cells or liver cells. However, the most 
common form of intervening cells is still manipulating the genome, usually to permanently 
alter the transcription of some target genes.  
In the context of recombinant protein production, it is desired to target the 
recombinant gene to a ‘hotspot’ to ensure high and stable transcription of the recombinant 
gene of interest. Efficient tools like CRISPR/Cas9, Zinc Finger Nuclease (ZFN) and 
Transcription Activator-Like Effector Nuclease (TALEN) have made targeted genome 
engineering accessible for use in bioprocessing. For these technologies to be applied for 
bioprocessing, a good reference genome must be available. It is also of interest to determine 
the integration site of a cell line to ascertain its propensity to become unstable over the 
course of expansion to the production stage. Such investigations necessitate having access 
to the organism’s genome. 
The previous section described the challenges in transcriptome assembly and 
annotation. One of the major challenges was the large number of contigs generated by the 
assemblers for high throughput sequencing data. The genome can be used as an aid to put 
together contigs from the same gene into full length transcripts. 
To this end, the CHO-K1 genome was sequenced in 2011 through a collaborative 
effort (Xu et al, 2011). However, knowing that CHO cells are genetically heterogeneous 
with many chromosomal aberrations (Worton et al, 1977) and aneuploidy (Kurano et al, 
1990), a reference sequence that is more invariable is suitable as a standard for genomic 
studies. So, our group initiated an effort to sequence, assemble and annotate the Chinese 
hamster genome in early 2010. Midway into our efforts, an independent group published 
the sequence of the Chinese hamster genome (Brinkrolf et al, 2013; Lewis et al, 2013). 
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This opened up an opportunity to improve the quality of the Chinese hamster genome 
assembly. 
Current technologies for assembly cannot be easily modified to accommodate 
reassembly or assembly improvements. The algorithms are either too memory intensive or 
take a long processing time. We used a two prong approach to improve the genome 
assembly: (1) using an in house assembly as the reference, and information from the public 
Chinese hamster sequencing to improve the assembly, and vice versa; (2) using the public 
assembly as the reference and the information from our in house sequencing to improve it. 
The decreasing cost of sequencing has fuelled a lot of efforts to sequence genomes, and 
such events requiring the combination of different genome assemblies or improving 
assemblies will be encountered often in the near future. Our approach and learning will 
definitely help similar efforts in other organisms. 
7.4.2 Materials and methods 
7.4.2.1 Source of genomic DNA 
DNA was extracted from the liver of a single, highly inbred, female Chinese 
hamster of the 17A/GY strain (Cytogen Hamsters, West Roxbury, MA). DNA was isolated 
using the DNeasy Blood and Tissue Kit (Qiagen, Valencia, CA) using standard 
manufacturer recommended protocols. 
7.4.2.2 DNA library preparation and sequencing 
The extracted DNA was fragmented by nebulization and ligated with Illumina 
sequencing adaptors to facilitate sequencing (Illumina, CA). For the short insert libraries, 
the DNA was size-selected using agarose gel electrophoresis. Fragments with insert sizes 
of 300 bp, 400 bp and 500 bp were selected and gel-purified. The size distribution of the 
DNA fragments was verified in a 2100 Bioanalyzeer using a DNA 7500 chip (Agilent, 
Santa Clara, CA). 
For the long insert libraries, the DNA was fragmented, end labelled with biotin, and 
then size selected for 3kb. The DNA fragments were circularized by ligation of either ends 
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of the linear fragment. The DNA was then fragmented and then the portion of the DNA 
near the site of ligation was selected using streptavidin bound magnetic beads. Illumina 
sequencing adaptors were ligated to these DNA fragments and then size selected prior to 
sequencing on an Illumina GAIIx flow cell. DNA-PET was used to generate 10 kbp and 
20 kbp long insert mate-pair libraries. Illumina v3 chemistry was used and the base calling 
was done by the GA 1.4.2 pipeline using recommended standard parameters. 
7.4.3 Results and discussion 
CHO cells, since their isolation in 1958 (Tijo & Puck, 1958) have been subjected 
to many mutagenic agents, many transfections and antibiotic selections. They have also 
been maintained in culture in many laboratories for many years. Accumulation of 
mutations over culture time is quite common along with chromosomal abnormalities and 
aneuploidy. Even though, the Chinese hamster has 11 chromosome pairs, CHO cells 
usually have a modal chromosome number of 20 or 21 (Worton et al, 1977; Wurm & 
Hacker, 2011). Several CHO cell lines derived from the mutagenesis of the first CHO cell 
derived by Puck also have several differences in chromosome number (Derouazi et al, 
2006). 
The chromosomal variability of CHO cells in culture prompted us to choose 
Chinese hamster as a reference genome instead of CHO cells. The 17A/GY strain of a 
female Chinese hamster was sequenced. 
7.4.3.1 Sequencing of the Chinese hamster genome 
The whole genome was sequenced by high throughput Illumina sequencing. In 
Illumina sequencing, the DNA is at first fragmented and then size selected to allow a 
narrow size distribution. Following this, sequencing adaptors are ligated to both ends of 
each fragment. Sequencing is done from both of the ends to generate a pair of reads for 
each fragment. The distance between the two reads is known a priori from the size 
distribution. Insert sizes of 300 bp, 400 bp and 500 bp were used in sequencing. The 
distribution of sequencing data among the libraries is shown in Table 0-8. A total of 273 
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Gbp of sequence data was used to assemble the Chinese hamster genome. Considering a 
genome size of 2.66 Gbp (Greilhuber et al, 1983), this amounts to about 100 X coverage 
of the genome.  
Table 0-8: Genome sequencing data- Short insert (300, 400 and 500 bp) and long 
insert sequence reads (3000, 10000 and 20000 bp) were obtained. A total of 273 Gbp 
of genome sequence was used for the assembly. 
Library type 
Number of 
Reads (x10-6) 
Insert Size 
(bp) 
Read 
Length (bp) 
Total Output 
(Gbp) 
Paired  End 796 300 90 71.65 
Paired End 513 400 150 76.93 
Paired End 499 500 150 74.89 
Mate Paired  End 235 3000 54 12.68 
DNA-pet 272 10000 76 20.71 
DNA-pet 216 20000 76 16.44 
Total 2766 ------ ------ 273 
 
7.4.3.2 Data pre-processing and assembly 
The sequencing data was pre-processed to remove low quality reads, reads with 
low complexity and trim the adapter sequences. Any read that has a consecutive 15bp 
match with a primer sequence was rejected along with its pair. A minimum quality cut-off 
of 5 on a scale of 0-40 was set for each base to be accepted. The first 3 bases of a read and 
the end of a read are trimmed off if they fall below this threshold. After trimming, only 
sequences longer than 32 bp were retained. Low complexity filtering was carried out to 
further improve the read quality. Any read containing 20 consecutive bases of low 
complexity was flagged. If the remaining non-low complexity parts of the read added up 
to 32 bases, then the read was kept. 
High throughput sequencing reads are usually short sequences that have to be 
assembled into contigs based on evidence of overlaps. Short read assemblers like AbySS 
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(Simpson et al, 2009) or SOAPdenovo (Luo et al, 2012) and ALLPATHS (Gnerre et al, 
2011) are designed to accommodate such short reads for assembly. Based on critical 
evaluations from (Bradnam et al, 2013; Earl et al, 2011; Salzberg et al, 2012), we decided 
to use the AbySS assembler for assembling the Chinese hamster genome. 
Sometimes for genome assemblies from high throughput sequencing, the 
sequencing data is preprocessed to correct for sequencing errors. Since high throughput 
sequencing generates gigabytes of data in a single run, even a small error rate results in a 
large number of erroneous base calls that is spread out among the sequencing reads. Some 
assemblers include an error correction module to correct such reads. Error correctors scan 
the reads for k-mers with low frequency of representation and substitute a few bases to 
increase its representation frequency. This is done under the premise that k-mers with much 
lower frequency than the median frequency probably arise from sequencing errors. In some 
cases, it is found that the resulting assemblies show better contiguity. In order to explore 
this possibility, we conducted error correction using the Musket substitution error based 
corrector, which is the major source of error in Illumina sequencing (Liu et al, 2013).  
 
Figure 0-40: k-mer sweep for in house assembly of the Chinese hamster genome. 
Several k-mer sizes from 65 – 80 bp were assessed for the transcriptome assembly. 
Prior to error correction (), the optimum k-mer was 70 bp, and for the error 
corrected reads (), the optimum k-mer increased to 72 bp. 
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AbySS is a typical de Bruijn graph-based genome assembler, where the reads are 
broken into k-size fragments, and then connected to each other based on evidence from 
individual reads. The paths with a high degree of confidence were joined together to make 
up the genome contigs. The parameter ‘k’ is very important for the optimal performance 
of the assembler, and has to be optimized before next step. A series of k-mer values from 
65 – 80 bp were tested on the short insert paired end reads in the first step of the assembly. 
The optimum parameter was found to be 70 for the preprocessed reads, and 71 for the 
preprocessed and error corrected assembly.  
 
Figure 0-41: Sequential assembly workflow for Chinese hamster draft genome – 
Following k-mer optimization, the optimum k-mer was used to assemble the short 
insert reads into contigs using AbySS. The 3 Kbp long insert reads were used to 
scaffold together the contigs from the assembly. Subsequently, the 10 Kbp long insert 
reads were used to re-scaffold the scaffolds from the previous stage of assembly. 
Similary, the 20 Kbp long insert reads were then used for further scaffolding. This 
genome assembly is referred to as the in-house assembly. 
We chose to use the assembly that was done without the error corrected reads 
because the improvement after error correction was not very significant (Figure 7-6). The 
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contig N50 at optimum k-mer was 4.2 Kbp for preprocessed reads, and improved only to 
4.4 Kbp for the error corrected assembly. 
The next step after contigging is scaffolding, which uses the long insert reads for 
establishing long-range ordering of the contigs, even if the intervening sequences between 
the contigs is unknown. Long-insert reads are essential for bridging repetitive and/or low 
complexity sequences that are longer than the short-insert size.  The final scaffold is a series 
of ordered contigs separated by stretches of N’s, where the length of the stretch is an 
estimate of the distance separating the contigs on the genome. The scaffolder estimates the 
insert size of the library by mapping the reads to the contig assembly. Hence, in order to 
be able to bridge the contigs using long insert reads, the contig length should be greater 
than the lowest insert size of the libraries used for scaffolding, or preferably longer than 
most of them. Even though the lowest insert size was 3 Kbp, the N50 of the contig assembly 
was 4.2 Kbp. However, it is still lower than the physical length of 10 Kbp and 20 Kbp 
insert size libraries. The standard scaffolding procedure had to be modified to overcome 
this limitation. A sequential assembly strategy was employed. The 3 Kbp long insert 
libraries were used to conduct the preliminary assembly. The 10 Kbp long insert reads were 
used to scaffold the preliminary assembly, and create a secondary assembly. The secondary 
assembly was then scaffolded using the 20 Kbp long insert reads to obtain the final Chinese 
hamster in-house draft assembly (Figure 0-41). 
7.4.3.3 Integration of public genome data into Chinese hamster genome 
assembly  
Two independent efforts towards the sequencing and assembly of the Chinese 
hamster genome were published recently. Some of the sequencing data was made 
publically available (Brinkrolf et al, 2013; Lewis et al, 2013). We used this opportunity to 
use the publically available data from these projects to enhance our in-house assembly. 
Only a portion of the raw sequence data was made publically available, so conducting a 
combined assembly was not possible. We had to develop a unique approach to integrate 
the information from public sources into our in-house assembly. We used the following 
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strategies- (1) Using the in-house assembly as the reference, we used the limited public 
sequencing data to enhance its contiguity (Figure 0-42A) (2) Using the raw sequencing 
reads from in house efforts, we attempted to improve the public Chinese hamster assembly 
(Figure 0-42B). 
The in-house assembly had 19% gaps in the genome (Table 0-9), a relatively high 
fraction for a genome assembly. This was much higher than the 2.5% gaps in the public 
assembly. So we chose to employ a gap filling approach to improve in-house data. By 
mapping the short insert reads back to the assembly, it can be locally reassembled to 
improve the contiguity of the draft genome. Gapcloser was used for this purpose (Tsai et 
al, 2010). The short insert reads (SIR) from public repository and the short insert and long 
insert reads (LIR) from our in-house sequencing efforts were used to fill in the gaps in the 
in house genome assembly (Figure 0-42A). By this approach, the gaps reduced from 19% 
to 8% (Table 0-9). Because of the high fraction of gaps, the software ran for 70 days until 
completion. 
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Figure 0-42: Workflow for genome assembly improvement. (A) Short insert reads 
(SIR) from public genome sequencing efforts and short and long insert reads from 
in house efforts were used to close the gaps in the in house assembly. This is the final 
enhanced in-house assembly. (B) In-house generated SIR and long insert reads 
(LIR) were used to close gaps in the public Chinese hamster genome draft assembly. 
This assembly was re-scaffolded using the long-insert reads, followed by further gap 
filling using public SIRs. 
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Table 0-9: Draft genome statistics at different stages of genome assembly 
enhancement showing continual improvement in contiguity after each step. 
 Enhancement of the in house 
genome 
Enhancement of the public Chinese hamster genome 
Parameter In house 
genome 
Enhanced in 
house genome 
Public 
genome 
(I) (II) Enhanced 
public 
genome 
Contigs 694,058 314,050 176,068 46,025 46,025 87,104 
Max Contig 
(bp) 
55,898 109,870 219,443 804,483 804,483 961,385 
Mean Contig 
(bp) 
2,933 7,376 12,980 50,189 50,189 26,757 
Contig N50 
(bp) 
4,036 13,950 27,317 127,489 127,489 121,600 
Contig N90 
(bp) 
1,458 3,363 7,453 34,453 34,453 32,129 
Total Contig 
Length (bp) 
2,035,409,935 2,316,301,122 2,285,446,913 2,309,963,092 2,309,963,092 2,330,639,248 
Assembly GC 
(%) 
41.69 41.43 41.39 41.42 41.42 41.43 
Scaffolds 83,691 83,691 10,868 10,867 7,876 49,719 
Max Scaffold 
(bp) 
16,416,848 16,386,994 8,324,132 8,320,503 60,518,007 60,517,459 
Mean Scaffold 
(bp) 
30,143 30,080 215,691 215,652 298,330 47,579 
Scaffold N50 
(bp) 
2,593,447 2,580,348 1,579,055 1,578,388 17,211,978 17,210,817 
Scaffold N90 
(bp) 
182,764 180,187 415,923 415,119 3,499,887 3,013,478 
Total Scaffold 
Length (bp) 
2,522,725,272 2,517,431,033 2,344,125,543 2,343,495,360 2,349,643,860 2,365,556,663 
Captured Gaps 610,367 230,359 165,200 35,158 38,149 37,385 
Max Gap (bp) 191,507 190,436 20,486 20,068 98,050 97,673 
Mean Gap (bp) 798 873 355 954 1,040 934 
Gap N50 (bp) 2,693 5,899 2,422 4,031 4,698 5,036 
Total Gap 
Length (bp) 
487,315,337 201,129,911 58,678,630 33,532,268 39,680,768 34,917,415 
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On the other hand, for improving the public Chinese hamster genome assembly, we 
had to use a slightly different approach due to the low fraction of gaps (2.5%) in the public 
genome. In comparison, the N50 scaffold length was lower (1.6 Mbp) compared to 2.6 
Mbp for the public genome. We used a re-scaffolding strategy to improve the public 
Chinese hamster assembly. However, we first gapclosed the assembly prior to re-
scaffolding. The fraction of gaps were reduced from 2.5% to 1.4% after gapclosing with 
the in-house short insert and long insert reads (Table 0-9). This gapclosed draft genome 
sequence was then re-scaffolded using the in-house long insert reads. AbySS standalone 
scaffolder was used with abyss-bwa as the mapping algorithm instead of abyss-map default 
mapping software (Jackman et al, 2013)   
Ideally, the long insert reads from the public data could have been used to re-
scaffold the in-house assembly to improve the scaffold lengths. However, this data was not 
deposited by the publishing group. By comparing the contiguity and gap length of the two 
draft assemblies (Table 0-9), the enhanced public genome was chosen to be used as the 
draft Chinese hamster genome.  
7.4.3.4 Quality assessments of the Chinese hamster draft genome 
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Figure 0-43: Scaffold GC content distribution shows no evidence of GC-bias in 
sequencing or assembly. The GC content of the scaffolds are evenly distributed 
around the average GC level. 
Quality assessments were done on the draft Chinese hamster genome by aligning 
the EST contigs using a spliced alignment software BLAT (Kent, 2002). Out of the 353,445 
EST contigs, almost 90% of the contigs, 315,432 contigs, aligned to the genome. The 
transcriptome assembly also contained the contigs from the transgenes in the CHO cells. It 
is obvious that the transgenes will not align to the Chinese hamster genome.  
Most sequences obtained from modern sequencing technologies, including 
Illumina, may have a bias towards higher GC content. Such bias can be identified from 
analyzing the GC content of longer scaffolds. The median GC content of the scaffolds was 
42%. The GC content profile is relatively flat at ~42% across all scaffold lengths, indicating 
unbiased sequencing and assembly and absence of GC-bias in sequencing (Figure 0-43). 
Another way to validate the genomic scaffolds is by analyzing the gene synteny of 
Chinese hamster to mouse. The CHO EST contigs that had mouse annotation were aligned 
to the Chinese hamster genome using BLAT. An EST may have multiple hits (alignments) 
to the Chinese hamster genome scaffolds with varying degrees of confidence. For 
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simplicity, only the most confident hit for each EST was listed and termed as the “best 
unique hit”. We first calculated a “score” for each hit, based on the difference between the 
total matches and mismatches within the hit (matches-mismatches). For each EST, the hit 
with the highest score was selected as the best unique hit. Each EST only had one such hit, 
hence they were “unique”. Hits lower than 500 bp in length were discarded for this analysis. 
The position of the gene on mouse chromosome was plotted against the position in Chinese 
hamster scaffolds. A couple of examples are shown where synteny can be observed 
between Chinese hamster and mouse (Figure 0-44).  
Most genes on Chinese hamster scaffold map to mouse genome contiguously. The 
close synteny similarity is suggestive of high quality scaffolding (Figure 0-44A). In the 
example on the lower panel, genes on Chinese hamster scaffold map to many mouse 
genome loci, specifically four different mouse chromosomes (Figure 0-44B). This is not 
necessarily indication of wrong scaffolding, because there could be many rearrangements 
between Chinese hamster and mouse, considering the evolutionary distance between them. 
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Figure 0-44: Quality assessment using synteny between mouse and Chinese hamster. 
The order of genes on mouse genome was compared to the order of genes in the 
assembled Chinese hamster genome. Conserved regions, shown in (A) exhibit high 
similarity in gene order between Chinese hamster and mouse. In this case, the gene 
ordering in a 60 Mbp region of mouse chromosome 2 is retained almost entirely in a 
Chinese hamster scaffold. In a region with lower conservation, such as shown in (B), 
a Chinese hamster scaffold shows hits to four different chromosomes in mouse. 
Within each hit, the genes are in the same order as mouse. 
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All the scaffolds that had more than 40 genes were assessed for the presence of 
such synteny. Out of 147 scaffolds tested, a total of 122 scaffolds showed good synteny 
conservation, similar to Figure 0-44A. 
7.4.3.5 Features of the Chinese hamster genome 
The average GC content in Chinese hamster genome is 41.4%, very close to the 
average of 42% in mouse. The GC content distribution of the genomes were also compared. 
The genome was divided into non overlapping windows of 20 Kbp and the GC content 
within these windows was calculated. The GC content distributions of Syrian hamster, 
Chinese hamster, mouse and rat genomes are very similar. GC content distribution in 
human is quite different from the rodents, with more windows showing lower GC content 
(Figure 0-45). 
 
Figure 0-45: GC content distribution for human, mouse, rat, Syrian hamster and 
Chinese hamster. The genome was divided into non-overlapping windows of 20 Kbp 
each and the GC content of each window was calculated. The distribution of this GC 
content is plotted on the graph. The GC content of Chinese hamster is very similar to 
mouse and Syrian hamster, and then to rat. Human genome has overall lower GC 
content compared to the rodent species. 
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 The EST contigs having Ensembl mouse annotation representing 24,516 unique 
Ensembl mouse genes were aligned to the Chinese hamster genome. A total of 920 
scaffolds out of 7,873 scaffolds contained all the transcriptome contigs. The remaining 
scaffolds either did not possess any gene or possessed only fractions of the other genes. 
The distribution of the genes among the scaffolds reveals that many of the scaffolds are 
very dense in genes, whereas others are rather sparse. About 130 scaffolds had more than 
50 genes per scaffold (Figure 0-46). 
 
Figure 0-46: Distribution of genes over the Chinese hamster genomic scaffolds (bins 
are not uniform). Most genes are present on few scaffolds. About 500 scaffolds have 
one gene per scaffold. 
Using the RepeatMasker program, the genome was also scanned for repetitive DNA 
sequences (Tarailo-Graovac & Chen, 2009; Tempel, 2012). Repeat sequences in the 
genome were searched against the repeat sequences in the genomes of the rodentia class in 
Repbase. A total of 35.4% of the genome was found to have evidence of repeats. This is 
comparable to the repeat content in mouse which is 38%, and is much lower than that in 
human (46%). Long interspersed nuclear elements (LINEs) were overrepresented in the 
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repeat sequences, comprising almost 14% of the genome. Short interspersed nuclear 
elements (SINEs) and long terminal repeats (LTRs) were the next most abundant, each 
represented 9% of the genome. While SINEs and LTRs are present at similar rates in mouse 
and Chinese hamster, the content of LINEs is estimated to be about 19% of the mouse 
genome as compared to 14% identified in the Chinese hamster genome.  
Table 0-10: Repeat sequence analysis in Chinese hamster genome. Repeatmasker 
was used to identify repetitive sequence elements in the genome by comparing the 
sequences to known repeats in rodent genomes. Similar to mouse, LINE sequences 
are a major component of the assembled repears, followed by SINEs and other LTR 
elements. 
  Number of 
elements* 
Length occupied 
(Mbp) 
Percentage 
of sequence 
SINEs  1,648,193 216 9.2 % 
 Alu/B1 655,144 77 3.29 % 
 B2-B4 712,243 113 4.79 % 
 IDs 94,050 7 0.29 % 
 MIRs 116,086 14 0.6 % 
LINEs  607,822 323 13.77 % 
 LINE1 538,196 311 13.24 % 
 LINE2 57,410 11 0.45 % 
 L3/CR1 10,530 2 0.07 % 
LTR elements  659,358 202 8.58 % 
 ERVL 89,244 26 1.09 % 
 ERVL-
MaLRs 
342,673 103 4.39 % 
 ERV_classI 47,873 14 0.61 % 
 ERV_classII 175,813 58 2.46 % 
DNA elements  149,677 31 1.3 % 
 hAT-Charlie 97,977 189 0.8 % 
 TcMar-Tigger 29,812 7 0.3 % 
Unclassified  27,253 129 0.55 % 
Total interspersed 
repeats 
  785 33.4 % 
* most repeats fragmented by insertions or deletions have been counted as one element 
However, the number of LINE elements are similar between Chinese hamster and 
mouse. This could be potentially caused by the difficulty in assembling longer repeats, 
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leading to incomplete assembly or large number of gaps between the genomic scaffolds 
containing the LINE elements (Table 0-10). 
7.4.4 Conclusions 
The decreasing costs of high throughput sequencing has brought in a major 
breakthrough for genomic studies. Progressively more genomes are getting sequenced, and 
large amounts of data are being generated by the day. Considering the importance of CHO 
cells in bioprocessing, it was very critical to generate and use genomic information for 
improving their performance. Several parallel efforts, towards sequencing the Chinese 
hamster genome between 2011 and 2013 made a lot of genomic sequence available. Our 
group also sequenced the Chinese hamster genome. We undertook the efforts to integrate 
the information from all these sources to generate a comprehensive and high quality 
reference genome for Chinese hamster. Although a large number of good softwares for 
assembling genomes are available and being improved on a regular basis, a major challenge 
in this process was the unavailability of software for conducting merging of such genome 
assemblies. Our rationale of approaching this challenge will certainly aid other researchers 
to guide similar efforts in the future.  
The availability of genome sequence for Chinese hamster opens up a plentitude of 
avenues for research. CHO cells have recently been referred to as a ‘quasispecies’ because 
of the extent of genomic variability observed among them. The availability of the genome 
can enable the detailed study of the genomic variability among different CHO cell lines. It 
will also help in estimating the genomic variability in culture. Regulatory bodies require 
therapeutics producing companies to use stable and clonal cell lines for production to avoid 
variability in product quality. Despite tightly controlling the process, the variability in 
product titer and quality is still high. Studying the genomic and transcriptomic changes in 
these cells at different stages of production can give important cues to intervene the 
processes and make them more consistent. 
Genome editing tools like ZFN, TALEN or CRISPR/Cas9 systems can be used to 
knockout genes that affect protein quality or efficacy. For example, the knockout of the 
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fut8 gene leads to defucosylated antibodies in CHO cells, and leads to improved efficacy 
of antibodies through increased ADCC activity. Genome editing tools can potentially be 
used to target transgenes to genomic regions that are stable and transcriptionally active. 
These regions can be discerned from transcriptomic studies. 
The applications of genomics in CHO cell bioprocessing are immense. The present 
state of efforts have just scratched the surface of the discovery space. The Chinese hamster 
genome sequence holds great promise for heightening the state-of-art practices in 
recombinant protein therapeutics production in CHO cells.  
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7.5 Integration site analysis- method development 
7.5.1 Introduction 
The duration of the process of developing a stable cell line for the production of a 
protein therapeutic drug candidate is 4-12 months. After every step in this process, the cells 
have to be screened in large numbers to ensure the stability of the recombinant gene 
expression. In most cases, tens of copies of the transgene are randomly integrated into the 
host cell’s genome. After the amplification step using MTX or MSX treatment, many of 
these copies get amplified to hundreds, or even thousands. After the selection pressure is 
withdrawn, the cells lose some of these copies. After the cells stabilize the gene copy 
numbers, they are selected for further processing. Often in this process, the cell lines 
become unstable because of the silencing of the transgenes or because of the loss of copy 
number. Instead of relying on random integration, by targeting the transgene to an active 
locus, one can ensure stable and high expression of the transgene. Moreover, a single copy 
of the transgene may be sufficient to achieve high expression, thus avoiding the 
amplification process entirely. The elimination of the amplification step will permit a major 
compression of the time required for cell line development from a few months to a few 
weeks. For example, the transgene of a single copy high producing cell line can be swapped 
with transgene of another drug candidate by a simple transfection, which may be followed 
by a sub-cloning step. One such example is already reported, where enhanced expression 
and stability regions have been identified by screening a large population of sites (Chen et 
al, 2010). 
The employment of amplification-free methods in bioprocess necessitates 
widespread efforts towards cataloguing the stability and expression of various integration 
sites. Another approach is to identify the integration of site of some very stable, high 
expression, low copy cell lines in use in the industry. The ability to quickly analyze the 
integration site of cell lines will facilitate such analyses and enable the discovery of such 
favorable genomic sites. Such attempts are especially feasible today because of the 
availability of the Chinese hamster genome.  
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Current methods for integration site analysis require the knowledge of the vector 
region flanking the insertion site. This enables region-specific primer design, leading to the 
enrichment of the region containing the integration site. Such methods are possible for 
retroviral or lentiviral based gene transfection because the integration site for these systems 
is precisely known (Bryda et al, 2006; Schmidt et al, 2007). In plasmid transfections, even 
if the vector is linearized, the integration site can vary considerably from the cut-site. 
Hence, a new method capable of identifying these sites is needed. This study attempts to 
find and evaluate a few methods for identifying such integration sites. 
In typical cell line development, an expression vector containing the transgene is 
linearized by restriction enzymes, and then transfected into CHO cells. The vector gets 
randomly integrated into the CHO genome, most probably at the cut-site. It is quite possible 
that the ends of the vector get chewed up prior to integration. Sometimes, non-linearized 
vectors are used for transfection, in which case, the site on the vector at which the 
integration occurs is not known. 
 
 
Figure 0-47: Primary and secondary insertion sites- When the plasmid vector is 
transfected into host cell, it randomly integrates at a certain site. This site is referred 
to as the primary insertion site. A cell may have many primary insertion sites. 
During the process of amplification, a part of region adjoining the integrated 
plasmid vector is co-amplified with the plasmid. This process may create many 
structural rearrangements. The amplification unit can also be transferred to 
different locations in the genome. This rearrangement creates secondary insertion 
sites. Each primary insertion site may have many corresponding secondary 
insertion sites. 
A producing cell subjected to the standard cell line development process, possesses 
two types of integration sites. The site where the exogenous DNA integrates is called the 
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primary insertion site. A cell may have more than one primary insertion site. To make 
higher amounts of protein, the cells are subjected to DHFR-based transgene amplification 
in CHO cells that are deficient in DHFR function. By adding methotrexate, a DHFR 
antagonist, amplification of the region around the transgene integration site occurs. This 
region contains the plasmid vector and the surrounding genomic region and the primary 
integration is co-amplified. This co-amplified region may be duplicated and translocated 
to different genomic regions. These translocated sites are secondary insertion sites. Each 
primary insertion site may have many secondary insertion sites (Figure 0-47). The method 
developed in this study determines only the primary insertion sites.  
 
 
Figure 0-48: Possible scenarios of amplification. During the amplification step, many 
structural rearrangements occur. A simple amplification will involve direct 
amplification of the amplification unit in a head to tail arrangement. This 
amplification unit may be inserted in an inverted orientation compared to the 
primary insertion. During amplification, portions of the vector or genome may be 
chewed up by nucleases prior to integration, causing the deletion of some intervening 
sequence. 
The actual amplification is very complex, and there may be many different ways 
that a genomic region may get amplified. A few possible scenarios are presented here to 
illustrate this complexity. The simplest amplification is the head to tail arrangement of 
amplification unit in tandem.  Other possibilities include a head to head arrangement of the 
amplification unit, similar to an inverted repeat; or a head to head arrangement of 
  142 
amplification unit along with the deletion of some of the intervening sequence (Figure 
0-48). 
7.5.2 Results and discussion 
We used a cell line with a known integration site to study different insertion site 
analysis methods. The integration site of these cell lines were determined a priori using 
whole genome sequencing. A high producing cell line with high vector copy number (300), 
and a high producing cell line with low vector copy number (15) were used for the study. 
We tested a few popular methods commonly used to detect integration sites in lentiviral 
transfectants. These methods did not work in our system (Bryda & Bauer, 2010; Zou et al, 
2003). Two of the methods that were successful for insertion site analysis were: (1) 
sequencing adaptor ligation-based PCR; and (2) physical separation using sequence 
capture, that is, solution-based methods for pull-down with biotinylated probes using 
streptavidin-coated beads. 
7.5.2.1 Sequencing adapter ligation based PCR for targeted sequence 
enrichment 
The genomic DNA was sheared and selected for a specific size, and then the DNA 
fragments were ligated with standard Illumina sequencing adapter. One primer from the 
vector sequence and the other primer from the adapter sequence, were used to amplify the 
conjunction sequences using PCR.  
Controlled shearing of the genomic DNA was achieved by sonication. The shorter 
fragments were discarded. Three types of DNA fragments were obtained after shearing, (1) 
fragments containing the vector only, (2) fragments containing the genome only and (3) 
fragments containing the junction between the genome and the vector. Our objective was 
to enrich the fragment of the type (3) (Figure 0-49).  
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Figure 0-49: Schematic of the sequencing adaptor ligation based PCR for sequence 
enrichment. The sheared genomic DNA from the subject cell line will have three kinds 
of fragments – (1) containing only genomic DNA, (2) containing only vector DNA or 
(3) containing the vector genome-junction sequence. The objective is to enrich this 
pool of fragments in fragments of type (3) for integration site analysis. The Illumina 
sequencing library is first prepared by ligation of sequencing adapters to either ends 
of all fragments. Then, a PCR primer specific to adapter, coupled with a vector-
specific PCR primer are used to conduct PCR. The PCR product will thus, be 
enriched for vector-containing regions, specifically regions of types (2) and (3). 
Another PCR with a nested primer is done along with the adapter-specific primer to 
enrich the pool further for vector-containing sequences. These fragments are then 
sequenced in an Illumina Mi-Seq machine. 
In the next step, all the DNA fragments were ligated with the standard Illumina 
indexed adapter and universal adapter. To enrich the specific DNA fragments containing 
the vector genomic DNA junction, a 20 bp primer hybridizing to the indexed adapter, and 
a primer containing 26 bp from the vector and also linked to the universal adapter were 
designed.  The universal adapter is necessary for the subsequent sequencing steps. The 
resulting PCR reaction is size-selected to remove smaller fragments, as they may not be 
long enough to sequence into the genome to identify the integration site confidently, and 
hence, will cause a loss of sequencing depth in the later steps.  Since the PCR will be 
successful only if the primer binds to the vector region; by sequencing long enough, one 
can identify the integration site by Illumina sequencing.  
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One important design criterion for using this method is the primer design, because, 
the detection of the integration site is limited to the location of primer. Plasmids are usually 
linearized prior to transfection, and hence there is a high probability of the integration site 
to occur at or near the cut site. So, our primer design focused more on the regions close to 
the cut-site.  
7.5.2.1.1 Sequencing adapter ligation based PCR method tested in high transgene copy 
number cell line 
 
Figure 0-50: Locations of the 6 known integration sites in the vector used for the 
high copy cell line are indicated on the plasmid DNA. Most of the integration sites 
are close to the cut site (position 1). Some of the integration sites (5 and 6) form 
truncated transcripts of the transgenes, and are thus, non-functional for protein 
production. 
A cell line with a known integration site was chosen to develop the methodology. 
The 6 known integration sites are mapped to the plasmid shown in the figure (Figure 0-50). 
The position 1 on the vector is the cut-site. Most integration sites (4 out of 6) occur within 
the first 900 bp of the plasmid cut-site, as we had expected. The direction of the arrow 
represents the portion of the plasmid that was retained at the integration site. Integration 
sites 5 and 6 are non-functional because a major portion of the transgene sections were 
truncated. The primer design was biased to preferentially span the region upstream of the 
light chain gene. 
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Figure 0-51: Primer design for the enrichment of the six known integration sites. The 
positions in the vectors are the number shown below the green bar (not to scale). 
Numbers on the green bar are the respective integration sites.  Primers P1 through 
P5 are used to probe for the known integration sites. Primer C1 is a control primer 
as there is no integration site in proximity to the portion of the plasmid that can be 
amplified by the primer. 
The first primer P1 was designed close to the cut site (< 100bp within the cut site). 
We designed three more primers C1, P2 and P3 in the region between the cut-site and the 
CMV promoter. This is because if any integration site exists beyond the CMV promoter, it 
will render the transgene inactive. So, we added more primers upstream of this region. We 
also designed two more primers P4 and P5 in order to enrich the other two integration sites. 
The primers were chosen such that there is one primer for every 200 bp. This made sure 
that any integration site within this region will show up in at least one PCR reaction. C1 is 
called a control primer because the results from that primer do not show any integration 
site. This was expected because there was no known integration site in close proximity to 
primer C1 (Figure 0-51). The PCR reactions from all the six primers were loaded into two 
MiSeq lanes. The read length obtained was 250 bp. Approximately, 12 million single-end 
reads were obtained from each lane.  
Following sequencing, bioinformatics processing was done to identify the 
integration site. Briefly, the reads mapping partially to the vector as well as the genome 
were filtered out, and the number of reads supporting the same vector-genome junction are 
calculated. The Smith Waterman based algorithm bwa-sw tool was used for mapping, in 
order to allow for partial hits to the genome and vector (Li & Durbin, 2010). We counted 
the frequency of the border base of vector-genome junction for all the integration sites. The 
site with the highest frequency is the most enriched fragment and is a real integration site. 
The number of reads supporting the junction, will be hereforth referred to as the “depth” 
of the integration site. The first bioinformatics step is the trimming of sequences from the 
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Illumina adapters from the reads. After this step there was almost no loss in the number of 
reads, which is indicative of good library preparation. The Chinese hamster genome is 
about 2.5 Gbp in length. The integration site represents only a very small fraction of this 
genome. Even though we have a sizeable enrichment in the integration site region after 
PCR, it is unavoidable to have some genomic background. Out of 21.4 million reads, 4.7 
million reads mapped completely to the genome because of background carry over. Out of 
the remaining 16.7 million reads, 12.2 million reads mapped entirely to the vector, i.e. 
having no genomic sequence. Such reads cannot be avoided, more so, in cell lines that have 
high copy number of the plasmid vector. The remaining 4.5 million reads were mapped to 
the vector and the genome to identify vector genome junctions. Out of these, 82 thousand 
reads were utilized towards identifying the integration sites. The remaining reads were not 
long enough to confidently contribute to the count of integration site and were then 
discarded.  
 
Figure 0-52: Depth of integration site from bioinformatics analysis for the sequencing 
adaptor ligation based PCR method. The data points marked 1, 3, 4, 5 and 6 are the 
data points corresponding to the integration site. Most integration sites are identified 
to very high depths, separating it from the background data points. 
For each of the identified vector-genome junctions, the depth was calculated and 
plotted across the length of the vector. The integration site nos. 1, 3, 4, 5 and 6 were 
identified at much higher depths compared to the depth of the other junctions that formed 
the background. Integration site 2 was not identified. Even in whole genome sequencing, 
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the depth of the integration site 2 was very shallow, probably because it came from a small 
sub-population of cells (Figure 0-52). Since the cells were confirmed to be clonal, this 
observation is puzzling. It is possible that the entire population possessed this site initially, 
but slowly lost this site during sub-culture, and only a small population of cells with this 
integration site remain. 
 
Figure 0-53: The pileup of reads mapping to genome and vector sections of the five 
integration sites identified by the sequencing adaptor ligation based PCR method. 
Genome mapping is shown on the left and vector mapping is shown on the right. 
The vector mapping shows a sharp boundary at the integration site, as well as the 
where the primer was designed. The genome mapping shows one sharp boundary at 
the integration site and a trailing boundary on another end. This is another 
confirmation of the presence of the integration site. 
It is necessary to confirm if the integration site is not a PCR artefact. This is done 
by inspecting the insertion site for the absence of such artefacts. A real integration site 
would show blunt mapping to genome on one side of all the reads corresponding to the 
vector genome junction, and a trailing of depth on the other side in a staircase-like pattern. 
The mapping to the vector will be blunt on both the sides of the integration site. Mapping 
to the vector will also be blunt on the other side where the PCR primer is bound. For all 
the integration sites identified in the chart, the nature of vector and genome mapping was 
as expected indicating the accurate identification of the integration sites (Figure 0-53). 
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7.5.2.2 Physical separation- Solution phase sequence capture of insertion site 
In solution-phase sequence capture, DNA fragments containing the target sequence 
are hybridized to biotin-labeled oligo probes (baits), which are subsequently pulled down 
by streptavidin-coated beads. The captured sequence can be sequenced by traditional 
Sanger or high-throughput sequencing methods (Figure 0-54).  
 
Figure 0-54: Schematic of the solution phase based sequence capture method for 
insertion site analysis. . The sheared genomic DNA from the subject cell line will 
have three kinds of fragments – (1) containing only genomic DNA, (2) containing 
only vector DNA or (3) containing the vector genome-junction sequence. The 
objective is to enrich this pool of fragments in fragments of type (3) for integration 
site analysis. The Illumina sequencing library is first prepared by ligation of 
sequencing adapters to either ends of all fragments. Biotinylated baits are 
constructed tiling the entire plasmid. The targeted sections of the genomic DNA are 
pulled down by the streptavidin-coated magnetic beads. These beads are separated 
from the solution using a magnet, and the captured sequences are eluted by 
denaturation. 
Two cell lines were used to test the effectiveness of the sequence capture method 
to identify the integration sites. One has a high copy number of vector (~300) with about 6 
known integration sites, and the other has a low copy number of vector (~15) with 3 known 
integration sites. The integration sites for these two cell lines were determined using whole 
genome sequencing. 
7.5.2.2.1 Sequence capture for high transgene copy number cell line 
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Similar to the previous discussion on primer design for Adapter PCR-based method 
for integration site analysis, the bait design for sequence capture-based integration site 
analysis also emphasized the first 400 bp of the vector. This is because, there is a higher 
probability of the integration site occurring close to the cut-site. Since, it is quite possible 
that the insertion occurred within another part of the vector, we also designed a few baits 
tiling the entire vector. Baits were designed with a lower density accounting for the lower 
probability of its occurrence. Therefore, 10 times more baits were designed at the first 400 
bp of the vector compared to the remaining vector length. 
 
Figure 0-55: Depth of the integration sites detected by solution phase sequence 
capture technique. The data points marked 1, 3, 4, 5 and 6 are indicated on the graph. 
In this case, some other integration sites were also detected at higher depths above 
background. These are indicated as A, B, C, F and G on the figure. 
  Using the same bioinformatics methodology outlined in the previous section, 
several vector-genome junctions were identified. In this case, we could easily identify 
integration sites 1, 3, 4, 5 and 6 because of their stark difference in the detection depth from 
that of the background. Interestingly, even in this case, the integration site 2 was not 
detected. In addition to these known integration sites, other vector-genome junctions A, B, 
C, F and G were identified.  
We further looked into the local mapping of the vector and genome regions at the 
candidate integration sites. For sequence capture, the mapping to genome should be blunt 
at the junction site for all the reads mapping to that region, and a trailing depth ladder on 
the other side. Similarly, mapping to the vector should also show blunt high depth at the 
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junction of the integration site, and a trailing depth like a staircase for the other side of the 
reads mapping to the vector. For each of the integration sites, we observed such a trend 
with blunt depth at the junction site and a trailing staircase-like depth on the other side for 
both the vector and the genome mapping.  
 
Figure 0-56: Pileup data of the captured sequences detected by the solution phase 
sequence capture method. Mapping to genome is shown on the left and mapping to 
vector is shown on the right. The integration sites 1, 3, 4, 5 and 6 show the expected 
mapping pattern with a sharp boundary at the integration site, and a trailing pattern 
on the other end for both vector and genome mapping. This confirms that the site 
detected has not been affected by PCR bias. Sites A, B and G may be other potential 
integration sites that were not detected earlier from whole genome sequencing. Sites 
C and F do not exhibit good quality mapping at the genome, thus dismissing the 
presence of these two integration sites. 
Similarly, for the novel vector genome junction sites A, B, C, F and G, we looked 
at the mapping patterns to determine if they could be real integration sites. For site A and 
B, the mapping patterns seem to be real. They may be additional novel integration sites 
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that were not detected in the whole genome sequencing. For sites C and F, the mapping 
results showed a lot of mismatches in the genome mapping. So, it probably not a real 
integration site. For site G, the double blunt end of genome mapping indicates that it is a 
PCR artefact and may not be a real integration site. 
7.5.2.2.2 Sequence capture for low transgene copy number cell line 
The plasmid vector was not linearized prior to transfection in the low transgene 
copy number cell line. Hence, the biotinylated baits were designed equi-spaced along the 
length of the vector (every 120 bp) with 1X tiling. Bioinformatics analysis was performed 
as described previously.  
 
Figure 0-57: Depth of the insertion sites detected by solution based sequence capture 
method in the low copy cell line. Integration sites 1 and 2 are detected at high depths 
above background. However, integration site 3 is represented at lower depth 
relative to background. Even from whole genome sequencing, the depth of 
integration site 3 was very low compared to the other two integration sites. 
The three known integration sites 1, 2, and 3 for the low-copy cell line were 
identified from the high contrast in depth compared to the background (Figure 0-57). For 
quality check, the mapping to vector and the genome were analyzed. As expected for a real 
integration site, the reads showed blunt mapping pattern at the integration site and a trailing 
pattern on the other side of the integration site. This was observed for mappings to the 
vector and the genome indicating that these integration sites are real (Figure 0-58).  
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Figure 0-58: Pileup of reads at the vector and genome regions for the three 
integration sites detected by the solution phase sequence capture method for the low 
copy cell line. Genome mapping is shown on the left and mapping to vector is shown 
on the right. As expected, all three show sharp boundary at the integration site and 
a trailing pattern on the other end. 
The neighboring regions near the integration site can play an important role in 
interacting with and regulating the expression level of the transgene. A summary of such 
immediate neighboring regions for all the integration sites is presented in Table 0-11. The 
absolute detection depths for the low copy cell line is higher than that for the high copy 
cell line. The lower vector amount in the low copy cell line has potentially reduced the 
background. Most of the baits captured the genomic region with the integration site, and 
only a few captured the vector background. Since both the cell lines are high producers (40 
pg/cell/day), the integration sites of these cells are potential sites that can be used for 
targeted integration. 
Most of the integration sites are intronic or intergenic. The expression level of the 
corresponding genes that were interrupted by the integration, was obtained from 
microarray data with a normalized average expression value of 500. The average 
expression level from RNA-Seq data was approximately 200. All the genes that were 
interrupted by the plasmid integration had average expression levels. Potentially, highly 
expressed genes are essential for the cell’s growth and survival, and hence, the interruption 
of its expression may prove to be harmful for the cell. The integration at a moderately 
expressed gene may not be very disruptive and yet have active chromatin positively 
impacting transgene expression. 
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Table 0-11: Description of the gene structure at the integration site for both cell 
lines. Since both the cell lines are high producers, the rate of transcription of the 
adjacent regions may be of relevance. Most integration sites occur with an intron of 
a moderately expressed gene. Wherever relevant, the gene expression values of those 
genes in CHO cells from RNA-Seq and microarray are indicated on the table. 
Insertion 
site 
Position 
Vector 
Depth Scaffold 
Number 
Scaffold 
position 
Insertion site 
description 
RNA-Seq 
RPKM 
Microarray 
Intensity 
High copy cell line 
1 9 707  261 743,321 Etv6(TF), 
Intron 
148 492 
3 505 742  261 747,518 Etv6(TF), 
Intron 
148 492 
4 654 828  261 747,631 Etv6(TF), 
Intron 
148 492 
5 6339 543  1094 141,082 Intergenic - - 
6 4466 480  1094 136,753 Intergenic   
Low copy cell line 
1 1594 30,360  79 1,569,795 Rc3h1, 
intron 
245 454 
2 7161 10,722  727 553,230 Vsp13b, 
intron 
1325 391 
3 5072 1,553  2011 192,652 Intergenic - - 
 
7.5.2.3 Comparison of integration site detection approaches 
For the high copy number cell line, the contrast between the background and the 
signal was higher in the adapter PCR-based method compared to the sequence capture 
method. It must be noted that the sequencing depth for the adapter PCR-based method was 
almost 4-times than that of the sequence capture. Sequencing adapter based enrichment 
methods rely heavily on primer design, requiring a discrete array of primers to probe all 
the integration sites. This method is more suitable when the vector is linearized prior to 
transfection. When the junction sequence is unknown, many primers have to be designed 
along the vector increasing the cost of the analysis. One advantage of this method is that it 
has a higher yield of specific sequences with insertion site, because PCR enriches the 
targeted sequence considerably. The success of PCR-based methods rely heavily on the 
primer design. In contrast, the sequence capture based enrichment method uses probes that 
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tile the entire vector, and a single experiment can probe for all possible integration sites. 
This method can be used even when vector is not linearized. A sequence capture library 
has to be developed for every vector used, which increases the capital cost of this method 
compared to the PCR-based method. Most of the IgG sequences are similar in sequence 
with a few changes. If the same backbone is used for most of the cell lines containing IgG 
sequences, a generic library can be constructed for wide applicability. It can also be made 
cost effective by probing the integration site for many cell lines in a single experiment. 
7.5.3 Conclusions 
Two methods based on PCR and sequence capture were developed and tested for 
integration site analysis. These methods were used to study the integration site of two high 
producing cell lines, one with high transgene copy, and the other with low transgene copy. 
Although the PCR-based method shows a high detection depth for the integration sites, the 
detection of the insertion site depends on its proximity to the primers. An array of primers 
need to be designed along the vector to probe for all the possible integration sites. It is more 
suitable to be used for cell lines created by linearized vector transfection, where the most 
probable region on the vector for the integration site is known and primer design can be 
restricted to that region. In contrast, the sequence capture based method exhibits lower 
detection depths, however, a single experiment can theoretically probe all the integration 
sites in the cell line. 
Most of the detected integration sites were located in the intronic regions, while a 
few of them were located in intergenic regions. The expression levels of the genes 
intercepted by the transgene integration is close to the average expression level. Since both 
the cell lines used were high producers, the location of these integration sites are of special 
interest for future cell engineering efforts.  
The integration site characterization methods will find applications not only for 
bioprocessing, but also in other studies where the transgene is randomly integrated in large 
genomic backgrounds. 
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Chapter 8: Conclusions and Future Directions 
Exciting times lay ahead for cell culture engineering, being in the peak of the 
‘genomics’ era. The past few years have seen the birth of a plentitude of genomic resources 
for Chinese hamster and CHO cells, which have also brought in a lot of new discoveries. 
A major part of this dissertation is dedicated to developing and improving genomic 
resources for CHO cells. Even though the genome and transcriptome sequences were 
available for use, the annotation of these sequence was lagging behind. This challenge was 
addressed by employing a rigorous homology-based annotation strategy expanding the 
repertoire of annotated sequences considerably. Such genomic information is extremely 
valuable for taking bioprocessing to the next stage of development. 
In the past few years, bioprocessing has seen increasingly more focus on process 
intensification and decentralization. The number of drug candidates that need to be 
developed are increasing, and the only way to remain competitive is to be fast in delivery. 
For a long time, recombinant protein therapeutics have been an elite drugs, mostly available 
in the developed countries, and to the better-offs. With many of the older and effective 
drugs going off-patent, developing countries are beginning to invest heavily in producing 
these drugs in house, and marketing them at much lower costs. The biotechnology industry 
has begun to have a more worldwide presence, especially in the past few years. Therefore, 
especially now, it is essential to make processes more time-efficient, more streamlined and 
well defined to ensure reproducibility. 
The easy access to genomic information can help address many of these very 
pertinent issues. The community is now motivated to understand the underlying scientific 
principles, to ensure reproducibility. In most cases, a platform process is adopted to ensure 
smooth and efficient process development and transfer. Despite this, deviations are often 
observed. A better understanding of the molecular changes can lead us to cues for avoiding 
deviations. For example, understanding the inherent variability in gene expression levels 
of key pathways relevant to the process can give us useful insights to control the process. 
Variability in gene expression among CHO cells of varied origin was studied using 
an expression microarray. RNA-seq analysis was used to compare expression levels in 
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CHO cells with the physiological levels in Chinese hamster tissues. A few important genes 
responsible for product quality are found to be absent in a few cell types. De-silencing 
these genes or knocking-in such genes can ensure consistent product quality. This variance 
in gene expression among CHO cells creates the necessary genetic diversity required for 
isolating high producing CHO cells for the protein production. 
These characteristics that make cells hyper-producers were studied by analyzing 
the transcriptome of the cells during the process of cell line development. A complete non-
producer that has no machinery to secrete proteins, gets transformed into a super-producer 
with productivities rivalling professional secretors like plasma and liver cells. Following 
transfection and selection, cells are usually subjected to an amplification step to increase 
the transgene copy number. From the transcriptome analysis of cells undergoing this 
transition, we speculate that amplification potentially creates a burst of messenger RNA 
overburdening the cells’ protein processing machinery possibly leading to the triggering of 
unfolded protein response. Only the cells that have sufficient machinery to process this 
large load of protein survive, leading to the selective isolation of high producers. The 
hyper-productivity traits largely involve growth signaling, mRNA and protein processing, 
cell cycle and energy metabolism. The leading genes conferring the hyper-productivity trait 
were combined with those identified from other studies, thus generating a hyper-
productivity gene set. The size of the gene set is too sparse and requires more data for 
further refinement before it becomes practically usable for screening cells. 
In addition to selecting high producing cells, it is also important to have a robust 
process to ensure high productivity in every bioreactor run. One of the outstanding issues 
is the production of lactate, a metabolite that is detrimental to cell growth and productivity. 
While some cultures have the propensity to consume lactate in the late stage and perform 
well, some others produce lactate even under identical processes. Lactate consumption was 
achieved by the reduction of glycolytic flux in the late stage of the culture. This was carried 
out by expressing a fructose transporter selectively in the late stage of the culture, while 
simultaneously switching the sugar source to fructose. The transporter was expressed using 
a novel dynamic promoter that drove expression in-sync with the cell’s growth, enabling 
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selective uptake of fructose only in the late stage of cell growth. The productivity of this 
culture was improved compared to the control culture. 
Consistency of performance also relies on the genetic stability of the clonal cell line 
selected for production. It is often observed that the integration site of the transgene plays 
an important role in determining the stability of the clone. Most practices still rely on 
random integration followed by intensive selection to identify a stable clone. In contrast, 
the state-of-art practices are moving towards a targeted integration approach where the 
transgene is directed to a predetermined stable and transcriptionally active genomic site. In 
order to identify such a site, a lot of integration sites are needed to be screened. Two 
methods for the identification of integration sites were optimized and evaluated. The 
integration sites of two stable and high producing cell lines were identified. The integration 
sites were found within the intron of a medium expression gene. More such sites need to 
be evaluated in the future, and a few candidate sites can then be used for targeted 
integration. 
An ideal bioprocessing practice should involve a combination of all the efforts 
presented in this dissertation. A targeted transgene integration approach applied for 
genetically stable clones, followed by a more refined transcriptome-based cell screening to 
identify high producers will open the door for faster and controlled process development. 
The selection of a high producing clone needs to be coupled with a robust process to ensure 
maximum productivity.  
8.1 Future directions 
The next phase of genomics in bioprocessing should involve exploration of the 
epigenome in addition to the transcriptome and genome. The transformation of CHO cells 
from non-producers to extremely high producers entail colossal changes in the 
transcriptome profiles, which potentially arise due to epigenetic changes. These epigenetic 
changes, if identified, can be engineered to make higher producers. The genes showing 
massive changes in gene expression levels, or those that are highly variable, are probably 
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subjected to epigenetic modification. The epigenetic states of some of these genes that are 
relevant for bioprocessing should be explored. 
One such gene is glutamine synthetase, which makes cells auxotrophic for 
glutamine. Glutamine is a metabolite that plays an important role in lactate metabolism. 
Since lactate metabolism is critical for bioprocessing, the epigenetic state of the glutamine 
synthetase gene is highly relevant. The upstream region of the gene has a dense and 
conserved CpG island. The frequency of obtaining glutamine independent cells after de-
silencing by 5-azacytidine had drastically increased (Figure 0-59A). A major fraction of 
DNA at the upstream region of the glutamine synthetase gene was unmethylated in 
comparison to control liver DNA which was totally unmethylated (Figure 0-59B). 
Glutamine independent cells can be isolated and probed at the upstream CpG island for 
reversal of DNA methylation. 
 
Figure 0-59: (A) Increased frequency of isolating glutamine independent cells on 
treating with 5-azacytidine, a de-silencing drug. (B) Methylation specific PCR 
showing a large fraction of methylated DNA at the upstream region of the glutamine 
synthetase promoter, where the PCR probes were designed. 
Similarly, another gene α(2,6)-sialyltransferase shows no expression in the CHO 
cells tested in our study. This gene also has upstream CpG islands that can be probed for 
potential silencing. Sialic acid linkage to glycoform in humans is α(2,6) type, as compared 
to the α(2,3) type in CHO cells. This can be attributed to the highly expressed α(2,3)-
sialyltransferase. Cells can be engineered to activate the endogeneous gene in order to 
obtain more human-like glycoform of the product. 
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Consistency in glycoform or product quality is one of the major roadblocks faced 
by the industry today. The extensive microarray data generated in this study can be used to 
study the bottlenecks of the glycosylation pathway. The historical mathematical models 
developed for the glycosylation pathway can be revamped by including more realistic 
enzyme levels estimates obtained from microarray data. Possible avenues for intervention 
can be explored. 
The possibility of targeted genome integration is another exciting avenue that can 
be pursued in the future. Random single copy integration of GFP gene followed by sorting 
high GFP expressers can be used to identify hot spots. Further, the cells can be cultured for 
extensive periods of time. The cells that continue to express high GFP levels can be isolated 
by sorting. The integration site of these cells can be identified and catalogued. GFP can be 
exchanged for a therapeutic protein, and the productivity of the cell can be ascertained. By 
targeting to a transcriptionally active and genetically stable site, a single copy high 
producer can potentially be obtained. This cell line will be very valuable because the 
transgenes can be swapped in the future for reproducibly isolating high producing clones 
for other drug candidates. 
Our hypothesis of the role of the amplification step in obtaining high producing 
cells can be further explored. The cells can be transiently transfected with a high 
concentration of mRNA of the product gene, and the frequency of isolating high producers 
can be evaluated. The expression profile of the genes can be probed and compared with 
that of the genes differentially expressed during the amplification step. This will give 
valuable hints for shortening the time-scale of cell line development. 
On the other hand, dynamic cell engineering can also be exploited for improving 
cellular productivity. The experiment in mixed substrate culture using cells dynamically 
expressing glut5 transporter with switch back to glucose (Figure 0-34), can be reattempted 
with pH control in a more controlled environment like a bioreactor. Anti-apoptosis 
engineering will also benefit from the use of a dynamic promoter. In cells engineered for 
anti-apoptosis because of slow death, cultures last longer and perform very well and have 
higher titers. However, invariably high expression of these gene in the growth stages 
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interferes with cell cycle control, leading to slower growth rates. They often have to be 
engineered using inducible promoters so that their expression can be activated in the late 
stages of the culture.  
We are just at the beginning of what can be achieved from application of genomics 
in developing productive, stable and reproducible processes. The genomics era will bring 
in innovative solutions for robust and efficient bioprocessing of the future. 
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Appendix 
Table 0-1: List of primers for qRT-PCR analysis 
Gene 
symbol 
Ensembl ID of mouse or 
mouse homolog 
Left primer Right primer 
actin ENSMUSG00000029580 GTCGTACCACTGGCATTGTG AGGGCAACATAGCACAGCTT 
hIgG HC - GGCTTCTATCCCAGCGACATC GGCGTGGTCTTGTAGTTGTTCTC 
hIgG LC - GGGCGTTATCCACCTTCCA CGTGGTGTGCCTGCTGAATA 
mDHFR ENSMUSG00000021707 TCTGTTTACCAGGAAGCCATGA AATTCCTGCATGATCCTTGTCA 
mGLUT5 ENSMUSG00000028976 CCTACATGATCGGAGGCAGT CCAAGCTCCTCCTCCTTCTT 
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Table 0-2: List of genes in the hyper productivity gene set 
Gene Symbol Description Fold 
Change in 
Selection 
(S) 
Fold Change in 
Amplification 
(A) 
Fold Change in 
High Producers 
vs Low 
Producers (H) 
Set I 
(S∩H) 
Set II 
(A∩H) 
Set III 
(Q∩H) 
Apoptosis 
Zfand5 zinc finger, AN1-type domain 5 Gene  -1.34 1.32 1.23 Y N N 
Cell cycle 
Xrcc5 X-ray repair complementing defective repair in Chinese hamster 
cells 5 Gene  
-1.75 1.09 -1.42 Y N N 
Nde1 nuclear distribution gene E homolog 1 (A nidulans) Gene  -1.66 -1.05 -2.50 Y N N 
Energy metabolism 
Rpe ribulose-5-phosphate-3-epimerase Gene  -1.96 -1.20 -1.36 Y N N 
Mrps24 mitochondrial ribosomal protein S24 Gene  -1.64 -1.23 -1.59 Y N N 
Gene expression 
Tdrd3 tudor domain containing 3 Gene  -2.80 1.20 -1.69 Y N N 
Pax3 paired box gene 3 Gene  -2.27 -1.01 -1.46 Y N N 
Ctbp1 C-terminal binding protein 1 Gene  -1.89 1.07 -1.69 Y N N 
Zfp346 zinc finger protein 346 Gene  -1.51 -1.04 -1.28 Y N N 
Ptrf polymerase I and transcript release factor Gene  -1.00 1.26 -2.17 Y N N 
E2f6 E2F transcription factor 6 Gene  1.06 1.05 -1.36 Y N Y 
Snrpc U1 small nuclear ribonucleoprotein C Gene  1.22 -1.02 1.15 Y N N 
Wtap Wilms' tumour 1-associating protein Gene  1.22 -1.04 -1.05 Y N N 
Cstf2t cleavage stimulation factor, 3' pre-RNA subunit 2, tau Gene  1.29 1.16 1.20 Y N N 
Zfp600 zinc finger protein 600 Gene  1.32 1.74 2.11 N Y N 
Papola poly (A) polymerase alpha Gene  1.38 -1.43 1.83 Y N N 
Utp11l UTP11-like, U3 small nucleolar ribonucleoprotein, (yeast) Gene  1.43 -1.04 -1.09 Y N N 
Prpf31 PRP31 pre-mRNA processing factor 31 homolog (yeast) Gene  1.70 1.45 1.79 Y N N 
Slu7 SLU7 splicing factor homolog (S. cerevisiae) Gene  1.75 -1.11 1.20 Y N N 
Glycosylation 
Stt3b STT3, subunit of the oligosaccharyltransferase complex, 
homolog B (S. cerevisiae) Gene  
-1.21 1.21 -1.12 Y Y N 
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Gene Symbol Description Fold 
Change in 
Selection 
(S) 
Fold Change in 
Amplification 
(A) 
Fold Change in 
High Producers 
vs Low 
Producers (H) 
Set I 
(S∩H) 
Set II 
(A∩H) 
Set III 
(Q∩H) 
Dpm1 dolichol-phosphate (beta-D) mannosyltransferase 1 Gene  1.31 -1.13 1.19 Y N N 
Ion transport 
Pxk PX domain containing serine/threonine kinase Gene  -1.95 -1.20 -1.69 Y N N 
Atp11b ATPase, class VI, type 11B Gene  1.26 -1.08 1.27 Y N N 
Lipid metabolism 
Cyp20a1 cytochrome P450, family 20, subfamily A, polypeptide 1 Gene  -2.56 -1.32 -1.67 Y N N 
GH511842.1 CCUF6931.b1 CCUF Peromyscus maniculatus bairdii BW:Nb 
Peromyscus maniculatus bairdii cDNA clone CCUF6931 5', 
mRNA sequence. 
-1.95 -1.46 -1.22 Y N N 
Dagla diacylglycerol lipase, alpha Gene  1.74 1.29 1.81 Y N N 
Unannotated or other functions 
FI847326.1 CH232-004M13.C7 CHORI-232 Microtus ochrogaster genomic 
clone CH232-004M13, genomic survey sequence. 
-2.15 1.22 1.61 Y Y N 
Twsg1 twisted gastrulation homolog 1 (Drosophila) Gene  -2.06 -1.07 -1.81 Y N N 
Adam9 a disintegrin and metallopeptidase domain 9 (meltrin gamma) 
Gene  
-1.93 1.19 -1.87 Y N N 
LOC680531 similar to CG3880-PA (LOC680531), mRNA  -1.66 -1.13 -1.42 Y N N 
D17Wsu104e DNA segment, Chr 17, Wayne State University 104, expressed 
Gene  
-1.65 1.25 -1.08 Y Y N 
Pcolce2 procollagen C-endopeptidase enhancer 2 Gene  -1.57 -1.02 -1.34 Y N N 
Nt5dc2 5'-nucleotidase domain containing 2 Gene  -1.55 -1.07 -1.21 Y N N 
Fam3a family with sequence similarity 3, member A Gene  -1.51 1.06 -1.63 Y N N 
Smc6 structural maintenance of chromosomes 6 Gene  -1.40 1.06 -1.27 Y N N 
Parp1 poly (ADP-ribose) polymerase family, member 1 Gene  -1.31 1.02 -1.06 Y N N 
Jmjd4 jumonji domain containing 4 Gene  1.35 1.13 1.54 Y N N 
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Gene Symbol Description Fold 
Change in 
Selection 
(S) 
Fold Change in 
Amplification 
(A) 
Fold Change in 
High Producers 
vs Low 
Producers (H) 
Set I 
(S∩H) 
Set II 
(A∩H) 
Set III 
(Q∩H) 
AL824707.7 Mouse DNA sequence from clone RP23-95O1 on chromosome 
4 Contains the 5' end of the gene for the likely ortholog of H. 
sapiens chromosome 9 open reading frame 138 (C9orf138), a 
novel gene, the Rraga gene for Ras-related GTP binding A, the 
gene for the lik 
1.37 -1.09 1.40 Y N N 
AB370295.1 Eukaryotic synthetic construct DHFR, hGM-CSF, DHFR genes 
for dihydrofolate reductase, human granulocyte-macrophage 
colony stimulating factor, dihydrofolate reductase, complete cds, 
cell_line: Chinese Hamster Ovary cell DR1000L-4N 
1.39 -1.46 1.22 Y Y N 
Gpatch3 G patch domain containing 3 Gene  1.48 1.16 1.40 Y N N 
CS391352.1 Sequence 627 from Patent WO2006025879 1.52 -1.70 -1.50 Y N N 
FQ075827.1 FQ075827 Rattus norvegicus brain Sprague-Dawley Rattus 
norvegicus cDNA clone TL0AAA70YN24 3', mRNA sequence. 
1.62 1.40 -1.23 Y N N 
GH524702.1 CCUG5603.b1 CCUG Peromyscus maniculatus bairdii 
BW:fetus Peromyscus maniculatus bairdii cDNA clone 
CCUG5603 5', mRNA sequence. 
1.68 1.43 1.92 Y N N 
2410001C21Rik RIKEN cDNA 2410001C21 gene Gene  1.71 1.15 1.48 Y N N 
AC016791.23 Mus musculus chromosome 19, clone RP23-187B17, complete 
sequence 
1.73 -1.01 1.26 Y N N 
Ythdf1 YTH domain family 1 Gene  1.80 -1.16 1.40 Y N N 
AL611927.21 Mouse DNA sequence from clone RP23-445E20 on 
chromosome 4 Contains the Hkr3 gene for GLI-Kruppel family 
member HKR3, the Tas1r1 gene for taste receptor, type 1, 
member 1, the Klhl21 gene for kelch-like 21 (Drosophila) 
1.91 1.56 2.49 N Y N 
AC132224.3 Mus musculus BAC clone RP24-554P12 from 1, complete 
sequence 
3.21 -1.27 2.17 N Y N 
Protein Processing 
Hspd1 heat shock protein 1 (chaperonin) Gene  -1.43 -1.04 -1.21 Y N N 
Ufm1 ubiquitin-fold modifier 1 Gene  1.12 -1.04 1.10 N Y N 
Protein Secretion 
Stk25 serine/threonine kinase 25 (yeast) Gene  -1.44 1.06 -1.23 Y N N 
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Gene Symbol Description Fold 
Change in 
Selection 
(S) 
Fold Change in 
Amplification 
(A) 
Fold Change in 
High Producers 
vs Low 
Producers (H) 
Set I 
(S∩H) 
Set II 
(A∩H) 
Set III 
(Q∩H) 
Stx7 syntaxin 7 Gene  1.14 -1.38 1.18 Y N N 
Scamp2 secretory carrier membrane protein 2 Gene  1.16 1.26 1.12 Y N N 
Snx21 sorting nexin family member 21 Gene  1.27 -1.40 1.46 N Y N 
Protein Synthesis 
Pin4 protein (peptidyl-prolyl cis/trans isomerase) NIMA-interacting, 
4 (parvulin) Gene  
1.32 1.08 1.14 Y N N 
Redox Balance 
Abcb6 ATP-binding cassette, sub-family B (MDR/TAP), member 6 
Gene  
-1.90 1.10 -1.56 Y N N 
Signaling 
Ing1 inhibitor of growth family, member 1 Gene  -1.81 1.02 -1.77 Y N N 
Smurf1 SMAD specific E3 ubiquitin protein ligase 1 Gene  -1.50 1.90 -1.17 Y Y N 
Ptpn14 protein tyrosine phosphatase, non-receptor type 14 Gene  1.25 1.40 -1.16 Y N N 
Rac1 RAS-related C3 botulinum substrate 1 Gene  1.30 1.19 -1.02 N Y N 
Traf6 TNF receptor-associated factor 6 Gene  1.54 1.01 1.24 Y N N 
NM_008350.4 Mus musculus interleukin 11 (Il11), mRNA 1.56 1.19 1.74 Y N N 
Zfp128 zinc finger protein 128 Gene  1.57 1.44 1.86 Y N N 
Gps2 G protein pathway suppressor 2 Gene  1.79 1.03 1.51 N Y N 
Arhgap29 Rho GTPase activating protein 29 Gene  1.90 -1.28 -1.46 Y N N 
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Table 0-3: List of samples used for transcriptome assembly, RNA-seq and 
microarray in Chapter 4. 
Name Description (mRNA Source) Total 
Output  
RNA-
Seq 
Microarray 
 Recombinant CHO-K1 (IgG) 
Normalized library 
Exponential growth phase, suspension 
culture 
GsuI digestion of polyA 
84.75 Mbp   
 Recombinant CHO-K1 (IgG) 
Normalized library 
Exponential growth phase, suspension 
culture 
GsuI digestion of polyA 
57.39 Mbp   
rDG_2 Recombinant DG44 (IgG) 
Exponential growth phase, suspension 
culture 
Serum independent 
2.57 Gbp  Y 
rDG_H Recombinant DG44 (EPO)- High Producer 
Exponential growth phase, suspension 
culture 
Serum independent 
Weak promoter, strong selection 
3.94 Gbp Y  
rDG_L Recombinant DG44 (EPO)- Low Producer 
Exponential growth phase, suspension 
culture 
Serum independent 
Weak promoter, strong selection 
4.29 Gbp Y  
rDG_4,Aza Recombinant DG44 (IgG)- High Producer 
Exponential growth phase, suspension 
culture 
Serum independent 
5-azacytidine treatment 
4.47 Gbp Y  
rDG_3 Recombinant DG44 (GFP)- Unamplified cell 
line 
Suspension culture 
0 mM MTX treatment 
Control for 50 mM MTX treatment 
0.55 Gbp Y  
rDG_3M Recombinant DG44 (GFP)- Unamplified cell 
line 
Suspension culture 
50 mM MTX treatment 
0.61 Gbp Y  
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Name Description (mRNA Source) Total 
Output  
RNA-
Seq 
Microarray 
DG44 Parental DG44 
Exponential growth phase, adherent culture 
Serum dependent 
3.32 Gbp Y Y 
Brain Chinese Hamster Brain Tissue 
Brain mRNA from one late adolescent virgin 
female hamster 
4.25 Gbp Y Y 
Liver Chinese Hamster Liver Tissue 
Liver mRNA from one late adolescent virgin 
female hamster 
6.59 Gbp Y Y 
rDX_1 Parental CHO cell line 
Untransfected 
9.20 Gbp   
Ovary Chinese hamster ovary tissue   Y 
DXB11 Parental DXB11   Y 
CHO-K1 Parental CHO-K1   Y 
rDX_1 DXB11-derived recombinant IgG producer 1   Y 
rDX_1M DXB11-derived recombinant IgG producer 1 
20 nM MTX treatment 
  Y 
rDX_3 DXB11-derived recombinant IgG producer 3   Y 
rDX_3M DXB11-derived recombinant IgG producer 3 
20 nM MTX treatment 
  Y 
rDX_2 DXB11-derived recombinant DHFR   Y 
rDX_2M DXB11-derived recombinant DHFR 
20 nM MTX treatment 
  Y 
rDX_4 DXB11-derived recombinant IgG TNF-
alpha fusion protein producer 
  Y 
rDG_2, 
NaBu 
Recombinant DG44 (IgG) 
Late phase, 2mM butyrate for 24 hr 
Serum independent 
  Y 
rDG_2, 
Late 
Recombinant DG44 (IgG) 
Late phase, suspension culture 
Serum independent 
  Y 
rDG_1 Recombinant DG44 (IgG TNF-alpha fusion 
protein producer) 
Exponential growth phase, suspension 
culture 
Serum independent 
  Y 
